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Abstract 
 Craniofacial birth defects are associated with significant morbidity and mortality 
and can be highly variable in their severity and presentation. One key regulator of proper 
craniofacial development is the action of bone morphogenetic proteins (BMPs). Twisted 
gastrulation (TWSG1) modulates BMP signaling and the mutation of TWSG1 in mice 
results in a range of mild to severe birth defects, including forms of holoprosencephaly 
and dysgnathia. TWSG1 is a glycoprotein with sugar modifications which are essential 
for proper BMP binding and normal activity of TWSG1. In the mouse TWSG1 protein 
these sugars are attached in the region of the protein encoded by exon 4. The variable 
phenotypes resulting from exon 4 deletion (Twsg1-/-) in mice are associated with distinct 
sets of transcriptional changes compared to wild type, even for apparently unaffected 
embryos. The action of p53 plays a key role in the manifestation of severe birth defects in 
Twsg1
-/- mice, correlating with previously observed increases in apoptosis. Genetic 
deficiency of p53 is associated with reduced defects in Twsg1-/- mice. Some of the 
craniofacial defects in Twsg1-/- mice, specifically defects associated with the first 
branchial arch but not holoprosencephaly or midline defects, can be limited by maternal 
dietary supplementation with methyl donor compounds including folate, choline, betaine 
and vitamin B12. Previous pregnancy increases the risk of birth defects in Twsg1-/- mice. 
A mouse model of TWSG1 over-expression has been generated to further investigate the 
action of this gene and provide a reagent for future experiments examining the role of 
TWSG1 in development.  
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Chapter 1: Background and significance 
Craniofacial development and craniofacial disorders  
 In the United States, a child is born with a birth defect approximately every 4.5 
minutes. Birth defects are the leading cause of infant mortality, accounting for 1 in 5 
infant deaths (March-of-Dimes, 2010). Of babies born with defects, up to 1 in 3 have 
anomalies of the head and face (Trainor, 2010). These defects can be associated with 
significant impact on quality of life, both socially and functionally. Care for children with 
these defects can also be very costly. For example, up to $697 million is spent per year 
for therapy related to cleft lip and/or cleft palate alone in the United States. Better 
strategies are needed to limit the incidence of craniofacial birth defects.  
 Craniofacial defects typically arise very early in development between the second 
and fifth weeks of gestation in humans, often before pregnancy is even recognized. In the 
middle of the third week of development in humans (Larsen et al., 2001), and about 
embryonic day 7.5 (E7.5) in mice (Aoto et al., 2009; Lipinski et al., 2010), the prechordal 
plate forms anterior to the notochord of the neurulating embryo. This structure is 
responsible for helping pattern the midline of the developing head and brain, one of the 
most important signaling molecules for this being Sonic hedgehog (SHH) (Dale et al., 
1997; Aoto et al., 2009). 
Holoprosencephaly (HPE) originates from a failure of proper midline division in 
the forebrain and midline facial development during early embryogenesis. HPE is 
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among the most common disorders of early development, and is seen in up to 1 in 250 
conceptuses, and 1 in 10,000 live births (Matsunaga and Shiota, 1977; Muenke and 
Beachy, 2000). HPE exhibits a range of phenotypes of varying severity with some 
individuals severely affected and others only minimally affected, with “microforms”, if at 
all (Roessler et al., 1996; Ming and Muenke, 2002; Hehr et al., 2004).  
In the beginning of the fourth week the neural tube begins to close. During this 
process neural crest cells (NCC) delaminate from the edges of the neural folds and 
migrate in streams to other points in the developing embryo. By the middle of the fourth 
week of development the branchial arches begin to form (Larsen et al., 2001). Branchial 
arch 1 (BA1) is an embryonic structure that will give rise to much of the lower half of the 
face. BA1 is made up of contributions from all three germ layers and, significantly a 
major portion of the mesenchyme of the branchial arches is NCC-derived. In BA1 the 
NCC come specifically from the caudal half of the midbrain and the first two 
rhombomeres of the hindbrain (Kontges and Lumsden, 1996) 
Defects of BA1 can result in poor growth or absence of the jaw. When 
accompanied by ventral displacement of the ears, this is called otocephaly. Otocephaly 
can be seen in conjunction with HPE in very severe cases (Pauli et al., 1983; Tovitto and 
Rodriguez, 2007; Gekas et al., 2010; Chaoui et al., 2011). The most extreme form of 
otocephaly is aprosopia, non-formation of the face (Tovitto and Rodriguez, 2007). 
Bone morphogenetic proteins (BMPs) are key signaling molecules during facial 
development. BMPs are involved in NCC formation, craniofacial skeleton 
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morphogenesis and palatal development (Nie et al., 2006) and cooperate with signals like 
SHH and Fibroblast Growth Factors (FGFs) to pattern the developing structures of the 
head.  
Action of TWSG1, interaction with BMPs 
 Twisted gastrulation (Tsg, called TWSG1 in mammals) is a secreted BMP 
binding glycoprotein (Mason et al., 1994; Vilmos et al., 2001). TWSG1 acts through 
regulation of BMP signaling and has been proposed to have both agonistic (Mason et al., 
1994; Oelgeschlager et al.; Oelgeschlager et al., 2003; Little and Mullins, 2004; Xie and 
Fisher, 2005) and antagonistic (Chang et al., 2001; Ross et al., 2001; Scott et al., 2001; 
Blitz et al., 2003; Gazzerro et al., 2005; Wills et al., 2006) actions on BMP signaling 
depending on the developmental context. Tsg was first discovered based on its impact on 
dorsal-ventral patterning in the early Drosophila embryo (Zusman and Wieschaus, 1985). 
The dorsal midline of the Drosophila embryo is patterned by a gradient of 
decapentaplegic (Dpp) (homologous with vertebrate BMPs 2 and 4) with peak signaling 
in the region that becomes an embryonic structure called the amnioserosa (Podos and 
Ferguson, 1999; Dale, 2000; Shimmi and O'Connor; Shimmi et al., 2005; O'Connor et al., 
2006). Mutation of tsg was found to block the formation of the amnioserosa (Mason et 
al., 1994; Mason et al., 1997). This suggested that Tsg might help promote Dpp/BMP 
signaling. Set against this, a later study found that Tsg could potentiate the action of a 
Dpp inhibitor, Sog (homologous with vertebrate Chordin, CHRD) and that loss of 
function of this inhibitor had a similar phenotype to that of loss of Tsg (Yu et al., 2000). 
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This inhibitory role of TWSG, especially in cooperation with CHRD, was further 
characterized in vertebrate studies (Chang et al., 2001; Ross et al., 2001; Scott et al., 
2001). The seeming paradox of TWSG1 being an inhibitor of BMPs while sometimes 
promoting BMP signaling was partially resolved by two hypotheses 1) that TWSG1 
might facilitate transport of BMP ligands to sites of peak action as part of a morphogen 
gradient (Harland, 2001; Shimmi and O'Connor, 2003; Shimmi et al., 2005; O'Connor et 
al., 2006; Sawala et al., 2012) and 2) that while TWSG1 can form a BMP-inhibitory 
complex with CHRD, it can also facilitate cleavage of CHRD by the protease 
BMP1/Tolloid (Larrain et al., 2001; Oelgeschlager et al.; Xie and Fisher, 2005). 
Although TWSG1 may have pro-BMP activities in some contexts, evidence from 
mammalian cell culture systems, both in cell lines and in primary cultures (Graf et al., 
2002; Gazzerro et al., 2005; Petryk et al., 2005; Schmidl et al., 2006; Sotillo Rodriguez et 
al., 2009; Tanno et al., 2009), supports the idea of TWSG1 as primarily an inhibitor of 
BMP signaling. 
Mouse models of TWSG1 deficiency 
 Several mouse models of TWSG1 deficiency have been developed to investigate 
the role of TWSG1 in mammalian development and in adult tissues. Exon 2 of the gene, 
which contains the initial ATG-start of protein translation, has been deleted in two 
different models, and replaced either with a simple neomycin resistance (neoR) cassette 
(Nosaka et al., 2003) or with a LacZ-neoR transgene (Zakin and De Robertis, 2004). 
Another model has disruption of the Twsg1 gene at exons 2 and 3 with a LacZ-neoR 
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insertion (Gazzerro et al., 2006). Our lab has developed a model of TWSG1 deficiency 
by LoxP-flanking and deleting the fourth exon of the Twsg1 gene (Petryk et al., 2004).  
 These models showed some common phenotypes in mixed or non-BL/6 
backgrounds including small size and vertebral and skeletal defects (Canalis et al., 2003; 
Nosaka et al., 2003; Petryk et al., 2004; Zakin and De Robertis, 2004). The osteopenia 
(Nosaka et al., 2003; Zakin and De Robertis, 2004) observed in Twsg1-/- mice has been 
shown to result from overactive osteoclasts secondary to excess BMP signaling (Sotillo 
Rodriguez et al., 2009).  
 In the C57BL/6 background, Twsg1-/- mice exhibited a range of striking 
craniofacial malformations (Petryk et al., 2004). These mutations included midline facial 
and forebrain defects characteristic of HPE as well as jaw defects ranging from 
micrognathia to agnathia, consistent with otocephaly. Pups affected with severe midline 
defects also showed agnathia, similar to the agnathia-holoprosencephaly complex (Pauli 
et al., 1983). The most severely affected pups had anterior truncation (aprosopia) and 
showed no development of anterior facial structures. Our lab has also observed cleft lip 
and palate in Twsg1-/- mice (cf. infra, Chapter 4). The craniofacial defects in Twsg1-/- 
mice showed incomplete penetrance with only 44% of homozygous mice showing 
craniofacial abnormalities. These mice also showed variable expressivity with a range of 
phenotypes being observed. The variation of phenotypes was visible as early as E9.5 
where embryos were observed to have midline defects and mandibular arch defects of 
differing severity (MacKenzie et al., 2009). The similarity of the phenotypes seen in 
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Twsg1
-/- mice to those seen in mice deficient for the BMP inhibitors CHRD and Noggin 
(NOG) (Anderson et al., 2002) suggests that TWSG1 acts as a BMP antagonist in 
promoting forebrain development. 
 TWSG1 deficiency was associated with reductions in Shh expression in the rostral 
ventral neural midline at embryonic day E9.5 (Petryk et al., 2004). Malformed Twsg1-/- 
embryos showed loss of expression of Msx1 and eHand (Hand1), ventrally shifted and 
reduced expression of Bmp4 and Msx2, and ectopic expansion of Fgf8 and Barx1 across 
the midline of a fused BA1. On a cellular level, premature BA1 fusion was associated 
with massively increased apoptosis (MacKenzie et al., 2009), consistent with the idea that 
ectopic and increased apoptosis is a potential mechanism of birth defects (Sulik et al., 
1988). Mice deficient for CHRD and NOG show similar increases in BA1 apoptosis 
indicating that ectopic BMP signaling can drive this increase in cell death (Stottmann et 
al., 2001). 
Single gene inheritance with multifactorial determination of phenotype 
as a conceptual framework for understanding the craniofacial defects of 
Twsg1
-/- 
mice  
 The variable expressivity and incomplete penetrance seen in craniofacial 
abnormalities such as defects of BA1, those in the HPE spectrum, or in orofacial clefting, 
suggests that these disorders are the result of multiple factors working together to 
generate the phenotype (Fraser, 1970; Murray, 2002; Dixon et al., 2011). In classical 
Mendelian genetics, inheritance is determined allelically, while in multifactorial 
inheritance the manifestation of a phenotype is due to complex interactions of genetic and 
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environmental factors. A given genetic defect may predispose an individual or family to 
certain birth defects, but the occurrence of the full effect of that predisposition is 
dependent on the combined action of genes at other loci and environmental factors (Nora, 
1968; Nussbaum et al., 2007). The hypothesis of complex or multifactorial etiology 
rather than simple single gene inheritance has a long history in craniofacial defects 
including all of the major craniofacial defects seen in the Twsg1 mutant mouse.  
 HPE presents an excellent example of a disease which can have multifactorial 
inheritance leading to variable penetrance and expressivity. Underlying this multifactorial 
inheritance is a wide range of genetic and environmental causes for HPE (Roessler and 
Muenke, 1999; Muenke and Beachy, 2000; Muenke and Cohen, 2000; Cohen and Shiota, 
2002). For example, even when a family has a genetic defect known to be highly 
predisposing for HPE, phenotypes range from apparently unaffected or minimally 
affected, all the way to profoundly affected (Roessler et al., 1996; Hehr et al., 2004). The 
vast range of causes associated with HPE that could act together as contributing factors, 
combined with the range of phenotypes seen, has led to a multiple hit hypothesis for the 
etiology of HPE (Ming and Muenke, 2002). 
 Otocephaly is much rarer than HPE or clefting in humans but, based on evidence 
from animal models dating as far back as the 1920s (Utkus et al., 2001) has also been 
proposed as having a multifactorial etiology, in at least some cases. Significantly, in three 
different mouse models for otocephaly, the Twsg1-/- mouse (Petryk et al., 2004), the  
Otx2
-/- mouse (Matsuo et al., 1995) and the Pgap1-/- mouse (Juriloff et al., 1985), the 
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C57BL/6 strain is an important permissive factor for otocephalic defects, with other 
inbred mouse strains being largely resistant. This strain dependence immediately suggests 
the action of other genetic loci, fixed in the strain, in exacerbating the molecular triggers 
leading to defects in each of these mice. Some of the other modifying loci in the BL/6 
strain have begun to be characterized for the Otx2 mouse (Hide et al., 2002). The action 
of other genes as modifiers of the phenotypes for each of these genes supports a multiple 
hit hypothesis for the mechanism of otocephalic defects in mice.  
 Taken together, these lines of evidence relating to the different types of defects 
seen in Twsg1 deficient mice suggest a model where the defects in these mice are 
multifactorial in origin, with mutation of Twsg1 predisposing to defects while other 
genetic and environmental factors act on that predisposition. The predisposition is based 
on a single gene (as in Mendelian inheritance) while the realization of the phenotype is 
subject to modification by other genetic and environmental factors (as in multifactorial 
inheritance). This interaction of a genetic lesion with other factors, in combination with 
the wide range of severity and phenotypes affecting nearly every aspect of craniofacial 
development make the Twsg1 deficient mouse an invaluable model. The model's inherent 
susceptibility to defects allows it to provide information not only about the molecular 
underpinnings of how craniofacial defects are actually realized, but also about the genetic 
and environmental factors that contribute to the prevention or actualization of those 
defects.  
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Objective, rationale, summary  
 The objective of this thesis project has been to uncover the molecular mechanisms 
underlying the phenotypes associated with Twsg1 mutation, and to identify contributing 
factors for and ways to ameliorate these phenotypes.  
 The rationale of these lines of investigation in the Twsg1 deficient mouse lies in 
the potential to develop preventive therapeutic interventions for craniofacial defects. If 
the factors which drive a predisposition towards an actual defect can be uncovered and 
eliminated, or conversely, if protective factors can be identified this will suggest 
preventive interventions to limit the incidence or severity of craniofacial defects.   
 This thesis examines some of the molecular consequences and modifying factors 
of Twsg1 mutation. It begins in the second chapter with the impact of mutation on the 
interaction between TWSG1 and BMPs and uncovers a role for protein glycosylation in 
that interaction. Next, in chapter 3, it explores the patterns of gene transcription changes 
underlying different BA1 phenotypes in Twsg1-/- animals. Drawing on these data it 
demonstrates a genetic strategy for reducing defects. Chapter 4, examines the  modifying 
effects of diet and parity as they impact the incidence and types of craniofacial defects of 
the Twsg1-/- mouse. Finally, the last chapter describes the generation and initial 
characterization of a transgenic mouse with increased Twsg1 expression to be used as a 
model in future studies. The thesis is organized around the pursuit of the following 
specific aims:  
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Specific Aims: 
Aim 1: Investigate the role of Twsg1 exon 4 in the interaction with BMP. 
Aim 2: Characterize the transcriptional changes in BA1 and the underlying molecular and 
cellular alterations associated with variable Twsg1-/- phenotypes.  
Aim 3: Investigate the role of maternal diet and maternal parity in modifying the 
frequency of Twsg1-/- phenotypes. 
Aim 4: Develop a conditional mouse model of Twsg1 overexpression.  
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Chapter 2: Glycosylation of Twisted gastrulation is required 
for BMP binding and activity during craniofacial development. 
Introduction 
 Twisted gastrulation (TWSG1 in mammals, Tsg in non-mammals) is one of 
several key regulators of bone morphogenetic proteins, including BMP2, BMP4, and 
BMP7, in the extracellular space (Chang et al., 2001; Ross et al., 2001; Scott et al., 2001; 
Blitz et al., 2003; Zakin et al., 2005). TWSG1 is highly evolutionarily conserved and 
mutations in Drosophila, Xenopus, and Danio rerio Tsg disrupt normal dorsal-ventral 
patterning (Mason et al., 1994; Oelgeschlager et al., 2000; Ross et al., 2001; Scott et al., 
2001). In mice, mutations in TWSG1 result in a range of craniofacial defects, including 
micrognathia and agnathia, due to abnormal development of the first branchial arch 
(mandibular arch), as well as cyclopia and other midline facial defects (Petryk et al., 
2004; Zakin and De Robertis, 2004; MacKenzie et al., 2009; Billington et al., 2011a). 
 The presumed biochemical basis of these craniofacial defects is impaired binding 
of TWSG1 to BMPs. Previous work in Xenopus has identified the importance of a set of 
conserved cysteines and a conserved tryptophan within the N-terminus of xTsg for 
binding (and inhibiting) BMPs. The C-terminus was shown to play a role in xTsg’s 
interaction with chordin and BMP-promoting activity (Oelgeschlager et al., 2000; 
Oelgeschlager et al., 2003), most likely through facilitation of Chordin (CHRD) cleavage 
(Larrain et al., 2001). Deletion of exon 4 (coding exon 3), which removes neither the 
cysteine-rich domain nor the C-terminus, produces similar craniofacial and skeletal 
phenotypes to those resulting from targeting the first and second coding exons 
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(exons 2 and 3) (Nosaka et al., 2003; Zakin and De Robertis, 2004; Gazzerro et al., 
2006), raising the possibility that exon 4 encodes a region of the TWSG1 protein with 
important biochemical properties.  
 That Tsg is a glycoprotein has been known since the early stages of 
characterization of this protein (Mason et al., 1994). Despite this history, little research 
has actually investigated the role of glycosylation in TWSG1 function. There are two 
common types of glycosylation, N- and O-linked. In N-linked glycosylation, sugar chains 
are linked to asparagine residues and are generally seen in an Asn-X-Ser/Thr triplet 
(where X is not proline) (Neuberger and Marshall, 1968; Gavel and von Heijne, 1990; 
Spiro, 2002). In O-glycosylation sugar modifications occur on serines or threonines 
(Spiro, 2002). In this report we demonstrate a role for exon 4-encoded sequences as the 
exclusive site of N-glycosylation of mTWSG1 and show that the glycosylation of 
mTWSG1 is critical for mediating BMP binding and activity of mTWSG1.  
Materials and Methods  
Animal care 
 Use and care of the mice in this study was approved by the University of 
Minnesota Institutional Animal Care and Use Committee. Wild type mice were in the 
C57BL/6 background.   
Protein sequence analysis 
 TWSG1 homolog protein sequences were downloaded from NCBI for Mus 
musculus, Rattus norvegicus, Homo sapiens, Bos taurus, Canis lupus familiaris, 
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Monodelphis domestica, Gallus gallus, and Xenopus laevis. Protein sequences were 
aligned using ClustalW in the MacVector (MacVector, Cary, NC) program. Protein 
phylogeny was calculated using MacVector’s phylogeny tool. Glycosylation sites were 
predicted in each protein using EnsemblGly (http://turing.cs.iastate.edu/EnsembleGly/) 
(Caragea et al., 2007) and confirmed using NetNGlyc 1.0 
(http://www.cbs.dtu.dk/services/NetNGlyc/). 
Plasmids 
 All plasmids for expression of mTWSG1 in HEK 293 cells were constructed in 
the C-terminal FLAG-tagged expression vector pCMVTag4c (Stratagene, Santa Clara 
CA). A full-length wild type Twsg1 ORF and a Twsg1 ORF lacking exon 4 were each 
cloned into this vector using EcoRI and XhoI to create pCMVTag-Twsg1WT and 
pCMVTag-Twsg1!ex4. Constructs with glycosylation site mutations (pCMVTag-
Twsg1N80Q, pCMVTag-Twsg1N146Q) were generated from the wild type construct using 
the QuickChange site directed mutagenesis kit (Stratagene) employing the following 
primers N80Q F: 5’-atgtgcaaccctcggcagtacagcgacaccccg, N80Q R: 5’-
cggggtgtcgctgtactgccgagggttgcacat, N146Q F: 5’-ccagctgcaccaccaacaggtgtctgttcccagc, 
N146Q R: 5’-gctgggaacagacacctgttggtggtgcagctgg). The double glycosylation site mutant 
was generated from the N80Q plasmid, adding the N146Q mutation to generate 
pCMVTag-Twsg1QQ. A glycosylation site at Asn51 was restored into mouse TWSG1 
using the primers P53S F: 5’-tggagaagggaactgcagctgctgtaaggagtgc and P53S R: 5’-
gcactccttacagcagctgcagttcccttctcca. Following mutation, plasmids were assessed by 
restriction digests to confirm mutation (RsaI for N80Q, AflIII for N146Q, PstI for 
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P53S) and sequenced to confirm no other changes had been introduced.  
For production of recombinant proteins in E. coli the cDNA mature parts of 
mTWSG1 and xTsg were cloned into the expression vector pET28b(+) (Novagen, 
Darmstadt) via the restriction sites NdeI and BamHI, resulting in proteins carrying an N-
terminal His6-Tag, which can be proteolytically removed using the protease thrombin. 
The expression construct for recombinant xTsg from insect cell expression was derived 
by cloning the mature part of xTsg into a modified version of the transfer vector pBAC-3 
(Novagen, Darmstadt) using the restriction sites BamHI and XhoI. The resulting construct 
for xTsg harbors a gp64 signal peptide for secretion into the medium and an N-terminal 
His6-Tag, which can be removed by thrombin proteolysis. The cDNAs encoding for 
mTWSG1 and xTsg were obtained from imaGenes (Berlin) and the correctness of all 
cloned cDNAs was verified by sequencing.  
Recombinant protein preparations 
 The E. coli strain BL21(DE3) was used for bacterial protein expression. 
Transformed cells were grown in shaking flasks in LB-Medium (Melford, Chelsworth) at 
37°C and 130rpm, selection of transformed cells was achieved using 30"g/ml kanamycin. 
Gene expression was induced at an optical density of OD600 = 0.6 by adding isopropyl-1-
thio-#-D-galactopyranoside (IPTG) to a final concentration of 1 mM and protein 
expression was continued for 4h and 37°C. Cells were harvested by centrifugation 
(6000xg, 15 min, 4°C) and the pellet was resuspended in TBSE buffer (10mM Tris-HCl 
pH 8.0, 150mM NaCl, 1mM EDTA). The recombinant proteins mTWSG1 and xTsg were 
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expressed in insoluble form as so-called inclusion bodies. To isolate the proteins, 10g 
bacterial cells were lysed on ice by sonication (Bandelin Sonopuls HD3200, 10min, 
150W). The suspension was centrifuged to harvest the insoluble protein fraction. 
Inclusion bodies were purified by mechanical washing and centrifugation using TBS 
buffer (10mM Tris-HCl pH 8.0, 150mM NaCl) with and without 1% Triton X-100. To 
extract the recombinant Tsg proteins the inclusion bodies were dissolved in 20 volumes 
(v/w) 100mM Na-Phosphate, 10mM Tris-HCl pH 8.0, 6M Guanidinium chloride (GuCl) 
and the mixture was stirred for 12h at 20°C. After centrifugation to remove insoluble 
impurities the supernatant was subjected to metal affinity chromatography (IMAC) using 
Ni2+-NTA resin (Amocol Bioprocedures Ltd., Teltow). Tsg protein was eluted employing 
a step gradient and 100mM Na-Phosphate, 10mM Tris pH 8.0, 6M GuCl, 300mM 
imidazole. Tsg-containing fractions were pooled, dialyzed against 50mM Tris-HCl pH 
8.0, 6M GuCl, 5mM EDTA and concentrated to a protein concentration of 5mg/ml. 
Refolding of Tsg was carried out by rapid dilution using the conditions reported for 
preparation of BMP2 from E. coli (Ruppert et al., 1996). The solution containing refolded 
Tsg was dialyzed against 50 volumes 20mM HEPES pH 8.0, 300mM NaCl and Tsg was 
purified first by an IMAC chromatography step under non-denaturing conditions. Tsg-
containing fractions were pooled and dialysed against 50 volumes 20mM HEPES pH 7.4, 
500mM NaCl. As a final purification step size exclusion chromatography was performed 
to separate monomeric Tsg protein from accompanying dimeric and oligomeric species 
(Superdex 75 16/60 prep grade, GE Healthcare, Freiburg). 
   
16 
 Recombinant xTsg protein from a eukaryotic source was generated by transient 
expression in baculovirus-transfected insect cells. The virus was prepared by co-
transfection of the transfer vector pBAC3 containing the mature part of xTsg along with 
linearized virus DNA, using the BacVector-3000 DNA Kit (Merck KGaA, Darmstadt) 
into Sf9 insect cells according to the manufacturer`s instructions. Recombinant virus was 
identified and picked by a plaque-assay and protein expression was tested from six clones 
during virus amplification. A high-expression virus clone was then amplified in Sf21 
insect cells to a titer of $ 107 - 108 pfu/ml. 
 For protein production, HighFive insect cells (BTI-TN-5B1-4, gift of R. Grabherr, 
VIBT, Vienna, Austria) were used, which were grown as adherent cell cultures in IPL-41 
medium supplemented with 1% Penicillin/Streptomycin (LONZA, Köln) and 1% Lipid 
Medium Supplement (Sigma-Aldrich, München) at 27°C. For large-scale expression 
HighFive cells were transferred to RollerBottles (Greiner Bio-One, Frickenhausen) and 
adapted to suspension culture. 8x105 cells/ml were infected with recombinant baculovirus 
at a multiplicity of infection of 5 and protein expression was continued for additional 4-5 
days. The cell suspension was clarified by centrifugation (6,000g, 20min, 4°C) and the 
protein-containing supernatant was dialyzed against 20mM Tris-HCl pH 7.9, 500mM 
NaCl, 20mM imidazole for IMAC purification. Pure xTsg was eluted in a step gradient 
using 20mM Tris-HCl pH 7.9, 500mM NaCl, 300mM imidazole. Tsg-containing 
fractions were pooled, dialyzed twice against 50 volumes 20mM HEPES pH 7.4, 500mM 
NaCl and frozen at -20°C until further use.  
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Cell culture, protein isolation and deglycosylation 
 HEK293 cells were cultured in Dulbecco’s minimum essential media 
supplemented with 10% fetal bovine serum and 1% 100X Anti-Anti antibiotic-
antimycotic (GIBCO, Carlsbad, CA). Cells were transfected using Lipofectamine with 
PLUS reagent (Invitrogen, Carlsbad, CA) in media without serum or antibiotics and lysed 
to isolate proteins after 16 hours. Proteins from transfected cells were isolated in lysis 
buffer (50mM Tris-HCl, 125mM NaCl, 1% NP-40 Substitute (BioChemika #74385), and 
0.5% sodium deoxycholate) with the addition of Complete protease inhibitor (Roche, 
Indianapolis, IN). Lysates were spun for 10 minutes at 10,000g to pellet cell debris. 
Supernatant fractions were analyzed using SDS-PAGE with and without deglycosylation. 
Transfection product proteins, insect cell xTsg, and E. coli mTWSG1 and  were 
deglycosylated using PNGase F (New England Biolabs (NEB), Ipswich, MA) according 
to manufacturer’s instructions. Recombinant mouse TWSG1 from murine myeloma cells 
(R&D systems, Minneapolis, MN) was deglycosylated using PNGaseF or protein 
deglycosylation mix (NEB) according to manufacturer’s instructions. Blots of FLAG 
tagged proteins were probed with 1:1000 Rabbit Anti-DYKDDDDK in 0.1% casein/PBS 
(Cell Signaling, Danvers MA). Untagged recombinant proteins were visualized using a 
rabbit antibody custom generated (Open Biosystems, Thermo Fisher Scientific) against 
the peptide EGDTQLNWNIVSFPVAEE (mTWSG1 aa.108-125) at 1:250 in 0.1% 
casein/PBS. All blots were pre-blocked in 0.1% casein/PBS. 
Immunoprecipitation 
 HEK293 cells were transfected with FLAG-tagged WT, QQ or !ex4 
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constructs while one plate was left untransfected. Cells were lysed after 16 hours in 250ul 
of 140mM NaCl, 0.4 mM TrisHCl pH 8.0, 1% Glycerol, 1% NP40 Substitute, 2% BSA 
with protease inhibitor cocktail. Lysates were spun at 10000g for 10 minutes and 
supernatant  was combined with EZview anti-FLAG M2 affinity beads (Sigma, St. Louis 
MO) as well as 100 ng recombinant BMP2 (R&D). IP beads, BMP ligand and lysate 
were allowed to interact for 6 hours at 4˚C in a rotary shaker. IP beads were washed four 
times in 280mM NaCl, 0.4 mM TrisHCl pH 8.0, 1% Glycerol, 1% NP40 Substitute. 
Samples were eluted by boiling 5 min in sample loading buffer (62.5 mM Tris-HCl 
pH6.8, 2% SDS, 10% glycerol 0.002% bromophenol blue) and analyzed by SDS PAGE 
immunoblotting. Duplicate blots of immunoprecipiated samples were probed with Rabbit 
Anti-DYKDDDDK (Cell Signaling) (1:5000) or with anti-BMP2 (R&D) (1:5000). Blots 
were blocked in 5% BSA and primary antibodies were probed in 5% dry milk. 
Surface plasmon resonance analysis 
 In vitro interaction analysis employing Surface Plasmon resonance (SPR) was 
performed using a ProteON XPR36 system (Biorad Laboratories Inc., Technion, Haifa, 
Israel). Recombinant BMP2 derived from E. coli expression was immobilized onto a 
ProteOn GLC-chip (Biorad Laboratories Inc., Technion, Haifa, Israel) via amino 
coupling. The alginate polymer surface was first activated with a freshly prepared 
mixture of 100mM 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride 
(EDC) and 25mM N-hydroxysulfosuccinimide (Sulfo-NHS). Then recombinant human 
BMP2 was immobilized on flow cells 1 and 2 by perfusing a solution of 200nM BMP2 in 
10mM sodium acetate pH 4.0 over the activated alginate surface until protein 
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densities of 100-200 (low density coating) and 400-500RU (medium density coating) on 
the biosensor surface were obtained. Non-glycosylated xTsg and mTsg from E. coli as 
well as glycosylated xTsg from insect cells were perfused as analytes over the biosensor 
surface. Six different analyte concentrations were used in a one-shot kinetic measurement 
setup. All measurements were performed at 25°C in HBST buffer (10mM HEPES pH 
7.4, 500mM NaCl, 0.005% Tween20, Sigma) using a flow rate of 100"l/min. The 
association phase was set to 240s, the dissociation phase was measured for 660s. The 
BMP2 biosensor surface was regenerated using a short pulse 30s of perfusion with 10mM 
glycine pH 1.5. The correct function of the BMP2 biosensor was tested using perfusion 
with the BMP type I receptor BMPRIA and the values obtained were compared to 
reported binding affinities in the literature (Heinecke et al., 2009).  
To account for bulk face effects a control flow cell (without BMP2 coating) was 
subtracted from all measurement flow cells. Interaction data were evaluated using the 
software ProteON Manager 2.1.2 Version 2.1.2.05. Apparent equilibrium binding 
constants KD were derived from the kinetic rate constants for association ka and 
dissociation kd by the equation KD=kd/ka. All measurements were performed in duplicate. 
Mandibular explants 
 Embryos were collected at embryonic day 10.5 (E10.5). Organ culture of 
mandibular processes was performed according to previously reported protocols (Jaskoll 
et al., 2005; Melnick et al., 2005). Briefly, the mandibular component of the first 
branchial arch was isolated by microdissection and explanted into a culture system using 
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serum-free chemically defined BGJb medium supplemented with 0.1 mg/ml ascorbic acid 
(Sigma) and 1% penicillin/streptomycin (Cellgro, Manassa VA). Explants were allowed 
to develop at 37°C and 5% CO2 for 1 hour before bead placement. Beads were soaked in 
either 1% BSA/PBS, 100ng/"l BMP4 (R&D systems), 50 ng/"l mTWSG1 (R&D 
Systems), 50 ng/"l xTsg derived from insect cell expression or 50 ng/"l mTWSG1 
produced by bacterial expression in E. coli and placed in the distal region of the explant 
with microforceps. Explants were cultured for additional 24 hours following bead 
placement. In situ hybridization for Msx2 was performed as previously published 
(MacKenzie et al., 1992; Sasaki and Hogan, 1993)  
Results 
Twisted gastrulation proteins have evolutionarily conserved glycosylation sites, 
mapping in rodents to exon 4  
Analysis of the mouse TWSG1 protein sequence using the EnsemblGly software 
predicts two putative N-linked glycosylation sites, at asparagines Asn80 and Asn146. No 
O–linked glycosylation sites were predicted (Caragea et al., 2007). Other vertebrate 
TWSG1/Tsg protein sequences were also analyzed. All other tetrapods also have the two 
putative glycosylation sites corresponding to those predicted in mice (Figure 1) A third 
putative glycosylation site at Asn51 is widely conserved in other organisms (Vilmos et 
al., 2001; Oelgeschlager et al., 2004) and has been shown in Xenopus to be an active site 
of in vivo glycosylation (Oelgeschlager et al., 2003). This site is not present in either 
mice or rats, where a consensus serine is substituted by proline, altering the N-X-S/T 
glycosylation sequon. Given that this site is widely conserved throughout other 
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tetrapods, we infer that a mutation specifically in the rodent lineage lead to a loss of this 
site. Interestingly, phylogenetic analysis of the protein sequences for these selected 
tetrapods recapitulated the expected species phylogeny with the rodents grouping 
together, the marsupial as an outgroup to the other mammals and avian and amphibian 
representatives on a more distant branch. 
 
 
Figure 1: Twisted gastrulation is a conserved glycoprotein with predicted conserved and non-
conserved glycosylation sites.  
The splicing map of the mouse cDNA sequence is shown at the top. The 4th exon, deleted in a 
mouse knockout with craniofacial defects (Petryk et al., 2004), is indicated by a dashed line.  
A general mapping of the known functional regions of  TWSG is indicated below the spliced 
message. The signal peptide cleaved in the mature protein is indicated in pink. In green is the cysteine-
rich domain thought to be important for BMP binding (Oelgeschlager et. al., 2000). Mutations studied 
in Xenopus experiment which ablated binding with BMP or association with Chordin are indicated in 
orange or light blue respectively (Oelgeschlager et. al., 2003). An N-terminal fragment necessary and 
sufficient for BMP binding is indicated below the general diagram, with the break between N and C 
termini indicated with black arrowheads (Oelgeschlager et. al. 2000). 
ClustalW aligned proteins from various tetrapods are shown to highlight the high degree of 
conservation of the Twisted gastrulation protein and to show the locations of conserved and non-
conserved glycosylation sites. A protein phylogenetic tree is shown at left, which also correlates with 
species phylogeny. The N-glycosylation sequons are indicated in context below with brackets at the 
bottom indicating the N-X-S sequons, while arrows in yellow or blue at the top indicate the asparagines 
to which sugars can be linked.  
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Most notably, both predicted glycosylation sites in mouse TWSG1 (Asn80 and Asn146) 
are in the region encoded by exon 4, suggesting that deletion of this exon in rodents 
would completely ablate the glycosylation of any truncated protein product.  
Mutational analysis confirms putative glycosylation sites  
 Our analysis of mTWSG1 sequences suggested that mTWSG1 is exclusively N-
glycosylated. We tested this by first deglycosylating the protein using a cocktail of 
endoglycosidases that is able to remove both N- and O-linked glycosylation from 
recombinant mTWSG1 (data not shown). We also deglycosylated the protein using 
PNGaseF, which specifically removes N-glycosylation directly at the asparagine-
carbohydrate linkage, and observed an equivalent increase in electrophoretic mobility 
(Figure 2A). This indicated that, as predicted, mTWSG1 is solely N-glycosylated.  
 Although two N-glycosylation sites are predicted in mTWSG1, they have not 
been previously confirmed experimentally. The only mutational analysis performed to 
confirm a glycosylation site on a Tsg molecule had been done in xTsg at the site not 
conserved in rodents. Therefore, we mutated each of the putative rodent glycosylation 
sites, replacing asparagine with glutamine as had been done on other glycoproteins 
(Barbosa et al., 1987; Yamaguchi et al., 1991; Buller et al., 1994), reasoning that this 
would prevent glycosylation without disrupting the overall protein structure (Figure 2).  
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 As expected, expression of an exon 4 deletion mutant construct (TWSG1!ex4) 
showed no change in protein mobility with PNGaseF treatment, indicating the expected 
lack of glycosylation (Figure 2B). Mutating either Asn80 or Asn146 alone to glutamine 
increased electrophoretic mobility compared to the wild type protein (Figure 2C,D). 
Notably, whereas the wild type protein runs on SDS PAGE as a doublet of roughly 27 
and 30 kD, the mutant forms no longer show the 30 kD band and instead run as doublets 
of ~25 and 27kD. These single mutant proteins showed further increased mobility, to a 
Figure 2: Twisted gastrulation in rodents is N-glycosylated at 2 residues, both in exon 4. 
(Top) Locations of mutations that remove or add glycosylation at conserved sites are 
shown with reference to the sequences in rodents and other tetrapods. (A) Wild type mTWSG1 is 
glycosylated and runs on SDS PAGE as a doublet of about 27 kD and 30 kD. (B) Exon 4-deleted 
mTWSG1 is not glycosylated. (C) The N80Q mutation removes one glycosylation site but is still 
glycosylated. (D) The N146Q mutation removes one glycosylation site but is still glycosylated. 
(E) When the N80Q and N146Q mutations are combined the resulting QQ-TWSG1 is not 
glycosylated. (F) Mutation of a proline in mTWSG1 to the consensus serine restores a third 
glycosylation site.  
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single band at ~25kD, the molecular weight predicted for the unmodified amino acid 
sequence, when treated with PNGaseF, suggesting that they were still glycosylated, 
although to a lesser degree than the wild type protein. When both mutations were 
combined, no change in mobility with PNGase treatment was observed and a single band 
was observed at ~25 kD, indicating a complete lack of glycosylation in the double mutant 
(Figure 2E).  
 Based on data for xTsg in which glycosylation at Asn52 has been shown to occur 
(Oelgeschlager et al., 2003), we hypothesized that if the consensus serine at position 53 
were restored in rodent TWSG1, Asn51 of mTWSG1 would also be a glycosylation site. 
As predicted, when Pro53 was mutated in the mouse sequence to serine, a decrease in 
electrophoretic mobility was observed, and a triplet of bands appeared on SDS-PAGE 
analysis at 27, 30 and 33 kD (Figure 2F). The glycosylability of this restored site strongly 
suggests that other tetrapods, including humans, have three active glycosylation sites on 
TWSG1.  
 The observation that the number of bands in SDS PAGE analysis roughly 
correlates with the number of glycosylation sites suggests that, at least in this in vitro 
system, there can be an equilibrium between fully and partially or non-glycosylated 
forms of the protein.  
Lack of glycosylation limits BMP binding  
 Since TWSG1’s primary known function is to modulate BMP activity in the 
extracellular space, we tested if glycosylation affected the binding of TWSG1 to 
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BMPs. We also wanted to confirm that the exon 4 deletion, presumed to be defective for 
BMP binding, actually did prevent binding of TWSG1 to BMPs.  
 Immunoprecipitation of BMP2 by the wild type TWSG1, but not by the !ex4 
mutant protein nor the QQ double glycosylation mutant, indicates that neither of these 
mutant proteins is able to bind BMP2 (Figure 3A). Immunoprecipitation experiments 
were also performed using BMP4 protein and showed similar results (Figure 3B) 
 
Glycosylation of TWSG1 recombinant proteins varies markedly by cellular source  
 Cells derived from different species have variable abilities to glycosylate proteins. 
For example, in gram-negative bacteria glycosylation is an extremely rare event, with E. 
coli only having two glycoproteins, AIDA-I and the TibA adhesin, both of which are 
potential virulence factors (Lindenthal and Elsinghorst, 1999; Benz and Schmidt, 
Figure 3: Immunoprecipitation indicates that glycosylation and exon 4 are necessary for BMP 
binding. 
Immunoprecipitation (IP) was performed with anti-FLAG and immunoblots (IB) were 
probed with either anti BMP2 (top) or anti FLAG (bottom); (A) BMP2 immunoprecipitates with wild 
type but not glycosylation defective TWSG1QQ or exon 4 deleted TWSG1!ex4. (B) BMP4 
immunoprecipitates with wild type but not glycosylation defective exon 4 deleted TWSG1!ex4. Or 
TWSG1QQ  
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2001). To allow for the heterologous expression of O- or N-glycosylated proteins from 
bacteria, a very complex setup is required using either coexpression of certain UDP-
GlcNac epimerase and transferase enzymes (Henderson et al., 2011) or the transfer of the 
glycosylation machinery of another bacterium, i.e. from the !-proteobacterium 
Campylobacter jejuni into E. coli (Wacker et al., 2002). Thus mammalian glycoproteins 
are usually obtained in unglycosylated form when expressed in E. coli. On the other 
hand, insect cells are able to glycosylate these proteins although they may do so with 
slightly different sugar moieties and generally reduced saccharide chain complexity 
(Jarvis et al., 1998; Tomiya et al., 2004). Here N-glycosylation usually displays a high-
mannose type unless engineered insect cells are used, which can mimic mammalian-type 
glysosylation. Following a common approach for investigating the role of sugar 
modifications on proteins (Walsh and Jefferis, 2006), we exploited this naturally 
occurring variation in glycosylation modification to test the biochemical and biological 
properties of mTWSG1.  
 We expressed TWSG1/Tsg in E. coli, which do not glycosylate the protein, as 
well as in HighFive insect cells, which should glycosylate the protein, and also used a 
commercially available preparation of mTWSG1 produced in murine myeloma cells for 
comparison. When we treated TWSG1/Tsg proteins with PNGaseF and analyzed them by 
electrophoresis, we were able to confirm differences in glycosylation (Figure 4). Murine 
TWSG1 made in murine cells was fully glycosylated. Xenopus Tsg made in the HighFive 
insect cell line was also N-glycosylated, although this glycosylation may differ in the 
kinds or size of sugar moieties compared to mammalian glycosylation, since the shift 
   
27 
in electrophoretic mobility was less than the apparent mobility shift observed upon 
deglycosylation of mTWSG1 from murine cells. Murine TWSG1 made in E. coli was not 
glycosylated and hence showed no change in mobility with PNGaseF treatment.  
 
 
Lack of glycosylation decreases the affinity of the BMP-TWSG1 interaction  
Our immunoprecipitation data suggest that TWSG1 can bind BMP2/4 only when 
glycosylated. However, Surface Plasmon Resonance (SPR) analysis allows for a more 
precise quantification of this change in affinity. To measure the affinity of the Tsg 
proteins for BMP2, the ligand BMP2 was immobilized on a biosensor chip surface by 
amino coupling. Varying concentrations of xTsg or mTWSG1 proteins made in insect 
cells or E. coli, respectively, were allowed to perfuse over the BMP2 biosensor surface 
and association and dissociation kinetics were measured (Figure 5). Quantitative analysis 
Figure 4: TWSG1 glycosylation varies depending on host source. 
 mTWSG1 made in murine myeloma cells is markedly glycosylated as indicated 
by the increase in mobility with PNGaseF treatment. Xenopus Tsg made in insect cells is 
also glycosylated but shows a smaller mobility shift. Murine TWSG1 made in E. coli is 
not glycosylated and shows no shift in mobility after treatment with PNGaseF. 
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of the sensorgram reveals that glycosylated xTsg has a 3-4 fold slower dissociation rate 
compared to non-glycosylated xTsg derived from E. coli (Table 1, Figure 5A,B) and also 
a 3-fold faster association. The change in association and dissociation kinetics results in 
an approximately 10-fold increased affinity of N-glycosylated xTsg compared to the non-
glycosylated form for BMP2. The difference in affinity and binding kinetics becomes 
most apparent by a overlay of two SPR sensorgrams of insect cell derived xTsg and E. 
coli derived xTsg at identical protein concentrations (Figure 5C).  
Ligand kon [M
-1s-1] koff [s
-1] KD [nM] 
xTsg 
from insect cells 
11±0.8x104 2.0±0.5x10-4 2.5 
xTsg 
from E. coli 
3.8±1x104 7.1±0.5x10-4 20.2 
mTWSG 
from E. coli 
4.4±0.3x104 
(10.7±3x104)a 
7.6±1.3x10-4 
(2.0±0.3x10-2) 
39.6 
(301) 
 
Despite large efforts mTWSG1 could not be obtained from insect cell expression, 
however mTWSG1 could be produced in sufficient quantities in E. coli using the same 
expression and purification scheme as used for the production of xTsg. Measuring the 
interaction of BMP2 and mTWSG1 from E. coli via SPR revealed also a fast dissociation 
rate constant. In contrast to the interaction of xTsg and BMP2 the binding of mTWSG1 to 
Table 1: Tsg affinity for BMP2 varies depending on host source. 
avalues in parenthesis denote low affinity interaction of the biphasic interaction between 
mTWSG1and BMP2 
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BMP2 exhibited a biphasic binding kinetics, which could not be analyzed by a simple 1:1 
Langmuir type interaction model (Figure 5D). Instead one interaction showed a fast 
association (on-rate) and a fast dissociation (off-rate) whereas the other interaction 
exhibited a slow on- and a slow off-rate. From the latter kinetics binding parameters 
could be deduced that were very similar to the ones determined for xTsg derived from E. 
coli (Table 1). Although we have no explanation why mTWSG1 shows two different 
binding kinetics for binding to BMP2 the comparison of mTWSG1 and xTsg produced in 
E. coli clearly suggests that the presence of the carbohydrate leads to a significant 
increase in binding affinity for BMP2. 
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Figure 5: Surface Plasmon Resonance (SPR) interaction analysis of BMP2 binding to 
recombinant Tsg proteins derived from different sources. 
Binding of recombinant Tsg proteins to a BMP2 biosensor was analyzed using SPR. BMP2 was 
immobilized on a GLC chip via amino coupling. Indicated concentrations of Tsg proteins were perfused 
over the biosensor surface, injection started at time point 0 with a duration of 240s (association phase) 
after which only buffer was again perfused for 660s to record the dissociation of Tsg from BMP2. 
(A,B). The BMP2 biosensor was perfused with varying concentrations of (A) xTsg derived from 
expression in insect cells or (B) xTsg produced in E. coli. (C) The different dissociation rate constants 
between xTsg protein derived from either a eukaryotic or a prokaryotic host is apparent from an overlay 
of two normalized SPR sensorgrams recorded for the interaction of different xTsg proteins (500nM 
concentration) with BMP2. (D) The interaction of mTWSG1 derived from E. coli expression reveals a 
biphasic interaction with BMP2. The binding kinetics following a slow association and a slow 
dissociation yields an equilibrium binding constant very similar to that of xTsg produced in bacteria. 
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TWSG1 proteins have different biological activity depending on expression system 
and glycosylation 
To demonstrate the biological effect of glycosylation loss, we chose a mandibular 
explant system, which has been used previously to examine the activity of BMPs and 
BMP binding proteins (Ekanayake and Hall, 1997; Tucker et al., 1998; Mina et al., 2002). 
Expression of the gene Msx2 was used as a reporter to assay of the effect of TWSG1/Tsg 
on BMP signaling in these explants.  
As previously shown (Semba et al., 2000), treatment with BMP4 strongly induced 
Msx2 expression (Figure 6A). When a bead soaked with glycosylated mTWSG1 
(expressed in murine cells) was placed in the Msx2 expression zone the TWSG1 was able 
to suppress Msx2 expression indicating local inhibition of BMP signaling (Figure 6B) 
Glycosylated xTsg from insect cells was similarly able to suppress Msx2 expression, 
indicating the competency of N-glycosylated protein from a different species and a 
heterologous expression system to inhibit BMP signaling (Figure 6C). On the other hand, 
mTWSG1 derived from E. coli expression, which is not glycosylated, showed no 
repression of Msx2, suggesting that it is unable to inhibit BMP signaling (Figure 6D). 
Thus, glycosylation appears to be essential for TWSG1’s BMP binding and BMP 
inhibitory functions in this tissue assay.  
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Discussion 
  Although mTWSG1 protein has been presumed to be glycosylated since its initial 
characterization, the role of glycosylation in mTWSG1 activity has not been studied in 
much detail. We report here, for the first time, that TWSG1 binding to BMPs is 
dependent on N-glycosylation. We also show that reduced BMP binding correlates with 
diminished TWSG1 BMP inhibitory activity.  
Our data complement those previously published (Oelgeschlager et al., 2003) in 
which mutation of a glycosylation site in xTsg led to a stronger biological effect than that 
of the wild type protein. When serine 54 of xTsg (corresponding to proline 53 in mice) 
Figure 6: TWSG1 biological activity varies depending on host source. 
Mandibular explants were treated with beads soaked in ligand solutions for 24 hours. In situ 
hybridization was performed to examine the expression of Msx2. Bead placements are indicated with 
dashed white lines where less visible due to dark Msx2 staining. Bead treatments were: (A) BMP4, 
showing induction of Msx2, (B) mTWSG, expressed in murine myeloma cells, showing suppression of 
Msx2 and indicating inhibition of BMP signaling, (C) Xenopus TSG derived from insect cell 
expression, with the same result, and (D) mTWSG1 expressed in E. coli, which shows no effect on 
Msx2 expression, indicating a lack of impact on BMP signaling. 
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was mutated to alanine, the electrophoretic mobility of the protein was increased. In 
addition, this S54A mutant showed enhanced ventralizing activity compared to wild type 
xTsg, which the authors attributed to increased diffusability of the protein in the tissue. 
Based on our results, it is also possible that BMP binding may have been compromised 
by reduced glycosylation. We predict that this would limit BMP binding but may not 
interfere with the ability of Tsg to stimulate CHRD cleavage. This model is consistent 
with other results reported by Oelgeschlager et. al. (2003), in which they showed that N-
terminal mutations of xTsg that were unable to bind BMPs still retained BMP promoting 
activity via the C terminus of the protein, that resulted in enhanced ventralization. These 
explanations are not mutually exclusive and diffusability differences of variable TWSG1 
glycoforms could represent an exciting new line of investigation. 
Our findings raise the possibility that TWSG1’s BMP modulatory activity may be 
dependent on, or regulated by, glycosylation and highlight the importance of sugar 
modifications in extracellular signaling interactions. Given that several other extracellular 
BMP modulating proteins are also predicted glycoproteins, for example CHRD 
(Gumienny and Padgett, 2002), CV2/BMPER (Kamimura et al., 2004), Noggin (Groppe 
et al., 2002), and the DAN family of BMP binding proteins (Stanley et al., 1998; Avsian-
Kretchmer and Hsueh, 2004), glycosylation may play a wider role in extracellular BMP 
regulation than presently recognized. The role of glycosylation in interactions of other 
proteins will have to be verified however. For example, Xenopus Lefty, which plays a 
role in Nodal signaling analogous to the role of TWSG1 in BMP signaling, is also a 
glycoprotein but does not require glycosylation for normal function (Westmoreland 
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et al., 2007). In addition to the BMP binding proteins, glycosylation of the ligand itself is 
also likely to play a role in regulation of extracellular signaling as illustrated by the 
absolute requirement of N-glycosylation for the specific interaction of BMP6 with its 
BMP type I receptor Alk2 (Saremba et al., 2008). Likewise, given the important role of 
the metalloproteinase Tolloid/Xolloid/BMP1 in regulating BMP action in combination 
with TWSG/Tsg and CHRD (Larrain et al., 2001), it is interesting that glycosylation has 
been identified as regulating the activity of the metalloproteinase MT1-MMP (Wu et al., 
2004) and even more interesting that glycosylation has been identified as a regulator of 
BMP1 secretion and stability (Garrigue-Antar et al., 2002) 
TWSG1 made in cells of various species may have differential glycosylation or 
complete lack of glycosylation. Given the correlation reported here between protein 
source, glycosylation, BMP binding activity and biological activity, we suggest that 
experiments using recombinant BMP modulating proteins should carefully consider the 
source and glycosylation status of these proteins. It is also interesting to speculate 
whether glycosylation of TWSG1 or other proteins may be regulated at a tissue specific 
level, allowing fine-tuning of protein activity in various contexts.  
The exon 4 deletion mutant, which led us to this line of inquiry, is deficient for 
normal TWSG1 activity and a lack of glycosylation may contribute to this deficiency and 
the ensuing craniofacial phenotypes. In the mandibular explant system, application of 
exogenous glycosylated mTWSG1 resulted in a reduction of Msx2 expression, consistent 
with TWSG1’s role as a BMP antagonist. The interactions between TWSG1 and BMPs in 
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vivo, however, are more complex. Functional TWSG1 serves to establish a BMP 
signaling gradient in the developing mandibular arch. Deletion of exon 4 disrupts the 
interactions between TWSG1 and BMPs, which, in affected embryos, results in loss of 
the BMP gradient, more diffuse BMP signaling, and ectopic apoptosis (MacKenzie et al., 
2009). Correspondingly, the expression of the BMP target gene Msx2 is shifted ventrally 
at E9.5 and then mostly lost by E10.5 (MacKenzie et al., 2009; Billington et al., 2011a). 
We believe that loss of expression of Msx2 as well as other BMP target genes by E10.5 is 
due to the loss of a proper BMP gradient and the resultant apoptosis of the distal tissues 
of the mandibular arch. While TWSG1 antagonizes BMP signaling within the mandibular 
arch in the explant culture system, we suggest that in vivo the BMP limiting action of 
TWSG1 can act to actually maintain proper BMP signaling levels in mandibular 
development and that this action is dependent on glycosylation of TWSG1. 
 Our results highlight the importance of a better understanding of both the various 
signaling molecules in craniofacial development as well as their potential post-
translational modifications. The complex extracellular regulation of BMPs has been 
compared to a baroque “court of intrigue” (Bier, 2008) based on all the surprising and 
nuanced interactions of the many players in BMP signaling. Our study adds to this 
complexity by highlighting the role of post-translational modifications. 
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Chapter 3: The molecular and cellular basis of variable 
craniofacial phenotypes and their genetic rescue in Twisted 
gastrulation mutant mice  
 
Introduction  
 Phenotypic variation is a well-known phenomenon in a number of developmental 
abnormalities. For example, patients with Treacher-Collins syndrome or 
holoprosencephaly (HPE) have an extremely wide range of clinical manifestations 
(Hansen et al., 1996; Roessler et al., 1996; Muenke and Cohen, 2000). In HPE, the most 
severe defects, such as cyclopia, are usually incompatible with life, while others 
including hypotelorism or microphthalmia represent milder forms (Ming et al., 2002). 
However, the molecular basis for such reduced penetrance and variable severity, even in 
the context of the same mutations on the same genetic background, has remained unclear.  
 Differences in genetic background and environmental influences are thought to be 
two major drivers of transcriptional variation, leading to phenotypic variation or reduced 
penetrance in both humans and mice (Champy et al., 2008; Butchbach et al., 2009). The 
contribution of epigenetic phenonema, including DNA methylation and histone 
modification, has also been increasingly recognized to be an important mechanism 
underlying variability in genetic expressivity, particularly in the case of imprinted genes 
(Peaston and Whitelaw, 2006; Dindot et al., 2009). For example, craniofacial 
manifestations of the Silver-Russell syndrome correlate with the degree of methylation at 
the H19-(Insulin-like Growth Factor) IGF2 locus (Bruce et al., 2009). This underscores 
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the importance of a better understanding of the basis of phenotypic variation of 
craniofacial malformations and identification of mammalian models that would facilitate 
such insights. An advantage in using inbred mouse models to study such phenotypic 
variation is that both strain differences and environmental differences can be controlled. 
 We previously reported that disruption of Twisted gastrulation (Twsg1), a 
modulator of BMP signaling, in mice leads to a spectrum of craniofacial defects on an 
isogenic, inbred C57BL/6 background (Petryk et al., 2004; MacKenzie et al., 2009). 
Within a single litter, some mice are born with normal craniofacial structures; some have 
mild defects, such as micrognathia and microphthalmia; and still others have profound 
craniofacial abnormalities including anterior truncation, cyclopia, agnathia, and HPE. 
While some of this variation could be attributed to a variable extent of apoptosis and thus 
variable loss of first branchial arch 1 (BA1) derivatives (MacKenzie et al., 2009), the 
underlying molecular mechanisms are not entirely understood. Manifestation of 
craniofacial defects is highly strain background-dependent and appears in about 40% of 
Twsg1
-/- mice on the C57BL/6 background. In early generations after derivation of the 
mutant allele on the C57BL/6 background, some as yet undiscovered modifier gene/s 
could partially account for the observed variation. However, this variation has persisted 
despite serial backcrossing of the mutant alleles onto the isogenic strain background. The 
ongoing occurrence of extreme differences in phenotypes, even within the same litter, 
raises the question of how phenotypic variation might occur despite virtually no 
differences in inherited genes. The Twsg1 mutant mouse model provides an excellent, 
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well-controlled experimental system in which to study the molecular mechanisms 
underlying the resulting phenotypic variation and reduced penetrance.  
In this study, we have analyzed transcriptional changes that are associated with 
development of distinct classes of craniofacial phenotypes in Twsg1 mutant mice. We 
anticipated that these differentially expressed transcripts would include previously 
unknown effectors of the mutant phenotype as well as genes that may compensate for the 
loss of TWSG1 and account for incomplete penetrance of Twsg1 mutation. In particular, 
we were interested in identifying transcriptional differences between unaffected and 
affected mutants that would shed light on potential mechanisms that allow an organism to 
cope with a predisposition to disease.  
Materials and Methods 
Mice and tissue collection  
 Generation and genotyping of mice deficient for TWSG1 (Petryk et al., 2004), 
p53 (Donehower et al., 1992) as well as transgenic Sox10-cre mice that express Cre 
recombinase in neural crest cells (NCC) (Matsuoka et al., 2005) have been previously 
reported. To generate mice with NCC-specific deletion of Twsg1 (Twsg1flox/flox;Sox10-
cre), mice carrying a conditional allele of Twsg1, with exon 4 (coding exon 3) flanked by 
loxP sites (Twsg1flox/flox, MGI: Twsg1tm1Aptr), were mated to Sox10-cre mice (MGI: 
Tg(Sox10-cre)1Wdr) to generate Twsg1flox/WT; Sox10-cre, which were then mated to 
Twsg1
flox/flox mice. Mice simultaneously deficient for both p53 and TWSG1 were 
produced by intercrossing Twsg1-/- (MGI: Twsg1tm1.1Mboc) and p53-/- mice (MGI: 
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Trp53
tm1Brd). All strains were on C57BL/6 background. Presence of a spermatic plug was 
counted as day 0.5 post conception (E0.5). Twsg1-/- embryos were classified as previously 
published as class A (phenotypically the same as wild type), class B (moderately 
affected), and class C (severely affected) (MacKenzie et al., 2009). For microarray 
analysis, mandibular prominences of BA1s from mutants of various phenotypic classes 
and WT embryos at E10.5 were dissected by cutting the BA1 at the junction between the 
maxillary and mandibular components using alkali etched tungsten needles. BA1s were 
flash-frozen in liquid nitrogen and stored at -80˚C. Both maxillary and mandibular 
prominences were dissected at E11.5 to confirm deletion of exon 4 of Twsg1 in NCC-
derived tissues. This embryonic stage was chosen to allow the analysis of individual 
samples in case of variable efficiency of Cre-mediated recombination. Use and care of 
the mice in this study was approved by the University of Minnesota Institutional Animal 
Care and Use Committee. 
RNA isolation  
 Frozen tissue samples were thawed in Trizol reagent (Invitrogen, Carlsbad, CA) 
and pooled according to the phenotypic class. RNA was purified using RNeasy micro kit 
spin columns (Qiagen, Valencia, CA). Five biological replicates of each mutant class and 
of WT (each representing a pool of 4-7 arches) were analyzed to achieve adequate 
statistical power for this microarray analysis (Pavlidis et al., 2003). Pooling was 
necessary to allow collection of sufficient RNA for microarray analysis (Bobola et al., 
2003; Feng et al., 2009).  
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Microarray analysis 
 Microarray analysis was performed at the Kimmel Cancer Center Cancer 
Genomics Core Facility, Thomas Jefferson University (Philadelphia, PA). Total RNA (50 
ng) was used to prepare amplified cDNA using the WT-Ovation Pico RNA amplification 
system (NuGen Technologies, Inc., San Carlos, CA). Sense transcript cDNA (ST-cDNA) 
was generated from 3 "g of amplified cDNA. Finally, 5.0 µg ST-cDNAs were labeled 
using FL-Ovation cDNA biotin module v2 (NuGen Technologies, Inc.) (Linton et al., 
2009). Affymetrix GeneChip mouse exon 1.0 ST arrays (Affymetrix, Santa Clara, CA) 
were used following manufacturer's recommendations. Samples were hybridized 
overnight, scanned and processed using Command Console Software. Background 
correction and normalization were done using Robust Multichip Average (RMA) with 
Genespring v10.0 software (Agilent, Palo Alto, CA, USA). 
Bioinformatics analysis  
 mRNA expression profile data were condensed using RMA to generate raw 
expression values log base 2. Two group T-tests were used to assess significance in 
pairwise comparisons between groups with correction for a false discovery rate (FDR) of 
10% or less (Benjamini and Hochberg, 1995). For inclusion in WT vs. C and A vs. C 
analyses, genes were also required to have an absolute value of fold change $1.5. 
Heatmaps were generated using Cluster3.0 and JavaTreeview. Expression profiles were 
clustered in both supervised and unsupervised methods to identify molecular patterns 
present in the data. Ingenuity Pathways Analysis (IPA; Ingenuity" Systems, 
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www.ingenuity.com) was used to identify biological functions regulated by differentially 
expressed genes.  
Quantitative PCR  
 Reverse transcription was carried out with the Thermoscript RT kit (Invitrogen) 
priming with random hexamers, followed by quantitative PCR (Q-PCR, MX3000p, 
Agilent, LaJolla, CA) using expression assays from Applied Biosystems (Foster City, 
CA) for Bambi (Mm03024088_g1), Bmp4 (Mm00432087_m1), Bmpr1b 
(Mm03023971_m1), Cyp26a1 (Mm00514486_m1), Dkk1 (Mm00438422_m1), Gpr50 
(Mm00439147_m1), Peg3 (Mm00493299_s1), Plagl1 (Mm00494250_m1), Satb2 
(Mm00507337_m) or using published primer sequences with SYBR green RT2 master 
mix (SABiosciences, Valencia, CA) for Dlk1, Igf2 (Varrault et al., 2006), and Msx2 
(Berdal et al., 2009). To detect Twsg1, the following primers were used (forward: 5’-
CTGAACTGGAACATCGTCTC-3’, reverse: 5’-GCAGTCATCAAAGTAAACCAC-
3’). Trp53inp1 was detected with primers from the MGH primer bank (Spandidos et al., 
2010) (PrimerBank ID 11230806a1; forward: 5’-AAGTGGTCCCAGAATGGAAGC-3’, 
reverse: 5’ –GGCGAAAACTCTTGGGTTGT-3’). All samples were normalized to 
expression of Gapdh (forward: 5’-TGCACCACCAACTGCTTAG-3’, reverse: 5’-
GATGCAGGGATGATGTTC-R for SYBR green assays; Applied Biosystems 4352339E 
for TaqMan assays). Assays were run in triplicate using N$3 pooled cDNA samples per 
probe.  
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In situ hybridization 
 In situ hybridization was performed by standard methods (Sasaki and Hogan, 
1993). cDNA probe fragments for Plagl1 (Tsuda et al., 2004), Peg3 (Kuroiwa et al., 
1996) and Satb2 (FitzPatrick et al., 2003) were amplified from a cDNA library obtained 
from E10.5 embryos and cloned into the pCRII-TOPO vector (Invitrogen). A probe for 
Dkk1 was a gift from Dr. William Shawlot (Finley et al., 2003). Msx2 probe was 
previously published (MacKenzie et al., 1992). Clones were transcribed to generate 
digoxigenin labeled probes using a DIG RNA labeling kit (Roche). At least 2-3 embryos 
were evaluated in each phenotypic class per probe. 
Western blotting 
 E10.5 embryos were isolated from pregnant females set up in timed matings, in 
ice-cold Tris buffered saline with EDTA (50 mM TrisHCl pH7.4, 150mM NaCl, 1mM 
EDTA). Embryos were homogenized in lysis buffer (Tris buffered saline with 1% 
TritonX-100), centrifuged for 10 min at 10,000 g at 4˚C, and supernatants were 
electrophoresed in a 10% polyacrylamide gel using the NextGel system (Amresco, Solon, 
OH). Proteins were transferred to ImmobilonFL PVDF membranes (Millipore, Billerica, 
MA) and probed with an anti p53 mouse monoclonal antibody at 1:1000 (clone 1C12, 
#2524, CellSignaling, Beverly, MA). The immunoblot was imaged with HRP conjugated 
anti mouse IgG secondary at 1:2500 (Promega, Madison, WI) and peroxide/luminol 
chemiluminescence with the SuperSignal West Pico kit (Pierce/Thermofisher, Rockford, 
IL). For loading control, blots were re-probed with mouse monoclonal anti-GAPDH 
(AM4300, Ambion, Foster City, CA) and imaged with goat anti-mouse secondary 
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conjugated to IR800 fluorophore on the LICOR Odyssey system (Lincoln, NE). Three 
samples per phenotypic class were analyzed. 
Statistical analyses 
 Student’s t-tests and Pearson’s correlations of Q-PCR data were performed in 
Prism 4 (GraphPad Software, LaJolla, CA). Significance was set at p<0.05. The 
incidence of Mendelian ratios and normal vs. abnormal phenotype incidence for 
Twsg1;p53 mice were compared using Chi-squared analyses and Chi-squared goodness 
of fit tests.  
Results  
Transcriptional changes correlate with classes of phenotypic severity  
 We previously classified Twsg1-/- embryos based on the severity of the phenotype 
into three classes at E9.5 (MacKenzie et al., 2009). Similarly, at E10.5, class A 
(unaffected) mutant embryos are morphologically indistinguishable from normal, wild 
type (WT) embryos, while class B embryos exhibit partial midline fusion of the 
mandibular components of BA1, and class C embryos have severe midline fusion (Figure 
7A). To determine if these phenotypic classes are associated with differences between 
their transcriptomes, we used mouse exon microarrays to analyze total RNAs isolated 
from BA1 samples at E10.5. Differences in gene expression between the classes 
increased with increasing phenotypic severity, and thus were greatest in the most severely 
affected (class C) embryos (Figure 7B).  
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Hierarchical clustering analysis was performed on the transcript expression 
profiles of a set of 127 genes exhibiting the greatest differences in expression between 
any two pools (Figure 7C). This analysis clearly distinguished class C phenotypic 
samples from WT and class A samples. In fact, the clustering algorithm placed class A 
embryos just as distantly from WT as class C from WT, implying that gene expression 
differences in class A embryos, albeit not as pronounced as in class C, may be sufficient 
to compensate for the Twsg1-/- genetic predisposition. Class B samples, representing an 
intermediate phenotype, clustered with either class A or class C. These results 
demonstrate that the variable morphological features of individual embryos with the same 
genetic mutations in Twsg1 on the same genetic background are associated strongly with 
distinct transcriptional profiles.  
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Figure 7: Association between phenotypic classes and expression differences 
(A) Morphological differences between phenotypic classes of E10.5 embryos are displayed. Dotted lines outline the mandibular components of 
BA1. (B): Gene expression levels are expressed on a log10 scale (y-axis) vs. an average of WT samples (Y=1) for a given gene. Each vertical line 
represents a biological replicate from given phenotypic classes (WT, A, B, or C). Genes that are differentially expressed between WT and class C, 
based on a fold change of 1.5 fold or greater and a false discovery rate of 10% or less, are highlighted (red). Compared with WT gene expression 
levels, variation is greatest in the most severely affected embryos (class C).  (C) Unsupervised hierarchical clustering of array data. Class C 
samples are clearly separated from WT and class A samples. Class B represents an intermediate phenotype, clustering alternatively with either A 
or C. The log2 scale of the expression values is shown in the key at the bottom.  
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 Figure 8: Gene expression differences between wild type and severely affected mutants. 
(A) A heatmap displays gene expression changes compared to the average of WT. Genes with expression changes >1.5 fold and with a false 
discovery rate of <10% are presented as rows. Each column represents a biological replicate. (B-G) Q-PCR confirmation; !genes confirmed by 
in situ hybridization in Fig. 4; *significance in comparison with WT. (H) Scatter plot showing close correlation between microarray data and Q-
PCR data  for genes in panels B-G (blue) and independent RNA samples (green) for Gpr50, Bmp4 and Bmpr1b. 
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Table 2: Genes showing significant change between WT and C or between A and C phenotypic classes.  
Name Description Affy-ID 
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Angpt1 angiopoietin 1 6835353 x     0.748 0.0065 0.68 0.0018 0.627 0.0009     
Bambi 
BMP and activin membrane-bound 
inhibitor homolog (Xenopus laevis) 6858465 x     0.828 0.0505 0.756 0.0158 0.605 0.0002     
Bmp5 bone morphogenetic protein 5 6990569 x     0.667 0.0016 0.583 0.0017 0.56 0.0006     
Ccdc80 coiled-coil domain containing 80 6841160 x     0.795 0.0059 0.744 0.0040 0.59 0.0002     
Cd59a 
CD59a antigen or CD59b antigen 
(Cd59b) 6879646 x     0.531 0.0002 0.519 0.0002 0.544 0.0002     
Cox7a2l 
cytochrome c oxidase subunit VIIa 
polypeptide 2-like  or  predicted 
gene, EG629383 6804268 x     2.84 0.0000 2.79 0.0000 3.18 0.0000     
Cyp51 
cytochrome P450, family 51, 
subfamily A, polypeptide 1 6935927 x     0.865 0.0089 0.847 0.0260 0.661 0.0001     
Ddc 
dopa decarboxylase (aromatic L-
amino acid decarboxylase) 6786045 x     0.761 0.0071 0.696 0.0084 0.632 0.0005     
Enpp1 
ectonucleotide 
pyrophosphatase/phosphodiesterase 1 6772802 x     0.755 0.0052 0.709 0.0047 0.624 0.0002     
Fgf9 
fibroblast growth factor 9 (glia-
activating factor) 6819442 x     0.861 0.2950 0.857 0.1720 0.66 0.0008     
Hmgcr 
3-hydroxy-3-methylglutaryl-
Coenzyme A reductase 6815305 x     0.935 0.2750 0.922 0.2830 0.664 0.0002     
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Hmgcs1 
3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 1 (soluble) or 
LOC100040592, similar to Hmgcs1 
protein 7005797 x     0.907 0.0893 0.88 0.0657 0.648 0.0000     
Id1 
inhibitor of DNA binding 1, 
dominant negative helix-loop-helix 
protein 6882315 x     0.891 0.0293 0.882 0.1010 0.599 0.0006     
Id2 
inhibitor of DNA binding 2, 
dominant negative helix-loop-helix 
protein 6799462 x     0.922 0.0919 0.861 0.0191 0.615 0.0000     
Id3 
inhibitor of DNA binding 3, 
dominant negative helix-loop-helix 
protein 6917809 x     0.919 0.3810 0.815 0.0356 0.628 0.0008     
Itm2a integral membrane protein 2A 7018847 x     0.811 0.0984 0.798 0.0531 0.652 0.0007     
Krt14 keratin 14 6791408 x     0.751 0.0001 0.734 0.0139 0.596 0.0011     
Lgi2 
leucine-rich repeat LGI family, 
member 2 6938171 x     0.866 0.0060 0.817 0.0010 0.664 0.0002     
Lrig3 
leucine-rich repeats and 
immunoglobulin-like domains 3 6771476 x     1.09 0.0174 1.19 0.0100 1.52 0.0000     
Mid2 
midline 2 or eukaryotic translation 
initiation factor 2C, 2 (Eif2c2) 7014171 x     0.886 0.0297 0.772 0.0014 0.613 0.0000     
Nell2 NEL-like 2 (chicken) 6838171 x     0.743 0.4070 0.666 0.0017 0.513 0.0000     
Nr2f1 
nuclear receptor subfamily 2, group 
F, member 1 6814557 x     1.37 0.0147 1.4 0.0143 1.79 0.0001     
Pcdh7 protocadherin 7 6931001 x     0.753 0.4350 0.71 0.3480 0.562 0.0002     
Pitx2 paired-like homeodomain 2 6901280 x     0.836 0.0016 0.822 0.0083 0.639 0.0000     
Sc4mol sterol-C4-methyl oxidase-like 6982921 x     0.716 0.0004 0.724 0.0055 0.538 0.0000     
Sox2 
SRY (sex determining region Y)-box 
2 6896695 x     0.708 0.0008 0.699 0.0189 0.593 0.0016     
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A930038C
07Rik A930038C07Rik 6946750   x   
0.886
0 0.1030 0.6970 0.0328 
0.355
0 0.0000 
0.401
0 0.0000 
Alx1 ALX homeobox 1 6776603   x   0.87 0.4430 0.506 0.0204 0.238 0.0000 0.274 0.0000 
Asb4 
ankyrin repeat and SOCS box-
containing protein 4 6943873   x   1.13 0.0656 1.12 0.2120 0.541 0.0001 0.479 0.0000 
AW551984 AW551984 6994790   x   
0.880
0 0.4710 0.7360 0.1020 
0.523
0 0.0011 
0.594
0 0.0037 
Bmp4 bone morphogenetic protein 4 6824266   x   0.841 0.1590 0.676 0.0177 0.373 0.0000 0.443 0.0000 
Bmpr1b 
bone morphogenetic protein receptor, 
type 1B 6909941   x   1.01 0.8110 1.11 0.0693 1.59 0.0000 1.58 0.0000 
Cyp26a1 
cytochrome P450, family 26, 
subfamily a, polypeptide 1 6869522   x   0.929 0.4170 1.1 0.2800 1.68 0.0004 1.81 0.0000 
Dclk1 doublecortin-like kinase 1 6897599   x   1 0.9810 1.11 0.0423 1.64 0.0002 1.64 0.0001 
Dgkk diacylglycerol kinase kappa 7009748   x   1.06 0.6430 0.833 0.1090 0.484 0.0001 0.455 0.0001 
Dkk1 
dickkopf homolog 1 (Xenopus 
laevis) or predicted gene, EG546723 
or protein phosphatase 1, regulatory 
(inhibitor) subunit 2 (Ppp1r2) 6872615   x   0.914 0.0776 0.703 0.0136 0.456 0.0000 0.498 0.0000 
Dlk1 delta-like 1 homolog (Drosophila) 6797978   x   1.24 0.0286 0.996 0.9670 0.579 0.0006 0.468 0.0001 
Dok5 docking protein 5 6883533   x   0.776 0.0062 0.654 0.0101 0.349 0.0000 0.45 0.0000 
E130114P1
8Rik|D130
039L10Rik|
A130013F1
2Rik 
E130114P18Rik or D130039L10Rik 
or A130013F12Rik 6923584   x   
0.908
0 0.0959 0.9870 0.8430 
0.567
0 0.0008 
0.625
0 0.0016 
Ebf1 early B-cell factor 1 6780443   x   1.12 0.0703 1.32 0.0127 1.89 0.0000 1.68 0.0000 
Figf c-fos induced growth factor 7015007   x   1.08 0.1660 0.945 0.5930 0.418 0.0010 0.386 0.0004 
Gata3 GATA binding protein 3 6884642   x   0.96 0.3670 0.727 0.0223 0.508 0.0000 0.529 0.0000 
Gpr50 G-protein-coupled receptor 50 7011861   x   1.55 0.0007 1.25 0.1490 0.11 0.0000 
0.071
4 0.0000 
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Isl1 
ISL1 transcription factor, 
LIM/homeodomain 6816288   x   0.741 0.0059 0.481 0.0029 0.308 0.0000 0.416 0.0000 
Kazald1 
Kazal-type serine peptidase inhibitor 
domain 1 6869981   x   0.796 0.0161 0.668 0.0101 0.508 0.0000 0.638 0.0002 
Lrrc17 leucine rich repeat containing 17 6929132   x   0.928 0.4640 0.832 0.2240 0.478 0.0002 0.515 0.0005 
Lrrn1 
leucine rich repeat protein 1, 
neuronal 6948878   x   0.948 0.2760 1.03 0.6500 1.51 0.0008 1.6 0.0007 
Mme membrane metallo endopeptidase 6898010   x   0.867 0.2080 0.726 0.0205 0.569 0.0001 0.656 0.0017 
Mstn myostatin 6749461   x   0.995 0.9520 1.04 0.6960 1.57 0.0015 1.58 0.0004 
Msx2 
homeobox, msh-like 2 or 
LOC100046255, similar to 
homeobox protein 6813259   x   0.946 0.4250 0.781 0.0016 0.608 0.0000 0.643 0.0000 
Nr2f2 
nuclear receptor subfamily 2, group 
F, member 2 6968201   x   1.11 0.1270 1.3 0.0021 1.84 0.0000 1.66 0.0002 
Nsdhl 
NAD(P) dependent steroid 
dehydrogenase-like 7011907   x   0.934 0.4330 0.921 0.3470 0.603 0.0002 0.646 0.0011 
Peg3 paternally expressed 3 6972750   x   1.29 0.0016 1.14 0.0925 0.613 0.0000 0.476 0.0000 
Plagl1 pleiomorphic adenoma gene-like 1 6766046   x   1.07 0.3900 0.682 0.0274 0.452 0.0000 0.424 0.0000 
Pmp22 peripheral myelin protein 6781612   x   0.857 0.0712 0.625 0.0093 0.532 0.0000 0.621 0.0000 
Rasgef1b RasGEF domain family, member 1B 6940303   x   0.86 0.0594 0.686 0.0006 0.475 0.0000 0.553 0.0001 
Rgs5 regulator of G-protein signaling 5 6755055   x   0.598 0.0007 0.216 0.0028 
0.058
1 0.0000 
0.097
2 0.0000 
Satb2 
special AT-rich sequence binding 
protein 2 6758862   x   1.42 0.0016 0.928 0.6590 0.331 0.0000 0.233 0.0000 
Scd1 stearoyl-Coenzyme A desaturase 1 6873271   x   0.891 0.1400 0.783 0.0006 0.476 0.0000 0.535 0.0002 
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Sema3e 
sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted, (semaphorin) 3E or 
hypothetical protein LOC100044162 6928880   x   0.886 0.0112 1.08 0.2240 1.5 0.0010 1.7 0.0001 
Speer4a 
spermatogenesis associated 
glutamate (E)-rich protein 4a or 
spermatogenesis associated 
glutamate (E)-rich protein 4b 
(Speer4b) 6936791   x   0.931 0.5190 0.827 0.2270 0.438 0.0009 0.47 0.0006 
Stom stomatin 6886039   x   1.04 0.5280 0.967 0.7580 0.605 0.0002 0.584 0.0000 
Tbx3 T-box 3 6933913   x   1.22 0.0261 0.939 0.4410 0.557 0.0006 0.457 0.0000 
Zcchc5 
zinc finger, CCHC domain 
containing 5 7018819   x   0.911 0.3740 0.694 0.0074 0.584 0.0000 0.641 0.0018 
Zic4 
zinc finger protein of the cerebellum 
4 or RIKEN cDNA B130024G19 
gene (B130024G19Rik) 6961396   x   1.1 0.3260 1.21 0.0885 1.96 0.0002 1.79 0.0002 
2610017I0
9Rik|LOC1
00044386 2610017I09Rik or LOC100044386 6758223     x 
0.821
0 0.0946 1.0400 0.6850 
1.320
0 0.0127 
1.610
0 0.0010 
9330120H1
1Rik 9330120H11Rik 6968842     x 
0.823
0 0.1380 0.8290 0.2280 
1.360
0 0.0358 
1.650
0 0.0014 
A930001N
09Rik A930001N09Rik 6849466     x 
0.807
0 0.0102 0.8860 0.0697 
1.230
0 0.0065 
1.530
0 0.0000 
Acta2 actin, alpha 2, smooth muscle, aorta 6872765     x 0.827 0.0002 1.06 0.3320 1.43 0.0002 1.73 0.0000 
Capsl calcyphosine-like 6828663     x 0.631 0.0003 0.647 0.0008 1.03 0.6550 1.64 0.0000 
Cldn8 claudin 8 6847680     x 0.744 0.0035 0.839 0.1530 1.28 0.0125 1.72 0.0001 
Cobll1 Cobl-like 1 6887286     x 0.726 0.0086 0.885 0.1360 1.14 0.0962 1.57 0.0004 
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Dab1 disabled homolog 1 (Drosophila) 6915993     x 0.757 0.0275 0.84 0.1210 1.18 0.0206 1.56 0.0025 
Dhcr24 24-dehydrocholesterol reductase 6916089     x 1.18 0.2060 1.03 0.7750 0.753 0.0257 0.639 0.0003 
E330013P0
4Rik E330013P04Rik 6870841     x 
0.771
0 0.0164 0.9670 0.6610 
1.410
0 0.0045 
1.830
0 0.0003 
Elovl6 
ELOVL family member 6, 
elongation of long chain fatty acids 
(yeast) 6901316     x 1.14 0.0783 1.06 0.3200 0.746 0.0036 0.654 0.0003 
Enpp2 
ectonucleotide 
pyrophosphatase/phosphodiesterase 2 6835759     x 0.784 0.0039 1.01 0.9160 1.31 0.0206 1.67 0.0006 
Enpp3 
ectonucleotide 
pyrophosphatase/phosphodiesterase 3 6772810     x 0.86 0.0087 0.993 0.9140 1.4 0.0002 1.63 0.0000 
Epha4 Eph receptor A4 6759905     x 1.11 0.1360 1.09 0.3200 0.653 0.0029 0.59 0.0010 
Etv5 ets variant gene 5 6844558     x 1.17 0.2360 1.21 0.0863 0.631 0.0032 0.541 0.0007 
Evi1 ecotropic viral integration site 1 6903875     x 1.21 0.0101 1.16 0.0313 0.791 0.0039 0.655 0.0000 
Eya4 eyes absent 4 homolog (Drosophila) 6772736     x 1.19 0.1160 1.06 0.5730 0.687 0.0011 0.578 0.0003 
Fabp7 fatty acid binding protein 7, brain 6768075     x 0.58 0.0145 0.79 0.3350 1.21 0.3250 2.09 0.0009 
Foxf1a forkhead box F1a 6979570     x 1.08 0.4460 0.805 0.0277 0.697 0.0056 0.645 0.0006 
Frem1 
Fras1 related extracellular matrix 
protein 1 6922890     x 1.1 0.1260 1.02 0.7380 0.706 0.0000 0.643 0.0000 
Grik2 
glutamate receptor, ionotropic, 
kainate 2 (beta 2) 6773802     x 0.824 0.0569 1.02 0.8750 1.46 0.0032 1.77 0.0000 
Hgf hepatocyte growth factor 6928939     x 0.809 0.0079 0.866 0.0965 1.28 0.0122 1.58 0.0002 
Igf2 insulin-like growth factor 2 6972317     x 1.12 0.1280 0.916 0.2730 0.703 0.0006 0.628 0.0000 
   
5
3
 
Lce3b 
late cornified envelope 3B or late 
cornified envelope 3C (Lce3c) 6899456     x 1.68 0.0010 1.55 0.0111 0.962 0.7710 0.571 0.0002 
Leprel1 leprecan-like 1 6844806     x 1.06 0.5160 0.867 0.0496 0.7 0.0020 0.661 0.0037 
Lhx8 LIM homeobox protein 8 6910727     x 1.35 0.0006 1.25 0.0221 0.559 0.0166 0.413 0.0016 
Lix1 limb expression 1 homolog 6848947     x 1.02 0.7910 0.983 0.8390 0.632 0.0019 0.619 0.0023 
Lyz1 lysozyme 1 or lysozyme 2 6777310     x 0.729 0.0031 0.742 0.0083 1.09 0.4880 1.500 0.0058 
Meg3 maternally expressed 3 6797969     x 1.34 0.0048 1.14 0.1490 0.707 0.0003 0.528 0.0000 
Mgst1 
microsomal glutathione S-transferase 
1 6950582     x 0.746 0.0134 0.764 0.0345 1.16 0.1360 1.56 0.0015 
Olfml3 olfactomedin-like 3 6907784     x 1.17 0.0320 0.939 0.4970 0.687 0.0015 0.584 0.0000 
Olfr1505 
olfactory receptor 1505 or olfactory 
receptor 1502 (Olfr1502) 6868243     x 0.689 0.0027 0.87 0.2810 1.06 0.5840 1.54 0.0041 
Pcolce2 
procollagen C-endopeptidase 
enhancer 2 6991538     x 1.07 0.2230 0.88 0.0368 0.683 0.0006 0.639 0.0002 
Prrx2 paired related homeobox 2 6876081     x 1.08 0.2260 1.09 0.1970 0.687 0.0047 0.634 0.0007 
Ptch1 patched homolog 1 6813844     x 1.16 0.1010 0.853 0.1720 0.767 0.0245 0.663 0.0003 
Slc2a3 
solute carrier family 2 (facilitated 
glucose transporter), member 3 6957051     x 0.778 0.0423 0.97 0.8040 1.25 0.0375 1.61 0.0003 
Tbx22 T-box 22 7013222     x 1.29 0.1780 1.32 0.1130 0.479 0.0062 0.37 0.0011 
Tcfap2b transcription factor AP-2 beta 6747919     x 0.756 0.0152 0.99 0.9200 1.32 0.0175 1.75 0.0005 
Tdg thymine DNA glycosylase 6769343     x 0.754 0.0949 0.819 0.2140 1.23 0.1960 1.64 0.0034 
Trp53inp1 
transformation related protein 53 
inducible nuclear protein 1 6911679     x 0.823 0.0023 0.826 0.0083 1.25 0.0227 1.51 0.0004 
Unc5c unc-5 homolog C (C.elegans) 6901898     x 1.03 0.6020 0.931 0.3360 0.675 0.0001 0.658 0.0000 
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Table 3: Human and mouse craniofacial phenotypes associated with genes showing altered expression in Twsg1-/- mice.  
Relative expression 
Name W
T
v
C
 
o
n
ly
 
B
o
th
 
A
v
C
 o
n
ly
 
Associated human syndrome features 
(OMIM) 
Mouse knockout phenotype (MGI) 
A/WT B/WT C/WT C/A 
Alx1  X    
short mandible and maxilla, abnormal calvaria, 
facial clefting  
0.87 0.51a 0.24c 0.27c 
Bmp4  X  
Microphthalmia/anopthalmia (OMIM 
#607932), orofacial clefting (OMIM #600625) 
shortened frontal and nasal bones, agnathia  0.84 0.68 a 0.37 c 0.44 c 
Bmp5 X     
small ears, small skull, short nasal bone, short 
mandible, short maxilla, abnormal hyoid  
0.67b 0.58 b 0.56 c 0.84 
Bmpr1b  X    short snout 1.01 1.11 1.59 c 1.58 c 
Cyp26a1  X    
branchial arch hypoplasia, abnormal facial/head 
morphology, microcephaly 
0.93 1.1 1.68 c 1.81 c 
Dkk1  X    
absent mandible, maxilla, nasal bone, abnormal 
calvaria and BA1 morphology, microcephaly 
0.91 0.70 a 0.46 c 0.50 c 
Dlk1  X  Facial malformations (OMIM 176290)   1.24a 1.0 0.58 c 0.47 c 
Evi1   X   abnormal branchial arch morphology 1.21 a 1.16 a 0.79 c 0.66 c 
Eya4   X   abnormal palate morphology 1.19 1.06 a 0.69 c 0.58 c 
Gata3  X    abnormal craniofacial bone morphology 0.96 0.73 a 0.51 c 0.53 c 
Igf2   X 
Silver Russell Syndrome (OMIM #180860), 
micrognathia, cleft palate (Bruce et. al 2009) 
variable cleft palate with (maternal) uniparental 
disomy 7 
1.12 0.92 0.70 c 0.63 c 
Isl1  X    abnormal branchial arch morphology 0.74 b 0.48b 0.30 c 0.42 c 
Lhx8   X   cleft palate 1.35c 1.25* 0.56* 0.41 b 
Lrig3 X     abnormal craniofacial morphology, short snout 1.09 a 1.19 b 1.52 c 1.39 c 
Msx2  X  Craniosynostosis type 2 (OMIM #604757) 
abnormal craniofacial development, cleft palate, 
short snout, abnormal calvaria, teeth, middle ear 
ossicles  
0.95 0.78 b 0.61 c 0.64 c 
Pitx2 X   
Axenfeld-Rieger syndrome (OMIM #180500), 
eye abnormalities, dental and maxillary 
hypoplasia  
abnormal Meckel's cartilage, mandible, maxilla, 
teeth, cleft palate 
0.84 b 0.82 0.64 c 0.76 c 
Prrx2   X   
micrognathia, abnormal maxilla, Meckel's 
cartilage, middle ear ossicles, hyoid, ears, teeth, 
cleft palate 
1.08 1.09 0.69 c 0.63 c 
Ptch1   X Holoprosencephaly (OMIM #610828) 
Abnormal craniofacial morphology, abnormal 
mandible, BA1 
1.16 0.85 0.77 a 0.66 c 
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Satb2  X  Isolated cleft palate (OMIM #119540) 
micrognathia, premaxilla hypoplasia, abnormal 
nasal capsule, microcephaly, cleft palate, tooth 
abnormalities, short snout 
1.42 b 0.93 0.33 c 0.23 c 
Sema3e  X  
CHARGE syndrome (OMIM #214800), facial 
dysmorphism, external ear abnormalities 
  0.89 b 1.08 1.5 b 1.7 c 
Sox2 X   microphthalmia/anopthalmia  (OMIM 184429)  abnormal palate morphology 0.71 c 0.7 a 0.59 b 0.84 
Tbx22   X 
X-linked cleft palate (OMIM #303400) with 
or without ankyloglossia  
abnormal calvaria, cleft palate 1.29 1.32 0.48 b 0.37 b 
 
 
 
 
 
 
  
Alx1, ALX homeobox 1; Bmp4, bone morphogenetic protein 4; Bmp5, bone morphogenetic protein 5; Bmpr1b, bone morphogenetic protein receptor, type 1B; 
Cyp26a1, cytochrome P450, family 26, subfamily a, polypeptide 1; Dkk1, dickkopf homolog 1 (Xenopus laevis) or predicted gene, EG546723 or protein phosphatase 1, 
regulatory (inhibitor) subunit 2 (Ppp1r2); Dlk1, delta-like 1 homolog (Drosophila); Evi1, ecotropic viral integration site 1; Eye4, eyes absent 4 homolog (Drosophila); 
Gata3, GATA binding protein 3; Igf2, insulin-like growth factor 2; Isl1, ISL1 transcription factor, LIM/homeodomain; Lhx8, LIM homeobox protein 8; Lrig3, leucine-
rich repeats and immunoglobulin-like domains 3; Msx2, homeobox, msh-like 2 or LOC100046255, similar to homeobox protein; Pitx2, paired-like homeodomain 2; 
Prrx2, paired related homeobox 2; Ptch1, patched 
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Identification of molecular and cellular effectors of craniofacial phenotype in Twsg1 
mutants  
To study the association between phenotypic variability and differential gene 
expression in more detail, we first focused upon samples representing the most divergent 
morphological classes, i.e. WT vs. class C embryos. Microarray analysis identified 65 
genes (represented by 66 exon probe sets, including two sets for Rgs5) with significantly 
different, reproducible patterns of expression between these classes (Figure 8A and Table 
2). While most of these full-length transcripts (82%) are downregulated in class C 
embryos, 12 transcripts (18%) are increased. To validate results from microarrays, we 
performed Q-PCR on selected, differentially expressed transcripts. The results closely 
corroborated those from microarrays (r=0.9541, p<0.0001) (Figure 8 B-G). This high 
degree of reproducibility of the microarray data was confirmed further using 
independently isolated mRNAs, by re-measuring expression levels of G-protein-coupled 
receptor 50 (Gpr50), Bmp4, and BMP receptor, type 1B (Bmpr1b) by Q-PCR (Fig 8H). 
Again, a high concordance between microarray and Q-PCR results exists across the 
different phenotypic classes (r=0.9321, p=0.0003) (Figure 8H). 
Among those genes that are differentially expressed between WT and class C 
mutants, 15 are known to be associated with craniofacial defects in mice and/or humans 
(Table 3), as annotated by Mouse Genome Informatics (MGI) and Online Mendelian 
Inheritance in Man (OMIM). Several encode ligands (Bmp4, Bmp5), receptors (Bmpr1b) 
and downstream targets of BMP signaling (Msx2; Pitx2) (Schlange et al., 2002; Du and 
Yip, 2009), which is consistent with the known role of TWSG1 in modulating BMP 
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signaling (Ross et al., 2001). Beyond confirming an expected role for BMPs in Twsg1
-/- 
phenotypes, transcriptome analysis facilitated identification of additional candidate 
effectors of the craniofacial phenotype in Twsg1
-/- 
mice. For example, there is an inverse 
correlation between Dkk1 expression and increasing phenotypic severity. Other genes 
showing a similar pattern to Dkk1 include Alx1 (Zhao et al., 1996), Gata3 (Pandolfi et al., 
1995), Isl1 (Pfaff et al., 1996), or Pitx2 (Sclafani et al., 2006), each known to play 
various roles in BA1 development, palate and craniofacial bone morphology.  
The genes that are differentially expressed between class C and WT regulate a 
number of biological processes that are important for normal craniofacial morphogenesis 
(Table 4; top 12 molecular and cellular functions represented by at least 3 molecules are 
shown based on the p value), including apoptosis, which was identified previously as a 
key cellular process that is altered in Twsg1
-/-
 mice (MacKenzie et al., 2009). In addition, 
a significant number of differentially expressed genes have been linked by Ingenuity 
Pathway Analysis (IPA; Ingenuity! Systems, www.ingenuity.com) to “small molecule 
biochemistry” and “lipid metabolism,” highlighting the importance of cholesterol 
biosynthesis and metabolism of fatty acids and acyl-CoA in normal craniofacial 
development (Muenke and Beachy, 2000).  
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Table 4: Predicted biological processes underlying craniofacial phenotype in Twsg1-/- 
mice. 
Molecular and Cellular 
Functions  
Highest 
P-value 
List of molecules 
Cellular Movement  
Migration of neurons 
2.54E-
06 
 
ANGPT1, BMP4n, DCLK1n, EBF1n, FGF9, FIGF, 
GATA3n, HMGCR, ID1, ID2, ID3, ISL1, MME, MSX2, 
NR2F1n, NR2F2n, PITX2, PMP22, SATB2n, SEMA3E  
Cellular Development  
 
2.54E-
06 
 
ANGPT1, BMP4, BMPR1B, CYP26A1, DLK1, EBF1, 
ENPP1, FGF9, FIGF, GATA3, ID1, ID2, ID3, ISL1, 
MSTN, MSX2, NR2F1, PITX2, PMP22, SATB2, 
SOX2, TBX3, 
Cellular Function and 
Maintenance  
1.58E-
05 
 
BMP4, BMP5, BMPR1B, GATA3, ID1, ID2, NR2F1  
Cellular Growth and 
Proliferation  
1.58E-
05 
 
ANGPT1, BMP4, BMP5, BMPR1B, DLK1, FGF9, 
FIGF, GATA3, ID1, ID2, ID3, HMGCR, ISL1, MSTN, 
MSX2, PITX2, PMP22, PLAGL1, SOX2, TBX3  
Gene Expression  1.58E-
05 
 
ALX1, TBX3, ISL1, GATA3, PITX2, ID2, BMPR1B, 
PLAGL1, SATB2, MSX2, DCLK1, SOX2, NR2F1, 
ID3, EBF1, MSTN, ID1, NR2F2, BMP4 
Cell Cycle  1.5E-04 
 
ANGPT1, BMP4, BMPR1B, FGF9, FIGF, ID1, ID2, 
ID3, SOX2, PITX2, PLAGL1, TBX3 
Cell Signaling  
BMP signaling pathway 
6.6E-04 
 
ANGPT1, BMP4b, BMPR1Bb, DOK5, ID1b, MSX2b 
Cell-To-Cell Signaling 
and Interaction  
1.1E-03 
 
ANGPT1, BMP4, BMPR1B, FIGF, ID1, ID3, PCDH7  
Lipid Metabolism  2.5E-03 BMP4, CYP26A1, CYP51A1, DLK1, FGF9, HMGCR, 
NSDHL, SCD 
Small Molecule 
Biochemistry  
2.5E-03 
 
ANGPT1, CYP26A1, CYP51A1, DDC, DLK1, ENPP1, 
FGF9, GATA3, HMGCR, KRT14, NSDHL, SCD, 
BMP4  
Cell Death  3.49E-
03 
 
BMP4, BMPR1B, DLK1, ID1, ID2, ISL1, MME, MSX2  
Cell Morphology 6.81E-
03 
 
ANGPT1, BMP4, DCLK1, EMA3E, ENPP1, FIGF, 
GATA3, ID1, ID3, MSX2, NR2F1, PLAGL1, PMP22, 
SDLK1  
bmolecules involved in BMP signaling pathway, nmolecules involved in migration of neurons 
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To determine whether NCC are the cellular effectors of the craniofacial 
phenotype in Twsg1
-/-
 mice, we generated mice with NCC-specific deletion of Twsg1 
(Twsg1
flox/flox
;Sox10-cre). Sox10-cre mice express Cre recombinase in NCC, as early as a 
premigratory stage, and in NCC derivatives, specifically the pharyngeal region 
(Matsuoka et al., 2005; Muller et al., 2008). The phenotype of these mice recapitulated 
the phenotype of global deletion of Twsg1 (MacKenzie et al., 2009), but the effect was 
dependent on the efficiency of Cre-mediated deletion of exon 4 of Twsg1 (Figure 3). A 
reduction of Twsg1 level to less than 
0.2% of the wild type expression in 
BA1 at E11.5 resulted in embryonic 
craniofacial defects, including 
premature fusion of the mandibular 
components of BA1, midline fusion 
of the frontonasal prominences and 
non-septation of the telecephalic 
vesicles.  
Figure 9: The frequency of craniofacial defects in mice with neural crest cell-specific deletion of 
Twsg1. 
The frequency of craniofacial defects in mice with NCC-specific deletion of Twsg1. Twsg1flox/flox; 
Sox10-cre + embryos included both (A) normal appearing embryos (black arrowheads point to the 
maxillary components of BA1; white arrowhead to the mandibular component; n, nasal prominences; t, 
telencephalic vesicles) and (B) embryos with craniofacial abnormalities, including fusion of the 
mandibular arches, nasal processes, and telencephalic vesicles (B!) Dissection of the mandibular and 
maxillary components of BA1 highlights hypoplasia and midline fusion of the mandibular prominences 
that characterizes the severe Twsg1 phenotype. (C) Expression levels of Twsg1, measured using 
primers to exon 4 and 5 were compared between Twsg1flox/flox;Sox10-cre- and Twsg1flox/flox;Sox10-cre+ 
depending on the presence or absence of external craniofacial abnormalities. A reduction of Twsg1 
levels to less than 0.2% of the wild type expression in BA1 at E11.5 resulted in craniofacial defects. 
Both maxillary and mandibular prominences were collected. Q-PCR was performed using individual 
mRNA samples. Three embryos per genotype were analyzed. 
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Transcriptional changes between class A and class C mutants and their functional 
significance 
 Class A and class C embryos share the same genetic mutation in Twsg1 but differ 
in the absence or presence of craniofacial defects. Therefore we extended our analysis to 
genes that are differentially expressed between these classes of mutants, as they may 
provide new insights into mechanisms underlying variable disease expressivity. We 
identified 80 genes that were differentially expressed between affected and unaffected 
Twsg1
-/-
 embryos (Table 2), including 41 additional transcripts that were not identified in 
the WT vs class C comparison. The number of genes that showed opposite trends in class 
A vs class C (Figure 10A) significantly increased compared to the class C vs WT 
comparison (Figure 8A) by using this approach. To highlight such changes, we grouped 
these differentially expressed genes into various expression patterns: P1 includes genes 
downregulated in class C; P2 genes upregulated in class A and downregulated in class C; 
P3 the reverse trend of P2; and P4 genes upregulated in class C (Figure 10A).   
Microarray results indicating differential gene expression between phenotypic 
classes A and C were validated further by both Q-PCR (Figure 10B-F) and in situ 
hybridizations (Figure 11). Despite their normal external appearance, class A mutants 
show a marked increase in expression for Plagl1, Satb2 and Peg3 (Figure 5 G-O). Other 
anatomic expression sites for these genes outside BA1 were not affected in the various 
classes of embryos, indicating a BA1-specific effect (data not shown). 
   
61 
 
 
 
Figure 10: Gene expression differences between unaffected and severely affected mutants.  
(A) A heatmap of expression changes in various phenotypic classes was compared to the average 
of WT. Genes with expression changes >1.5 fold and with a false discovery rate of <10% are 
presented as rows. !Imprinted genes. (B-F) Q-PCR confirmation. Significance levels in 
comparison with WT (*) or with class A (†); three symbols represent p<0.001; two, p<0.01; one, 
p<0.05. 
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The ontological categories of genes whose expression levels differ between class 
A and class C are shown in Table 5. Again, apoptosis is among the key biological 
processes. Tumor protein 53-induced nuclear protein 1 (Trp53inp1) was identified 
among a set of genes that play a role in regulating apoptosis, which are uniquely altered 
between affected and unaffected mutants. Additional biological processes were identified 
as distinguishing between affected and unaffected embryos, including cellular assembly 
and organization, carbohydrate metabolism, and DNA replication, recombination, and 
repair.  
Figure 11: Validation of differential gene expression by in situ hybridization.  
Photomicrographs of embryos from different phenotype classes, probed by in situ 
hybridization for (A-C) Dkk1 and (D-F) Msx2, show similar expression levels between WT 
and class A, but profoundly decreased expression in class C. (G-I) Plagl1, (J-L) Satb2 and 
(M-O) Peg3 show increased expression in class A and markedly decreased expression in 
class C. These represent various patterns of differential gene expression as described in the 
text. Arrowheads indicate expression domains within BA1. 
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Table 5: Predicted biological processes regulated by genes uniquely altered between 
class A and class C mutants. 
Molecular and Cellular 
Functions  
Highest 
P-value 
List of molecules 
Cellular Movement  
 
1.1E-02  DAB1, ENPP2, EPHA4, ETV5, FABP7, FOXF1, 
HGF, IGF2, UNC5C 
Cell-To-Cell Signaling and 
Interaction 
1.32E-
02  
ENPP3, FABP7, GRIK2, HGF, IGF2  
Cellular Growth and 
Proliferation 
1.6E-02  DHCR24, ENPP2, ENPP3, EVI1, FABP7, FOXF1, 
HGF, IGF2, PRRX2, PTCH1, TFAP2B, TP53INP1, 
UNC5C  
Cellular Assembly and 
Organization* 
1.71E-
02  
DAB1, ENPP2, EPHA4, FABP7, HGF, IGF2, PTCH1, 
TFAP2B,  
Small Molecule 
Biochemistry 
1.71E-
02  
DHCR24, ENPP2, ENPP3, ELOVL6, FABP7, HGF, 
IGF2, TP53INP1,  
Cellular Development 1.71E-
02  
 
FABP7, FOXF1, HGF, IGF2, LHX8, UNC5C 
Carbohydrate 
Metabolism* 
1.71E-
02  
 
ENPP2, HGF, IGF2, TP53INP1 
Cell Death 1.71E-
02  
DHCR24, GRIK2, HGF, IGF2, MGST1, TFAP2B, 
TRP53INP1, UNC5C 
Cellular Function and 
Maintenance 
1.71E-
02  
EPHA4, EVI1, FABP7, HGF, IGF2  
Lipid Metabolism 1.71E-
02  
 
DHCR24, ELOVL6, ENPP2, FABP7, HGF 
Molecular Transport* 1.71E-
02  
 
ENPP2, FABP7, HGF, IGF2, TP53INP1 
Gene Expression 1.84E-
02  
 
ETV5, EVI1, FOXF1, HGF, IGF2, TBX22, TFAP2B  
DNA Replication, 
Recombination, and 
Repair* 
1.84E-
02  
ENPP3, HGF, IGF2, PTCH1 
*Processes identified as significant based on class C vs class A comparison, but not class C vs 
wild type comparison 
 
 Among the differentially expressed transcripts that were not identified in class C 
vs WT embryo comparisons, but were identified in comparisons of class A vs. C 
   
64 
embryos, seven play known roles in craniofacial development in mice and/or humans 
(Evi1, Eya4, Igf2, Lhx8, Prrx2, Ptch1, Tbx22) (Hoyt et al., 1997; ten Berge et al., 1998; 
Zhao et al., 1999; Braybrook et al., 2001; Ming et al., 2002; Depreux et al., 2008; Bruce 
et al., 2009) (Table 3). Interestingly, each of these genes groups in expression pattern P2. 
While each transcript showed less than 1.5-fold decrease in expression in class C 
compared to WT, the difference from class A was accentuated by a small increase in their 
expression in class A mutants. Since many of these genes may serve similar functions 
during craniofacial development, it is plausible that additive effects of these small 
changes may compensate for the loss of TWSG1 during BA1 morphogenesis, and protect 
class A embryos against manifestation of disease. Other genes, including imprinted 
genes, also are upregulated in class A and downregulated in class C, suggesting that they 
either are co-regulated within gene networks important for craniofacial development or 
may play a direct role in craniofacial development (Feng et al., 2009).  
Genetic deletion of p53 reduces incidence of craniofacial defects in Twsg1
-/-
 mice  
Further comparison of class A vs. C differentially expressed transcripts identified 
genes that are downregulated in class A and upregulated in class C. This pattern (P3) was 
not observed in the comparison between WT and class C mutants except for Sema3e. 
Among them was a p53-inducible gene, Trp53inp1 (Tomasini et al., 2003). The pattern of 
Trp53inp1 expression in the different phenotypic classes suggested that increased p53 
activity could play a role in mediating the phenotype. Western blotting on whole embryos 
demonstrated that p53 levels were, in fact increased in severely affected homozygous 
mutants (class C) with lower levels of p53 in unaffected homozygous mutants (class 
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A), or WT embryos (Figure 12A). Q-PCR analysis of Trp53inp1 transcript levels 
confirmed microarray data indicating upregulation of this gene in class C embryos with a 
trend toward reduction in class A embryos compared to WT (Figure 12B). 
 
 
 
Based on upregulation of p53 and Trp53inp1 in class C embryos that show the 
highest degree of apoptosis in BA1, and since suppression of p53 prevents the 
neurocristopathy of Treacher-Collins syndrome through inhibition of NCC apoptosis 
(Jones et al., 2008), we hypothesized that a similar phenotypic rescue might be observed 
after a genetic deletion of p53 on the Twsg1
-/-
 background.  
Figure 12: Suppression of craniofacial defects Twsg1-/- mice by a genetic deletion of p53.  
(A) Western blotting for p53 using whole E10.5 embryos indicates increased p53 protein levels in 
Twsg1-/- class C, compared to Twsg1-/- class A or WT embryos. GAPDH levels were consistent 
across these samples (B) Q-PCR measurement of Trp53inp1 transcript levels confirms microarray 
data indicating upregulation of this gene in class C embryos with a trend toward reduction in class 
A embryos (C) Decreasing incidence of craniofacial defects among Twsg1-/- pups is associated with 
reduced p53 gene dosage. *p<0.05, **p<0.01, ***p=0.001. 
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Progeny from Twsg1
+/-
p53
+/-
 intercrosses or Twsg1
+/-
p53
+/-
 " Twsg1
-/-
p53
+/-
 
matings were analyzed (both neonates and embryos at E17.5) for the presence of external 
craniofacial defects. The rate of recovery of Twsg1
-/-
p53
+/-
 and Twsg1
-/-
p53
-/- 
genotypes is 
consistent with the predicted distribution based on Mendelian inheritance. The frequency 
of Twsg1-related craniofacial defects significantly decreased with a reduction of p53 gene 
dosage from 44% in Twsg1
-/-
p53
+/+
 pups (N=675) (Sun et al., 2010) to 30% in Twsg1
-/-
p53
+/-
 (N=47, p=0.04) and 15% in Twsg1
-/-
p53
-/-
 littermates (N=39, p=0.001) (Figure 
12C). While craniofacial defects were prevented to a large degree by a loss of two copies 
of p53, there was also a high degree of perinatal death among Twsg1
-/-
p53
-/-
 neonates (up 
to 66%), suggesting involvement of other organ systems. As previously published, we 
observed that homozygous deletion of p53 leads variably to exencephaly (Sah et al., 
1995). This phenotype appeared independently of Twsg1 genotype.  
Imprinted genes are overrepresented among genes that are upregulated in class A 
and downregulated in class C mutants 
The various expression patterns defined for groups of differentially expressed 
genes may help identify a common regulatory mechanism for each group. Interestingly, 
we found that group P2, with an increase or a trend toward increase from WT in class A 
and a decrease in expression in class C mutants, is highly enriched in imprinted genes. 
Using a list of imprinted loci (Morison et al., 2001; Morison et al., 2005), we identified 
68 transcript clusters corresponding to imprinted loci in the array of 16755 transcript 
clusters. Of these 68, six are differentially regulated between class A and class C: Plagl1 
(Figure 10B), Igf2 (Figure 10C), Dlk1 (Figure 10D), paternally expressed 3 (Peg3) 
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(Figure 10F), ankyrin repeat and SOCS box-containing protein 4 (Asb4), and maternally 
expressed 3 (Meg3). This proportion of imprinted genes is much higher than predicted by 
chance, as indicated by a #
2 
analysis yielding a p-value of < 2.92*10 
–23
. To confirm the 
enrichment of imprinted genes, a more stringent approach was also taken. In this case, we 
estimated the number of imprinted genes to represent 2.5% of the mouse genome (Luedi 
et al., 2005). Finding six imprinted genes represented in the 81 differentially expressed 
transcript clusters was again significant, with a p value of <0.0046.  
 
Discussion 
Differential gene expression is associated with Twsg1
-/-
 phenotypic severity 
 Transcriptional profiling has been used previously to identify genes important in 
normal development of individual facial prominences (Feng et al., 2009) as well as 
downstream targets of mutated genes (Jeong et al., 2008). Mouse knockouts with variable 
phenotypes present a particular challenge and an opportunity to gain insights into the 
basis of this variability. For the first time, we undertook an effort to correlate phenotypic 
severity of craniofacial defects with changes in the transcriptome, based on the premise 
that both unaffected and affected Twsg1
-/-
 mutants would show changes in gene 
expression compared to WT mice and to each other.  
 We observed reproducible transcriptional profiles that cluster into distinct groups, 
and are strongly associated with the observed phenotypic categories in Twsg1
-/-
 mice. 
This observation strongly suggests that these transcriptional patterns help to define the 
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distinct morphological and functional groups of Twsg1
-/- 
mice. Among the genes that are 
differentially expressed between class C and WT BA1, about 20% are associated directly 
with known human or mouse craniofacial defects. Others may represent new candidate 
genes that may contribute to human craniofacial diseases. Most of these genes are 
downregulated in class C mutants; since they regulate development of similar 
craniofacial structures, their loss of expression helps to explain observed craniofacial 
defects in Twsg1 mutants. As an example, significantly reduced Dkk1 expression could 
contribute to the anterior truncation phenotype (Mukhopadhyay et al., 2001) of some 
Twsg1
-/- 
mice.  
 We were able to distinguish transcript differences not only between WT and 
affected mutants, but also between unaffected and affected Twsg1
-/-
 mutants. This led to 
three main conclusions. First, class A Twsg1
-/- 
embryos, despite appearing normal on a 
morphological level, are not “normal” on a molecular level. Second, genes that are 
differentially expressed between the genetic mutants and the WT embryos, but not 
differentially expressed between phenotypic class A vs. class C mutants, presumably do 
not play a role in development of the severe mutant phenotype. Third, genes that are 
differentially expressed between class A and class C mutants may provide clues about 
possible compensatory mechanisms that prevent class A mutants from developing 
craniofacial defects. In particular, upregulation of craniofacial genes which regulate 
development of BA1, palate, maxilla, nasal capsule, and teeth (Evi1, Eya4, Igf2, Lhx8, 
Prrx2, Ptch1, Satb2, and Tbx22) in class A mutants may compensate for the loss of 
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TWSG1 function during craniofacial morphogenesis.  
A role for a stress response in craniofacial pathology  
 It has been suggested that NCC are particularly sensitive to cellular stress during 
embryogenesis and that suppression of p53 can prevent craniofacial defects in a murine 
model of Treacher-Collins syndrome (Jones et al., 2008), Tcof1
+/-
 mice. Our experiments 
showing a genetic rescue of craniofacial defects in Twsg1
-/-
 mice corroborate this data 
and suggest that this approach may have broader implications for the prevention of 
craniofacial defects by targeting the p53 pathway.  
 The end-result of increased p53 signaling in Tcof1
+/-
 mice was proposed to be an 
increase in NCC apoptosis and deficient formation of NCC, leading to craniofacial 
defects. Similarly, increased neuroepithelial apoptosis is at the core of neural tube defects 
in Pax3-deficient embryos, which also can be rescued by a loss of p53 function (Pani et 
al., 2002). We have previously shown that abnormal BA1 development in Twsg1
-/-
 mice 
is also associated with increased apoptosis, albeit at a later stage, once NCC have 
populated the branchial arches (MacKenzie et al., 2009). Thus, an increase in apoptosis is 
a common link between these mouse models of birth defects, which each show 
phenotypic rescue by suppression of p53.  
 In Twsg1
-/-
 mice, this increase in apoptosis is thought to be due to disruption of a 
BMP gradient in BA1 (MacKenzie et al., 2009). While BMPs are known to have 
proapoptotic effects during embryonic development (Graham et al., 1994; Mina et al., 
2002), understanding of downstream molecular mechanisms remains limited. There is 
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some evidence from in vitro studies that BMP4-induced apoptosis may be p53-dependent 
(Fukuda et al., 2006). Interestingly, BMPs have been implicated in modulating cellular 
responses to stress and TWSG1 as a modulator of BMPs (Oelgeschlager et al., 2000; 
Ross et al., 2001) would also hence be implicated in this process. For example, BMP7 
can have a direct antioxidative effect in the kidneys and in neurons (Tsai et al., 2007; Yeh 
et al., 2009). On the other hand, BMP2 and BMP4 have been shown to have pro-
oxidative stress effects in endothelial cells (Csiszar et al., 2006; Csiszar et al., 2008; 
Wong et al., 2010). With TWSG1’s bifunctional role, being able to either promote or 
inhibit BMP signaling depending on context, the effects on modulation of stress may also 
be context dependent. We propose that the cell’s variable ability to cope with stress may 
underlie the variable apoptosis and phenotypic variability. The effectors and drivers of 
this adaptability are not yet known.  
A possible role for epigenetic regulation of craniofacial phenotypes cannot be 
excluded in view of a growing body of evidence that epigenetic phenomena contribute to 
phenotypic variability in humans and mice (Whitelaw and Martin, 2001; Dolinoy et al., 
2007). Imprinted genes are known genomic targets of epigenetic regulation (Waterland 
and Jirtle, 2004). Whether they also play a role in generating craniofacial variability 
remains to be determined. While several imprinted genes have been previously shown to 
be overrepresented in the mandibular prominence compared to the maxillary prominence 
or the frontonasal prominence in wild type mouse embryos (Feng et al., 2009), our study 
suggests that altered regulation of the imprinted genes may contribute to generating 
phenotypic variation in Twsg1
-/- 
mice. Notably, most of these genes show gains and 
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losses of expression between unaffected class A and affected class C Twsg1
-/-
mutants, 
respectively. Other genes showing this expression pattern also are known to mediate 
epigenetic effects during development and disease, for example Satb2 (Gyorgy et al., 
2008), Evi1 (Spensberger and Delwel, 2008), Eya4 (Osborn et al., 2006), and Ptch1 
(Diede et al., 2009). Several “metastable epialleles” have been described in mice (A
vy
, 
Axin
Fu
, Cabp
IAP
) (Rakyan et al., 2003; Waterland and Jirtle, 2003; Druker et al., 2004; 
Dolinoy, 2007), although none that would confer predisposition to the development of 
craniofacial defects. Stress response, epigenetics, and gene expression can be interrelated. 
P53 can interact with both DNA methyltransferase 1 (DNMT1) and DNMT3a to alter 
gene methylation (Esteve et al., 2005; Wang et al., 2005; Gibney and Nolan, 2010). 
Cellular stress can also change the expression of imprinted genes, including Igf2, H19, 
and Meg3, independent of the stress-responsive tumor suppressors, for example due to de 
novo methylation in cancer cells (Pantoja et al., 2005). Cellular stress and methylation are 
also both impacted by shared biochemical pathways in the metabolism of folate, 
homocysteine and the synthesis of glutathione (Chern et al., 2001; Tchantchou, 2006) 
Future studies will examine global methylation patterns in various classes of Twsg1 
mutants to determine if there is indeed a role for epigenetic regulation of craniofacial 
phenotypes and to identify targets of such regulation. 
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Multifactorial model of craniofacial defects in Twsg1
-/-
 mice 
 We have developed a model that integrates various processes that may be 
involved in establishing phenotypic variation in Twsg1
-/- 
mutant mice (Figure 13). The 
most immediate effect, which has been corroborated further by transcriptome analysis 
described here, is the loss of the normal BMP signaling gradient, leading to mispatterning 
of BA1, reduced outgrowth and excessive apoptosis (MacKenzie et al., 2009). Loss of 
tissue by apoptosis and loss of peak BMP activity lead to a reduction in BMP targets and 
Figure 13: Model for interrelated processes leading to craniofacial phenotypes and craniofacial 
phenotypic variability in Twsg1-/- mice.  
Loss of TWSG1 disrupts the BMP gradient within BA1, which leads to mispatterning of 
BA1, increased cellular stress, increased apoptosis, and reduced outgrowth. Apoptotic tissue loss and 
loss of peak BMP activity lead to a reduction in BMP targets and other genes expressed in the distal 
region of BA1 and evoke stress and metabolic responses as well as compensatory changes in gene 
expression. This is compounded by likely changes in the epigenome as well as stochastic fluctuations 
in gene expression and signaling pathways, leading to phenotypic variation. 
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other genes expressed in the distal region of BA1, and evoke compensatory changes in 
gene expression, changes in cellular metabolism and stress responses. These effects 
presumably are compounded by stochastic fluctuations in gene expression and signaling 
pathways (Spudich and Koshland, 1976; Melnick et al., 2006), and possibly by changes 
in the epigenome at various regulatory elements.  
Conclusions 
 We show here that phenotypic classes of Twsg1
-/-
 embryos are associated strongly 
with distinct patterns of differentially expressed transcripts. This suggests that the 
phenotypic variation observed in Twsg1
-/- 
mice may be caused by heretofore unidentified 
“master regulators” which in turn would bring about coordinate changes in expression of 
many downstream genes. An initiating event is disruption of BMP signaling in BA1 of 
Twsg1
-/-
 mice that evokes a number of cellular and molecular responses, including a 
cellular stress response, which appears to play a key role in the pathogenesis of 
craniofacial defects. Occurrence of these defects can be suppressed by a reduction in p53 
dosage. Further study of transcriptional, and probably epigenetic, contributions to 
phenotypic variation may not merely explain the wide variation of craniofacial 
phenotypes in clinical craniofacial syndromes, but also suggest how craniofacial 
morphological diversity might be enhanced through evolutionary processes (Brugmann et 
al., 2006). That the face is a key site for morphological evolution is suggested by the 
wide diversity of craniofacial adaptations in vertebrates (Brugmann et al., 2006). To 
provide the phenotypic “space” for these adaptations, craniofacial development must 
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be particularly plastic. The changes we observe highlight the extreme plasticity of 
transcriptional states and likely the epigenetic states of genes involved in craniofacial 
development. 
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Chapter 4: Maternal diet supplementation with methyl donors 
and increased parity alter the incidence of craniofacial defects 
in the offspring of Twisted gastrulation mutant mice   
Introduction  
Dietary folate has proven to be a potent preventive factor against neural tube 
defects (NTD). The effect of folate against NTD was first proposed in the early 1980s 
and has been robustly confirmed by many subsequent studies in humans (Smithells and 
Sheppard, 1980; MRC, 1991; Czeizel and Dudas, 1992; Berry et al., 1999; Berry and Li, 
2002; De-Regil et al., 2010). This has led to successful public health interventions to 
fortify foods with additional folate in several countries (Honein et al., 2001; Botto et al., 
2006). Other nutrients that act as methyl donors such as choline, its metabolite betaine, 
and the enzyme co-factor vitamin B12, can facilitate folate metabolism and one-carbon 
metabolism (see illustration, Figure 14), (Zeisel and Blusztajn, 1994; Scott, 1999; 
Niculescu and Zeisel, 2002) and can also have protective effects against NTD in concert 
with or independent of folate (Ray and Blom, 2003; Shaw et al., 2004; Zeisel, 2009).  
The dramatic success of folate in prevention of NTD raises the question of 
whether methyl-donor compounds might also prevent birth defects other than NTD. Their 
effectiveness in prevention of craniofacial defects is still unclear, with some studies 
demonstrating beneficial effects of methyl donor nutrients (Tolarova, 1982; Shaw et al., 
1995; Tolarova and Harris, 1995; Loffredo et al., 2001) while other studies indicate no 
beneficial effects (Botto et al., 2006; Shaw et al., 2006; De-Regil et al., 2010; Wehby and 
Murray, 2010).  
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 Mouse models offer an experimental advantage for studying effects of dietary 
supplementation on craniofacial defects because variables like environment and genetic 
background can be controlled and disease-causing mutations, if present, are defined and 
constant. For example, in the A/WySnBk mouse strain, which has a high incidence of 
spontaneous orofacial clefting, maternal supplementation with the folic acid derivative 
folinic acid reduces incidence of clefting by a factor of 4 (Paros and Beck, 1999). Mice 
lacking folate receptor 1 (Folr1, also called Folbp1) exhibit multiple birth defects 
Figure 14: The folate and methionine cycles include key cellular reactions aided by methyl donor 
nutrients.  
Folate enters into metabolism by conversion to tetrahydrofolate (THF). THF is, in turn, converted to 
methylene-THF and then to methyl THF which serves as the donor for remethylating homcysteine 
(HCY) back to Methionine (MET), a reaction catalyzed by methionine synthase with a vitamin B12 
(B12) cofactor. HCY is also methylated to MET in a betaine-dependent reaction catalyzed by betaine-
homocysteine methyltransferase. (Betaine is a metabolite of choline). MET serves as the substrate to 
generate S-adenosyl methionine (SAM). SAM is the primary cellular donor of methyl groups to 
substrates such as DNA or proteins. When SAM transfers its methyl group it becomes S-adenosyl 
homocysteine (SAH), which is converted back to cysteine to complete the cycle. If sufficient 
metabolites are available, methylene THF can also be used to generate nucleotide bases. Likewise if 
there is sufficient SAM, this allows the conversion of HCY to glutathione, the primary cellular 
antioxidant, in a Vitamin B6 (B6) dependent reaction. 
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including not only NTD but also midline cleft lip, cleft palate, and jaw defects 
(micrognathia and agnathia) among others (Spiegelstein et al., 2004). Supplementation 
with folinic acid bypasses the folate receptor defect and ameliorates defects in a dose-
dependent manner. In that study there was a trend toward reduced incidence of 
micrognathia and agnathia in response to folinic acid supplementation, but these defects 
were too rare in Folr1
-/-
 mice to analyze statistically.  
 Mice deficient in Twisted gastrulation (TWSG1), on the other hand, show 
relatively high incidence of jaw defects (micrognathia and agnathia) with or without 
midline facial and brain defects characteristic of holoprosencephaly (HPE) (Petryk et al., 
2004). The combination of jaw defects and HPE in humans is referred to as agnathia-
HPE complex (or dysgnathia-otocephaly; OMIM #202650) (Pauli et al., 1983).  In 
Twsg1
-/-
 mice, these defects show incomplete penetrance and variable expressivity 
(Petryk et al., 2004; Billington et al., 2011a). This array of craniofacial defects in a mouse 
model with a defined mutation and genetic background (C57BL/6) provides an 
opportunity to study the effects of methyl donors on jaw and midline facial defects, 
which have distinct embryologic origins.  
 Jaw defects stem from abnormal outgrowth and patterning of the first branchial 
arch (BA1), an embryonic structure giving rise to the lower and upper jaws and the 
secondary palate (Thomas et al., 1998; Liu et al., 2010). The most striking BA1 defect 
seen in Twsg1
-/-
 mice is agnathia, absence of the lower jaw (Petryk et al., 2004). 
Micrognathia (small jaw) represents a less severe BA1 defect (MacKenzie et al., 2009). 
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Orofacial clefting may also arise from defective BA1 development since clefting of both 
palate (Stanier and Moore, 2004; Dixon et al., 2011) and lip (Merritt, 2005; Juriloff and 
Harris, 2008) can derive from deficient growth of the maxillary component of BA1. 
Defects of midline formation, on the other hand, arise from failure of proper patterning or 
signaling from the prechordal plate and ventral forebrain (Muenke and Beachy, 2000; 
Chong et al., 2012) and the frontonasal ectodermal zone, which direct the formation of 
the midline of the face (Pera and Kessel, 1997; Hu and Marcucio, 2009b; Hu and 
Marcucio, 2009a).  
This study's primary aim was to investigate whether maternal dietary methyl 
donors reduce the incidence of craniofacial defects in Twsg1
-/- 
mice and whether this 
effect differs for jaw versus midline facial defects. Based on the trend towards reduced 
agnathia and micrognathia with added folate derivatives in Folr1
-/-
 mice, we 
hypothesized that Twsg1
-/-
 mice would show reduced incidence of jaw defects with 
dietary supplementation of methyl donors.  
 This study's secondary aim was to examine whether parity has any effect on the 
incidence or types of defects seen in Twsg1
-/-
 mice. Increased parity has been associated 
with increased risk of NTD (Vieira, 2004), orofacial clefting (Vieira and Orioli, 2002), 
ear defects (Castilla and Orioli, 1986; Mastroiacovo et al., 1995), and congenital heart 
defects (Zhan et al., 1991) in humans. On the other hand, some defects, including 
esophageal defects, limb defects, and hypospadias show decreased incidence with 
increased birth order (Hay and Barbano, 1972; Duong et al., 2012). No studies of the 
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effect of parity on craniofacial defects in mice have been published. In fact, parity is 
typically not taken into account in mouse model studies. Hence, in addition to studying 
the effect of methyl donors on craniofacial development we have examined parity as a 
potential factor in Twsg1
-/-
 birth defects. This secondary aim is important to consider 
along with the effect of dietary supplementation particularly given that folate, at least, has 
been proposed to help reduce risk of recurrence of defects such as clefting in a second 
pregnancy following a previously affected pregnancy in humans (Tolarova, 1982; 
Tolarova and Harris, 1995). 
Materials and Methods 
Mouse care and diet  
 Generation of mice carrying a deletion of exon 4 in the Twisted gastrulation gene 
(Twsg1
–
, MGI: Twsg1
tm1.1Mboc
) was
 
previously described (Petryk et al., 2004). All mice 
were in the C57BL/6 background after backcrossing to C57BL/6NTac mice from 
Taconic (Hudson, NY) for at least ten generations. Mice were maintained under specific 
pathogen free conditions in filter-lidded, 18x29 cm cages lined with pulverized corncob 
bedding, with cotton fiber blocks for nesting material. Cages were changed weekly. 
Ambient conditions were: air temperature 20-23˚C, humidity 30-70%, with 14h/10h 
light/dark cycle.  
 Water was provided in glass bottles ad libitum. Mice were given a control diet 
(NIH31, Harlan-Teklad 7017, repelleted as TD.95262) or a previously described (Wolff 
et al., 1998; Cooney et al., 2002) form of this diet supplemented with methyl donor 
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compounds (MDS diet) including folate, vitamin B12, choline, and betaine (Harlan 
Teklad-TD.01308). Female mice were fed experimental diets for at least 2 weeks prior to 
mating. Duration of feeding experimental diets past this initial period varied depending 
on the time to pregnancy and whether litters were kept until weaning. This two week 
dietary preload period is consistent with previous studies employing these diets (Wolff et 
al., 1998; Cooney et al., 2002; Waterland and Jirtle, 2003). Physiological levels of 
nutrients like folate are able to respond to dietary changes rapidly, altering significantly 
within days of a dietary change (Kitami et al., 2008). Male mice were given the control 
diet prior to mating and then fed the control or MDS diet along with the females. Ages of 
females set up for matings ranged from 7 to 35 weeks. Ages of males ranged from 8 to 
103 weeks old. For second pregnancies, dams were set up for mating as soon as possible 
after weaning of first pregnancy offspring. 
To generate offspring for the present study, 47 homozygous (Twsg1
-/-
) or 
heterozygous (Twsg1
+/-
) female mice from 32 different litters were mated to 15 
homozygous (Twsg1
-/-
) males, all from different litters. Mice were monitored closely as 
delivery approached to prevent dams from eating dead or deformed pups before they 
could be assessed. In some cases pregnant dams were killed, using CO2 euthanasia, 
between embryonic day 15.5 (E15.5) and E18.5, and the fetuses explanted. Pups and 
fetuses were genotyped by PCR amplification of DNA prepared from tail snips using 
primers for the wild-type allele (5’-ataggagggttgggcgttgaag-F and 5’-
acctgacggctaacacagatgc-R), and for the Twsg1 deletion allele (5’-caacctccctgttagcccac-F, 
5’-actgccttgggaaaagcgcc-R). Genotypes of the mice were verified to confirm numbers 
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of mice in expected Mendelian ratios between +/- and -/- genotypes. Subsequent analyses 
considered only Twsg1
-/- 
offspring.  
The University of Minnesota Institutional Animal Care and Use Committee 
approved the care and use of the mice in this study.  
Phenotype scoring  
 The study's primary outcome was occurrence of jaw and midline facial defects. 
Pups were assessed by inspection for craniofacial defects including cleft lip, cleft palate, 
micrognathia, agnathia, cyclopia, proboscis, and anterior truncation. Eye defects such as 
microphthalmia and anophthalmia were noted but were not included in scoring because 
they are seen at relatively high prevalence (4-10%) in the endogenous, wild type 
C57BL/6 background (Chase, 1942; Kalter, 1968). Wild type C57BL/6 mice do not show 
any incidence of jaw and midline defects. Pups with abnormalities were scored and 
photographed by one investigator and scoring was independently assessed from the 
photograph by a second investigator blinded to the diet and pregnancy status of the 
mother. 
Pups with abnormalities are stillborn or die shortly after birth. Clefting of the 
palate was observed by dilating the jaws with a forceps and, where suspected, confirmed 
by surgically opening the jaw to expose the palate. Agnathia was defined by absence of a 
mandible with or without ventral displacement of the ears. Micrognathia was noted where 
some mandibular structures were present but visibly reduced in size. Proboscis was noted 
where there was an elongated dysmorphic nose-like structure in place of a snout. 
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Cyclopia was characterized by a midline eye-like structure. Embryos with no 
recognizable facial features at all were assessed as having anterior truncation 
(corresponding to human aprosopia).  
 Pups with no defects or with isolated eye defects were classed as “Normal” with 
respect to BA1-derived and midline facial structures. Mice with clefting and/or 
micrognathia were grouped together for statistical purposes as having mild BA1 defects 
while presence of isolated agnathia (without midline defects) was classified as a severe 
BA1 defect. For some comparisons all BA1 defects were grouped together. The 
additional presence of proboscis, cyclopia, or anterior truncation was counted as a 
midline defect. These midline phenotypes were always seen with concomitant agnathia.  
Statistical analyses  
 The effect of diet for each pregnancy and the parity effect within each diet were 
assessed by permutation tests to account for clustering of pups into litters. The test 
statistic used in the permutation tests was the 2-sided p-value from Fisher’s exact test. 
For permutation tests comparing diets and involving only the first pregnancy or only the 
second pregnancy, diet labels were permuted among litters (dams).  For permutation tests 
comparing parity and involving only a single diet, parity labels were permuted among 
litters if a dam had only one pregnancy for that diet or between a dam's two pregnancies 
if she had both pregnancies on the same diet.  The p-value of the permutation test is the 
proportion of test statistics from the 1000 permutation samples that were as extreme as or 
more extreme than the observed test statistic from the actual data.   
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Generalized estimating equations (GEE) accounting for clustering by dam and 
litter was used to investigate the effects of diet, parity, any potential interaction between 
diet and parity, and maternal age.  These analyses had the form of a logistic regression; 
robust variance estimates were used in computing confidence intervals.  2-way and 3-way 
interactions of factors did not test significant so only the main effects of maternal age, 
diet, and parity are included in the analyses reported here. P-values are two-sided; those 
less than or equal to 0.05 were deemed statistically significant. All analyses used the SAS 
system (v. 9.2, SAS institute, Cary, NC, USA); GEE analyses were done using the 
GENMOD procedure. 27 dams had a single pregnancy in the data set, while 21 dams had 
two pregnancies.  Of the latter, 5 dams were fed the MDS diet for both pregnancies and 
16 were fed the NIH31 diet for the first pregnancy and the MDS diet for the second 
pregnancy.   
Results 
Methyl donor supplementation reduces the incidence of BA1-derived but not 
midline facial defects among Twsg1
-/- 
offspring from previously nulliparous dams 
 Twsg1
-/-
 pups born to mothers being fed each diet continued to show variable 
defects including pups with defects as well as unaffected pups (Figure 15A, B). Observed 
malformations included isolated defects of BA1-derived tissues such as clefting in the 
secondary palate (Figure 15 C, F), micrognathia (Figure 15 D, G), and agnathia (Figure 
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15 E, H). Cleft lip was also observed in a few cases (not shown). In each diet group some 
pups showed severe defects of the upper face, with mispatterning of midline structures, 
including proboscis, which was seen with cyclopia (Figure 15 I, L), or with absent eyes 
(Figure 15 J, M). These defects were always accompanied by agnathia in these Twsg1
-/-
 
animals. 
 
Figure 15: The full range of Twsg1
-/-
 phenotypes is seen in mouse pups born to mothers fed either 
control or methyl donor supplemented diets.  
With either control or MDS diet, some Twsg1-/- mice are born with no defects (A,B). Some have defects of 
BA1 derived structures (C-H): palatal clefting (C, F) with normal palates (C’, F’) included for reference; 
(D,G) micrognathia, with jaw rudiment indicated by the black arrowhead.; (E, H) agnathia. Some have 
severe midline defects (I-N); (I,L) Cyclopia with proboscis; (J,M) Proboscis; (K,N) Anterior truncation.   
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We first analyzed pups born to previously virgin females. In the control diet 
group, the rate of defects was 37.7% (29 of 77 Twsg1
-/- 
pups from 20 litters); this rate was 
almost halved with the MDS diet, to 19.1% (9 of 47 pups from 11 litters) (Figure 16A, 
Table 6).  The permutation test found this difference statistically significant (p=0.03), 
indicating a beneficial effect of the MDS diet for pups born from their mother’s first 
pregnancy.  
 We next considered whether dietary intervention affects the variable phenotypes 
evenly and found that the MDS diet protected exclusively against BA1-derived defects 
(Table 6, Figure 16A). In the first pregnancy, clefting, micrognathia, and agnathia 
together decreased by more than half (12.8% in MDS vs. 32.5% in control) with the MDS 
diet, and this decrease alone was significant (p=0.02; Figure 16B, Table 6). Midline and 
anterior head defects showed no impact from the MDS diet and occurred at nearly the 
same frequency in each diet group, 5.2% in the control diet group and 6.4% in the MDS 
diet group (Figure 16C, Table 6; p=1.00). 
The incidence of craniofacial defects increases in the second pregnancy. 
  Offspring of second pregnancies during which mothers were fed either diet had 
markedly more defects than offspring of first pregnancies. In the control diet group, the 
incidence of defects increased from 37.7% to 59.5% (p=0.04; Figure 17A, Table 6). With 
the MDS diet the second pregnancy was also associated with increased prevalence of 
defects. The incidence of craniofacial defects was 19.1% among the first MDS pregnancy 
offspring and 45.3% among the second MDS pregnancy offspring (p=0.045; Figure 17B, 
Table 6).  
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Figure 16: Methyl donor supplemented maternal 
diet protects against craniofacial defects seen in 
Twsg1
-/-
 mice born from first pregnancies, 
specifically BA1 but not midline defects.  
Bars represent the percent of each group of 
pups that show a given phenotype. (A) Reduced 
incidence of any defect with maternal MDS diet. 
Phenotypes of pups born to mothers given control 
diet (77 pups total, n=20 dams) or MDS diet (47 
pups total, n=11 dams) are categorized by type and 
severity into severe midline defects (dark gray), and 
severe (mid gray) and mild (light gray) BA1 defects. 
(B) Reduced incidence of defects of BA1 
derivatives with MDS diet. (C) Equivalent incidence 
of severe midline defects between control and MDS 
diet groups. P-value is calculated vs. control diet 
group by permutation test, * p<0.05. Significance 
tests are indicated for the combined total represented 
by a column. More complete statistics can be found 
in Table 6. Abbreviations: BA1, first branchial arch; 
MDS, methyl donor supplemented.  
 
 
 
Figure 17: Parity increases defects in Twsg1
-/-
 mice regardless of diet.  
Bars represent the percent of each group of pups that show a given phenotype. (A) First and second 
pregnancy phenotype incidence with control diet (77 Twsg1-/- pups from first pregnancies, n=20 dams, and 
37 from second pregnancies, n=14 dams). (B) First and second pregnancy phenotype incidence with MDS 
diet (47 Twsg1-/- pups from first pregnancies, n=11 dams, and 106 Twsg1-/- pups from second pregnancies, 
n=24 dams). Overall defects in (A) and (B) are subcategorized by type and severity into severe midline 
defects, and severe and mild BA1 defects. * p<0.05, by permutation test for difference from first 
pregnancy. Significance tests are indicated for the combined total represented by a whole column. 
Complete statistics can be found in Table 6. BA1, first branchial arch; MDS, methyl donor supplemented. 
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Table 6: Summary of craniofacial malformations seen in Twsg1
-/- 
mouse pups, to dams given control or methyl donor 
supplemented diets, from both first and second pregnancies 
 
 
1 Numbers in the table are totals for each category of phenotype. In parentheses is the percent of the total with that phenotype within the group with the same 
parity and diet. Clefting and micrognathia are considered together as mild (BA1) defects and were frequently seen in the same mouse. Agnathia is classed as a 
severe BA1 defect. “Orofacial clefting” includes cleft lip and/or cleft palate. “Midline defects” includes all mice with proboscis, anterior truncation or cyclopia. 
Mice with midline defects also all had agnathia, but are not counted in the upper rows of the chart for having jaw defects due to overriding presence of the severe 
midline defect. 
2,3,4 Categories are mutually exclusive up to the same level of indentation and can be added to make up total numbers. 
5 Categories are nonexclusive and cannot be added to make totals. 
6 Abbreviations: BA1, first branchial arch; MDS Methyl donor supplemented; Preg, pregnancy.
 First pregnancy Second pregnancy Permutation Test p-values 
Variable Control 
diet 
n (%) 
MDS 
diet 
n (%) 
Control 
diet 
n (%) 
MDS 
Diet 
n (%) 
1st preg6 2nd preg Control 
diet 
MDS diet 
Counts of Twsg1-/- offspring phenotypes1  77 (100) 47 (100) 37 (100) 106 (100) 
Control 
vs. MDS 
Control 
vs. MDS 
1st vs. 2nd 
preg. 
1st vs. 2nd 
preg. 
Normal2,3,4 48 (62.3) 38 (80.9) 15 (40.5) 58 (54.7) 
– – – – 
BA16 + midline defects2 29 (37.7) 9 (19.1) 22 (59.5) 48 (45.3) 0.03 0.37 0.04 0.045 
     BA16 defects,3 
-Mild BA1 defects: 4 
              -Micrognathia5 
                 -Orofacial clefting5  
                         –Cleft Lip5 
                         –Cleft Palate5 
-Severe BA1 defects: Agnathia4 
25 (32.5) 
17 (22.1) 
12 (15.6) 
7 (9.1) 
3 (3.9) 
6 (7.8) 
8 (10.4) 
6 (12.8) 
4 (8.5) 
3 (6.4) 
1 (2.1) 
0 (0) 
1 (2.1) 
2 (4.3) 
18 (48.6) 
8 (21.6) 
7 (18.9) 
3 (8.1) 
1 (2.7) 
3 (8.1) 
10 (27.0) 
24 (22.6) 
11(10.4) 
10 (9.4) 
2 (1.9) 
1 (0.9) 
1 (0.9) 
13 (12.3) 
0.02 0.08 0.08 0.23 
    Midline defects: 3,4 
                 -Proboscis5 
                 -Anterior Truncation5 
                 -Cyclopia5 
4 (5.2) 
4 (5.2) 
0 (0) 
2 (2.6) 
3 (6.4) 
3 (6.4) 
0 (0) 
2 (4.3) 
4 (10.8) 
1 (2.7) 
3 (8.1) 
1 (2.7) 
24 (22.6) 
20 (18.9) 
4 (3.8) 
9 (8.5) 
1.0 0.30 0.34 0.08 
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Increased parity raised the incidence of severe BA1 phenotypes (agnathia) and 
midline defects, but not incidence of mild BA1 phenotypes (micrognathia and/or 
clefting). Pups with micrognathia and/or clefting were seen at nearly the same rate in 
both first and second pregnancies in both diet groups (Control: 22.1% vs. 
21.6%, P=0.99, MDS: 8.5% vs. 10.8%, P=0.99, Table 6 and Figure 17). On the other 
hand, agnathia incidence nearly tripled among mice born from second pregnancies given 
control diet (10.4% up to 27.0% in the second control diet pregnancy, P=0.03), but the 
change in prevalence was not significantly different among mice born from second 
pregnancies given MDS diet (4.3% up to 12.3% in the second MDS pregnancy,  
P=0.25, Table 6 and Figure 17). Midline defects in second pregnancies tended to increase 
relative to first pregnancies from 6.4% to 22.6% with the maternal MDS diet (P=0.08) 
but not with the maternal control diet (5.2% to 10.4%) (P=0.34). Notably, the most severe 
form of the Twsg1
-/- 
phenotype, anterior truncation, characterized by absence of any 
recognizable anterior head and face structures, was seen only in mice born from second 
pregnancies in each diet group (Figure 15 K, N).  
Methyl donor supplementation has protective effects regardless of parity 
Given that both diet and parity, considered separately, had significant impacts on 
the frequency of defects, we were interested in whether methyl donor supplementation 
had the same effect in the second pregnancy as in the first. We did two analyses using 
generalized estimating equations (GEE), including both first and second pregnancies and 
both diets. The first analysis, Model 1, included a test of the so-called interaction of diet 
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and pregnancy (Table 7). This interaction term indicates whether the effect of diet differs 
between the two pregnancies (1
st
 or 2
nd
) or equivalently whether the effect of parity 
differs between the two diets (Control or MDS). The interaction of diet and parity did not 
test significant (p=0.59), meaning these data provide no evidence that the effect of diet 
differs between first and second pregnancies. Therefore, a second analytical model 
(Model 2) excluded the interaction term and considered diet and parity only as acting 
separately. Consistent with the permutation tests for first and second pregnancies 
separately, the MDS diet was associated with reduced risk of defects regardless of parity 
(Table7, Model 2). Likewise, first pregnancies had significantly lower frequency of 
defects after controlling for diet (Table 7, Model 2).  
Table 7: Effect of diet and parity on the incidence of defects in Twsg1
-/-
 mice.   
 
Model 11 
with interaction 
P-value 
Model 21 
without interaction 
P-value 
Comparison Subset OR (95% CI) - OR (95% CI) - 
MDS2 vs. Control 
diet 
1st Pregnancy 
2nd Pregnancy 
0.38 (0.17, 0.85) 
0.54 (0.22, 1.30) 
0.03 0.47 (0.26, 0.86) 0.03 
1st vs. 2nd 
pregnancy 
MS diet 
NIH diet 
0.28 (0.12, 0.66) 
0.39 (0.17, 0.90) 
0.001 0.33 (0.19, 0.60) 0.002 
 
1 A generalized estimating equations analysis (GEE) with the form of a logistic regression and using robust 
variance estimates was performed for two different models and used to generate odds ratios and P-values. 
Model 1 proposed that diet and parity might be acting synergistically (i.e., showing a statistical interaction) 
on the incidence of defects. The P-value for the interaction of diet and parity was 0.59. Model 2 proposed 
that diet and parity acted separately and did not show a statistical interaction. Since this analysis did not 
include the interaction of diet and parity, only one odds ratio is estimated and tested for each factor. 
2Abbreviation: MDS, Methyl donor supplemented.  
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Increased maternal age does not account for the effect of parity on craniofacial 
defects  
 Finally, we considered the possibility that increased maternal age in second 
pregnancies might account for the increased incidence of defects. The mouse dams in the 
study gave birth over a range of ages from 72 to 261 days. Not surprisingly, dams were 
significantly older when giving birth to their second litter, for either diet individually or 
considering the whole group together (p<0.0001, by unpaired Student’s t-test). Age 
distribution did not differ significantly between diet groups (Student’s t-test p=0.23 for 
first pregnancies, and p=0.97 for second pregnancies) (Figure 18). We again used a GEE-
logistic regression to test whether maternal age had an effect on incidence of defects after 
accounting for the confounding effect of parity (Table 8). In an analysis accounting for 
diet and parity, the estimated age effect was extremely small, with an odds ratio of 1.02 
for an increase of 50 days in maternal age (p = 0.94). Thus, there is no indication that 
maternal age had an independent effect on the incidence of defects.  
 
Figure 18: Distribution of maternal ages in study group.  
Each point indicates a litter delivered at a given maternal age. Vertical lines indicate mean ages for 
the category. *** p<0.001. 
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Table 8: Effect of maternal age on incidence of defects in Twsg1
-/- 
mice, adjusting for 
diet and parity 
 OR1 (95% CI) P-value1 
MDS Diet: Yes vs. No 0.47 (0.26, 0.86)  0.03 
1st Pregnancy: Yes vs. No 0.34 (0.14, 0.82)  0.01 
Maternal Age: 50-day increase 1.02 (0.65, 1.59)  0.94 
 
1 Odds ratios (OR) and 95% CI and p-values were calculated using a generalized estimating equations 
analysis with the form of a logistic regression and using robust variance estimates.  
Discussion 
The role of methyl donor supplementation in prevention of defects arising from the 
first branchial arch 
 Recommendations for increased folate intake during pregnancy and particularly 
population-level folate fortification have significantly reduced NTDs (Honein et al., 
2001) but have not had such clear effects on other types of birth defects (Canfield et al., 
2005; Botto et al., 2006). Experiments in animal models present a suitable way to study 
this potential effect and the effects of other methyl donors in a controlled experimental 
setting. The current study in TWSG1-deficient mice supports the role of maternal dietary 
methyl donor supplementation, including folate, in prevention of birth defects beyond 
those of the neural tube, specifically those of BA1.   
The BA1 mesenchyme is populated with neural crest cells (NCC) derived from 
the margins of the developing neural tube. Like the neural tube, NCCs appear to be 
particularly sensitive to maternal dietary and plasma folate levels during development 
(Burgoon et al., 2002; Spiegelstein et al., 2004; Blom et al., 2006) and methyl donor 
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supplementation supports the role of folate in one-carbon metabolism. This may partially 
explain how the NCC-populated BA1 mesenchyme could be a suitable target for methyl 
donor action.  
Methyl donor supplementation did not protect against non-BA1 craniofacial 
defects observed in Twsg1
-/-
 mice, including cyclopia, proboscis, or anterior truncation. 
This suggests that, rather than being part of a single continuum of severity of the same 
pathological process, the variable phenotypes in Twsg1
-/-
 mice are actually a constellation 
of pathologies with differing responses to dietary intervention. The observation that 
Folr1
-/-
 mice do not show midline defects of HPE (Spiegelstein et al., 2004) supports the 
notion that methyl donor metabolism is not likely to play a major role in the pathogenesis 
or prevention of these defects.  
 The mechanism of dietary folate, choline or B12 actions in prevention of birth 
defects, including NTDs, remains unknown (Blom et al., 2006), but several potential 
mechanisms have been proposed. First, these nutrients are all involved in one-carbon 
metabolism, which is required for synthesis of nucleotides (Stover, 2004). This is 
particularly important for rapidly dividing cells (Botto et al., 1999) such as NCC. Thus, 
increased availability of these nutrients may act to promote development of an embryonic 
structure such as BA1 by facilitating rapid cell proliferation and growth. Second, folate 
and methyl donors provide methyl groups for DNA and protein methylation (Choi et al., 
2005; Blom et al., 2006). Given increasing attention to the role of epigenetics in NCC 
regulation and action (Liu and Xiao, 2011), it is conceivable that the protective action of 
   93 
dietary methyl donors is through facilitation of epigenetic gene regulation in NCC of 
BA1. This idea is supported by the observation that the supplemented diet used in this 
study is able to alter DNA methylation status and gene regulation at epigenetically labile 
loci, such as those seen in the agouti viable yellow (Wolff et al., 1998; Cooney et al., 
2002; Waterland and Jirtle, 2003) and axin fused (Waterland et al., 2006) strains. It is 
currently unknown if genes important for craniofacial development can act as metastable 
epialleles (Rakyan et al., 2002) in the response of Twsg1
-/-
 mice to dietary 
supplementation. Third, methyl donors are also required for remethylation of 
homocysteine to methionine (Tchantchou, 2006). Rising homocysteine levels in the 
absence of adequate ability to detoxify this compound can have deleterious effects on 
NCC (Boot et al., 2003; Li et al., 2005), so methyl donor sufficiency would have 
protective effect on NCC. Finally, sufficiency of methyl donors may also provide an 
antioxidant effect, which could protect NCC from apoptosis induced by oxidative stress 
(Loeken, 2004).  
Parity as a potential variable in dysmorphology  
Previous pregnancy has been hypothesized to increase the risk of certain types of 
defects in human studies, particularly NTD (specifically spina bifida) (Vieira, 2004) and 
orofacial clefts (Vieira and Orioli, 2002). The effect of increased parity has been 
controversial, however, with recent studies not finding an effect of parity on these same 
defects (Duong et al., 2012). We report a significant effect of parity in increasing 
incidence of craniofacial defects in mice, particularly severe BA1 defects (agnathia) and 
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severe defects of midline formation and head patterning. Our finding of an impact of a 
previous pregnancy on subsequent pregnancy outcome is, as far as we know, a novel 
finding in mouse research. Twsg1
-/- 
mice represent a potentially important model for 
studying mechanisms of the effect of birth order on birth defects. Other mouse model 
dysmorphology studies may also need to account for parity as a potential variable.  
The effect of increased parity has several potential explanations. Maternal age 
would be one potential confounding variable to consider. In humans, age, particularly 
maternal age >40 years, has been associated with increased risk for defects, for example, 
congenital heart defects, trisomy 21 and neural tube defects (Hay and Barbano, 1972; 
Vieira and Taucher, 2005). In our mouse study, we found no effect of age on craniofacial 
defects after accounting for parity. However, it is unclear what would be a proper mouse 
model of human advanced maternal age. Further studies of age-matched mice in their 
first and second pregnancies could provide additional direct information on the question 
of the extent to which age plays a role in the effect of parity in Twsg1
-/- 
mice. Apart from 
age, it is possible that increased pregnancy is associated with depletion of maternal 
nutrients necessary for healthy gestation (Todoroff and Shaw, 2000). Notably, it has been 
reported that methyl donors can be depleted as a result of pregnancy in both rodents 
(Zeisel et al., 1995; Achón et al., 2000) and humans (McMahon and Farrell, 1985; Bailey, 
1992). Iron could be another potential micronutrient subject to depletion (Sharma et al., 
1991; Milman et al., 1992). Depletion of iron with increased parity has been proposed as 
a mechanism of increased ethanol teratogenicity with increased parity (Rufer, 2010). 
Since the phenotypes seen with ethanol toxicity in mice (Higashiyama et al., 2007; 
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Aoto et al., 2008) resemble those seen in Twsg1
-/-
 mice, some shared pathologic 
mechanisms could be involved. Finally, increased maternal oxidative stress with higher 
parity may play a role. Increases in markers of oxidative stress have been seen in human 
mothers and in rats with increased parity (Tawfik et al., 2008; Mutlu et al., 2012). 
Effects of folate in prevention of birth defects of the neural tube and face appear to 
be stage and region-specific  
It is interesting that the preventive effects of methyl donors against defects are 
region-specific. This suggests that the embryonic origins of impacted structures and 
differences in underlying processes may play a role in differing responses to dietary 
supplementation. The findings of this and other studies (Yan et al., 2012) lead us to 
propose a model where the effects of methyl donor supplementation are specific to the 
embryonic origin of craniofacial and neural structures. Our model subdivides embryonic 
development of these structures into three steps (Figure 19).  Each step must proceed 
properly to allow normal embryonic development. 
   96 
 
Figure 19: A multifactorial model of craniofacial defects in Twsg1
-/-
 mice.  
Craniofacial development is subdivided into three stages, neural tube development, midline 
division and branchial arch development. The consequence of failure is indicated at the left of each step. In 
each stage, three factors are considered for their inferred effects: deficiency of TWSG1, MDS (methyl 
donor supplementation), and increased parity. Grayed factors in the first, neural tube step indicate this 
portion of the model is derived from literature review and not from the results of this study: for MDS 
references (Smithells and Sheppard, 1980; MRC, 1991; Fisher et al., 2001; Shaw et al., 2004; Spiegelstein 
et al., 2004; Burren et al., 2008); for parity reference (Vieira, 2004). 
 
Early in embryonic development, the neural tube forms as the neural folds grow 
together and fuse in the midline. This takes place from embryonic day 8.5 (E8.5) to (E10) 
in mice (Ybot-Gonzalez et al., 2002) and in the fourth week of development (Days 21-24) 
in humans (Northrup and Volcik, 2000; Larsen et al., 2001). Failure at this step leads to 
NTDs. Twsg1
-/-
 mice do not show NTDs, indicating the dispensability of TWSG1 for 
neural tube development. The protective effect of methyl donors on NTD development 
has been previously established in both NTD-susceptible mice (Fisher et al., 2001; 
Spiegelstein et al., 2004; Burren et al., 2008) and in humans (Smithells and Sheppard, 
1980; MRC, 1991; Shaw et al., 2004). In contrast to the effect of methyl donor 
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supplementation, increased parity may act to favor NTD, based on work in humans 
(Vieira, 2004).  
Paralleling the process of neural tube closure is early head patterning and midline 
specification, which begins around E7.5 (Aoto et al., 2009) in mice or at stage 7-10 
(weeks 3-4) of human development (Larsen et al., 2001; Muller and O'Rahilly, 2003). 
Failure of this process leads to HPE and associated midline facial defects, such as 
cyclopia or proboscis. We did not see any protection from these defects by methyl donor 
supplementation, suggesting that methyl donors are unable to protect normal midline 
patterning. Midline defects tended to appear at increased incidence in second pregnancy 
offspring of dams fed the MDS diet (P=0.08). 
 Somewhat later in development, around E9 in mouse development (Thomas et 
al., 1998) or around 24 days in humans (Larsen et al., 2001), the branchial arches become 
apparent as NCC-derived mesenchyme begins to condense. For normal development to 
proceed, the NCC-derived mesenchyme must maintain a proper balance between 
proliferation and apoptosis. This allows normal jaw outgrowth and palatal formation. 
Precise regulation of bone morphogenetic protein signaling is essential for mandibular 
outgrowth (Stottmann et al., 2001) and specifically TWSG1 is important for limiting 
apoptosis in BA1 (MacKenzie et al., 2009). We observed notable protection by methyl 
donor dietary supplementation of structures derived from BA1 in Twsg1
-/-
 mice, possibly 
through facilitating NCC mesenchymal proliferation. The incidence of agnathia increased 
with higher parity among mice born from pregnancies given control diet (P=0.03). 
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In summary, we found that dietary methyl donor supplementation and maternal 
parity both had significant effects on Twsg1
-/-
 pregnancy outcomes in terms of 
craniofacial defects. These results suggest that environmental factors can alter the 
incidence of phenotypes arising from the genetic susceptibility conferred by Twsg1 
mutation. Differential responses of different types of defects to diet and parity suggest 
that a heterogenous set of pathologies underlies the complexity and variation of the 
Twsg1
-/-
 phenotype. This highlights the possibility that different defects within a given 
syndrome may show different responses to specific interventions. This study also 
highlights the importance of accounting for parity when analyzing the results of any 
preventive approach. It should be noted, however, that this study has several limitations, 
such as lack of direct measurement of folate or other methyl donor levels in the maternal 
serum or variable duration of feeding with experimental diets, largely due to variable 
time to pregnancy. Future studies should explore whether there is a correlation between 
maternal and/or fetal nutrient levels and the incidence or type of craniofacial defects as 
well as the mechanisms through which increased parity may increase the incidence of 
craniofacial defects.  
   99 
Chapter 5: Generation of a conditional mouse model of Twsg1 
overexpression 
Introduction 
 Twisted gastrulation (TSG or TWSG1 in mammals) is a conserved extracellular 
BMP binding protein. It was first identified based on the effect of mutation on dorsal-
ventral patterning in the early Drosophila embryo (Zusman and Wieschaus, 1985; Mason 
et al., 1994; Mason et al., 1997). Homologs have been identified in other species as well, 
including vertebrates such as frogs, fish, chickens, mice and humans (Oelgeschlager et 
al., 2000; Chang et al., 2001; Graf et al., 2001; Ross et al., 2001; Scott et al., 2001). Most 
of the mechanistic studies of TSG action have been performed in non-mammals. TSG has 
been primarily reported as an antagonist of BMP action, based on studies performed in 
flies, frogs and fish. This antagonism takes place due to binding of TSG to BMPs and 
particularly through TSG potentiating the action another BMP inhibitor, Chordin (Yu et 
al., 2000; Chang et al., 2001; Ross et al., 2001; Scott et al., 2001; Blitz et al., 2003; Wills 
et al., 2006). Intriguingly, TSG can also serve in some situations to promote BMP 
signaling (Oelgeschlager et al., 2000; Little and Mullins, 2004). The seeming paradox of 
these dual activities of TSG inhibiting or promoting BMP signaling has been explained as 
a consequence of TSG helping facilitate BMP ligand transport and proteolytic cleavage 
of Chordin (Oelgeschlager et al., 2000; Harland, 2001; Larrain et al., 2001; O'Connor et 
al., 2006). 
 In mice Twsg1 is robustly expressed in mouse embryonic and postnatal tissues 
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beginning as early as embryonic day 7 (E7) (Graf et al., 2001). In order to understand the 
role of TWSG1 in mice we generated mice deficient in TWSG1 by deleting the fourth 
exon of the mouse Twsg1 gene (Petryk et al., 2004). Deletion of this exon makes TWSG1 
unable to bind BMP, even if TWSG1 protein is made (Billington et al., 2011b). Other 
existing TWSG1-deficient mouse models have been generated by replacing exon 2 
(Nosaka et al., 2003; Zakin and De Robertis, 2004), or parts of exons 2 and 3 (Gazzerro 
et al., 2006), of the Twsg1 gene with neo
R
 or LacZ gene cassettes. Disruption of Twsg1 
resulted in both embryonic and postnatal phenotypes. The most striking embryonic 
phenotype resulting from TWSG1 deficiency is abnormal craniofacial development 
(holoprosencephaly and jaw defects) in the C57BL/6 background (Petryk et al., 2004). 
Other abnormalities of development in Twsg1
-/- 
mice include improper development of 
the vertebrae (Nosaka et al., 2003; Petryk et al., 2004; Zakin and De Robertis, 2004; 
Gazzerro et al., 2006) as well as the salivary gland abnormalities (Melnick et al., 2006). 
In conjunction with Crossveinless 2, TWSG has also been implicated in embryonic 
kidney development (Ikeya et al., 2010). 
Postnatally, TWSG1 has been implicated in immune cell development and 
function (Nosaka et al., 2003; Tsalavos et al., 2011), iron homeostasis (Tanno et al., 
2009), and particularly in bone homeostasis, as indicated both by the in vitro studies 
(Gazzerro et al., 2005; Petryk et al., 2005) and by the osteopenia seen in Twsg1
-/-
 mice 
(Nosaka et al., 2003; Petryk et al., 2004; Gazzerro et al., 2006). The lower perinatal 
mortality of Twsg1
-/- 
mice in the 129SvEv background allowed us to study the basis of 
osteopenia in these mice. We found that deficiency of TWSG1 led to increased 
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osteoclastogenesis, manifesting as larger and more numerous osteoclasts with increased 
ability to resorb bone (Sotillo Rodriguez et al., 2009; Pham et al., 2011). The pleiotropic 
effects of TWSG1 acting in widely varying tissues and processes are not surprising given 
its role to modulate BMPs, which themselves regulate a wide range of embryonic and 
postnatal processes in normal development and disease (Wagner et al., 2010).  
 While the consequences of loss-of-function of Twsg1 have been well described, a 
mouse model over-expressing the Twsg1 gene has not yet been generated. The 
overexpression studies that have been performed so far with mouse tissues or cells have 
utilized exogenously applied TWSG proteins (Petryk et al., 2005; Billington et al., 
2011b) or have used viral transduction (Gazzerro et al., 2005; Pham et al., 2011) to model 
overexpression of Twsg1. The goal of this study was to generate transgenic mice 
overexpressing Twsg1 to examine its effects on craniofacial skeletal development and 
postnatal bone homeostasis. Our hypothesis was that excess TWSG1 would be protective 
against craniofacial defects during embryonic development and postnatally, 
overexpression of TWSG1 would limit osteoclast differentiation and function. It is 
important to understand the effect of under-and overexpression of TWSG1 on osteoclast 
function because of potential clinical implications. Stimulation of osteoclastogenesis is 
important for treatment of diseases with impaired osteoclast function, such as 
osteopetrosis (Marks, 1987). On the other hand, inhibition of osteoclast function would 
be beneficial in diseases with pathologically increased osteoclast function, such as 
osteoporosis (Teitelbaum and Ross, 2003). An in vivo model would provide an additional 
reagent that will facilitate further study.  
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Materials and Methods 
Plasmids  
pBigT and pROSA26PA plasmids for targeting ROSA26 locus were a kind gift of Dr. 
Sankar Srinivas (Srinivas et al., 2001). The Twsg1 coding DNA Sequence (CDS) was 
amplified by PCR using the primers 5’- aatgcgtcgacctttgagccaccatgaagtc-F and 5’- 
tccccgcggcctctttaaaacatgcagttc-R with engineered SalI and SacII restriction sites and 5’ 
Kozak sequence (Kozak, 1987). The resultant Twsg1 amplicon was cloned into the 
pCR2-Topo vector according to manufacturer’s instructions (Invitrogen, Carlsbad CA) 
and confirmed by sequencing. The Twsg1 insert was cut from the pCR2-Topo plasmid 
using SalI and SacII and ligated into pBigT using a rapid DNA ligation kit (Roche, 
Indianapolis, IN). The resulting pBigT-Twsg1 plasmid was then digested with PacI and 
AscI and ligated into the pROSA26PA plasmid in which an XbaI site 1.1 kb to 3’ from 
the 5’ end of the ROSA26 homologous sequence has been replaced by a PacI-SwaI-AscI 
linker. This insertion of the pBigT-Twsg1 sequences into pROSA26PA yielded the 
targeting vector.  
ES cell injection screening and mouse generation  
The pROSA26PA-pBigT-Twsg1 plasmid was linearized by digestion with KpnI 
and cleaned up by phenol-choloroform extraction for electroporation into mouse 
CJ7/129SV ES cells. ES cell electroporations were performed at the Mouse Genetics 
Laboratory at the University of Minnesota. Clones were selected for G418 resistance and 
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picked for screening. Genomic DNA was initially screened by PCR using a primer of P1: 
5’-TAGGTAGGGGATCGGGACTC-F and P2: 5’-TCATCAAGGAAACCCTGGAC-R. 
Following an approach previously described (Soriano, 1999), this primer pair has one 
primer complimentary to the endogenous genomic locus outside the region of homology 
(P1) and one end in the splice acceptor sequence (P2) PCR yields an 1194 bp 
amplification band if targeting takes place. Primers were designed using the NCBI primer 
BLAST tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and MacVector 
(MacVector, Cary, NC). Positive clones by PCR were confirmed by Southern blotting 
after EcoRV digestion of genomic DNA samples.  Restriction fragments were detected 
using a 559 bp 
32
P-labeled probe complimentary to the 5’ flanking region for ROSA26. 
The probe template was generated by PCR amplification of CJ7/129SV ES cell genomic 
DNA using the primers 5’-AATACCCAGGCAAAAAGGGGAGACC-F and 5’- 
GCTCAGAGACTCACGCAGCCCTAGT-R and probe labeling was performed using the 
Prime-a-gene labeling system (Promega, Madison, WI). This probe detects an 11kb wild 
type band and a 4.1 kb targeted band after EcoRV digestion. Selected positive clones 
were also further confirmed by Southern blotting after SacI digestion, yielding a wild 
type band of 17kb and a targeted band of 5.7 kb.  Confirmed targeted clones were sent for 
cytogenetic analysis. Clones without identifiable chromosomal abnormalities were 
injected into blastocysts and then the blastocysts implanted into pseudopregnant dams to 
generate chimeras. Offspring of the chimeras were screened for germline transmission by 
PCR and Southern blotting as described above. After confirmation of targeted colony 
founders, subsequent genotyping was performed by PCR, using primers P1 and P2 to 
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detect the targeted allele and primers P3 5’- TTGGAGGCAGGAAGCACTTG-F, and P4 
5’- CCGACAAAACCGAAAATCTGTG-R to detect the wild type allele “R26
+
”.  
Mice  
Mice were housed in SPF conditions in filter-lidded, 18x29cm cages lined with 
pulverized corncob bedding, with cotton fiber blocks for nesting material. Cages were 
changed weekly. Standard chow (Teklad) and water were provided ad libitum. Ambient 
conditions were maintained with air temperature 20-23˚C, humidity 30-70%, and a 
14h/10h light/dark cycle. All animal procedures in this report were approved by the 
University of Minnesota Institutional Animal Care and Use Committee.   
In addition to the targeted R26
(fs)Twsg1 
allele (fs: floxed STOP) generated as 
described above, several other lines were used. C57BL/6 mice for backcrossing were 
obtained from Taconic (Hudson, NY). EIIa-cre mice, MGI: Tg(EIIa-cre)C5379Lmgd, 
(Lakso et al., 1996) were a gift of Dr. York Marahrens. LysM-cre mice (Clausen et al., 
1999) were provided by Dr. Kim Mansky and Dr. Rajaram Gopalakrishnan. EIIa-cre and 
LysM-cre mice were genotyped using primers designed to detect the cre gene insertion: 
5’- CTGCCACGACCAAGTGACAGC-F, 5’-CTTCTCTACACCTGCGGTGCT-R.  
Generation of mice with global overexpression of Twsg1  
The latent conditional ROSA26-Twsg1 targeted allele, R26
(fs)Twsg1
 was activated to 
generate a globally overexpressing line, R26
Twsg1
, by crossing ROSA targeted mice with 
EIIa-cre mice (Lakso et. al., 1996). EIIa-cre mice express Cre recombinase in the early 
embryo and in the germline. Offspring of the mating of EIIa-cre and R26
(fs)Twsg1/+
 mice 
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yielded mice which were R26
Twsg1/+
;EIIa-cre+ The offspring of these mice were expected 
to have and transmit the activated form of the ROSA26 targeted allele, R26
Twsg1
, with 
fixed deletion of the floxed STOP cassette now independent of Cre activity. 
Recombination was detected by PCR using primers P3 and P4, which were expected to 
yield a 1619bp band after cassette deletion. Cassette deletion was confirmed by Southern 
blotting with the probe as described above, after SacI digestion.  This yielded a band of 
3.1kb after cassette deletion compared to 5.7 kb prior to deletion.  Subsequent genotyping 
was performed by PCR. LysM-cre mice were crossed to R26 
(fs)Twsg1/+
 or R26 
(fs)Twsg1/ 
(fs)Twsg1
 mice to generate R26 
(fs)Twsg1/+
;LysMcre+ or R26 
(fs)Twsg1/ (fs)Twsg1
;LysMcre+ mice 
which would over-express Twsg1 only in cells of the myeloid lineage.  
Isolation, culture and characterization of osteoclast cells  
Osteoclasts were cultured from bone marrow of 5-week old mice and grown in 
alpha-MEM with 10% fetal bovine serum with L-glutamine and antibiotics similarly to 
previously reported protocols (Sharma et al., 2007; Sotillo Rodriguez et al., 2009). 
Briefly, bone marrow was flushed with media and the resulting suspension was allowed 
to plate overnight in 100mm dishes. The next day, the non-adherent fraction was treated 
with erythrocyte lysis buffer to yield a preparation containing primarily monocytes. 
These cells were then moved to culture plates in growth media with the addition of 10% 
conditioned media from L-cells to provide m-csf. After 2 days RANKL (R&D systems, 
Minneapolis, MN) was added at 60 ng/mL and the osteoclasts were allowed to 
differentiate for 5 days. Cells were stained for TRAP using a commercially available kit 
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(Sigma, St. Louis, MO). Photographed osteoclasts were analyzed in Adobe Photoshop 
(Adobe, San Jose, CA).  
Tissue harvests and overexpression confirmation  
Timed matings were set up to obtain first branchial arch (BA1) tissue at E11.5 
(counting the appearance of spermatic plug as E0.5). Mandibular and maxillary 
components of BA1 were microdissected with etched tungsten needles and flash frozen in 
liquid nitrogen, while remaining embryonic tissues were saved for genotyping.  Adult 
mice were sacrificed by CO2 inhalation and kidneys and lungs were dissected and 
homogenized in Trizol (Invitrogen). Osteoclast RNA was harvested by lysing cultured 
osteoclasts in the culture dish with Trizol. RNA was isolated from tissue or cell 
homogenates in Trizol according to manufacturer’s instructions. cDNA was synthesized 
from RNA using the Thermoscript reverse transcription kit according to manufacturer’s 
instructions (Invitrogen).  
After cDNA synthesis, samples were assayed by qPCR using primers directed 
against the CDS or the un-translated regions (UTR) of the native Twsg1 transcript. CDS 
primers used were 5’-TGAGCAAATGCCTCATTCAG-F, 5’-
GGTTGCACATACCGACACAG-R which amplifies a region spanning exons 2, 3 and 4 
of the Twsg1 mRNA, UTR primers were 5’-CTCCCGATCCTCATGTGACT-F, 5’- 
TGCATGTTTTAAAGAGGGGG-R in the exon 5 3’ UTR Expression was normalized to 
amplification from Gapdh, 5’-TGCACCACCAACTGCTTAG-F, 5’- 
GATGCAGGGATGATGTTC-R. PCR was performed using 2x mastermix with ROX 
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from SA biosciences (Valencia, CA) and performed on an Mx3000p thermocycler 
(Stratagene, La Jolla, CA) with analysis using the MxPro software (Stratagene). 
Results 
Targeting to the ROSA26 locus inserts allows generation of a conditional Twsg1 
overexpression allele  
We were able to generate a mouse that has conditional overexpression of Twsg1 
from the ROSA26 locus. The ROSA26-Twsg1 transgenic strategy was based on previous 
work (Srinivas et al., 2001) and takes advantage of ubiquitous expression of sequences 
inserted into the ROSA26 locus (Soriano, 1999; Srinivas et al., 2001). A floxed triple 
polyadenylation sequence upstream of the inserted gene functions as a transcriptional 
STOP cassette and prevents expression without the action of Cre recombinase (Figure 
20A).  We screened 480 electroporated ES cell clones by PCR (Figure 20B) and were 
able to identify 8 with targeting, 5 of these were confirmed by Southern blotting. Of 
these, 2 were suitable for injection after karyotyping. We generated several chimeras and 
established a mouse line from a chimera that showed germline transmission of the 
conditional targeted allele R26
(fs)Twsg1
. Mice from this line had a targeted insertion at the 
ROSA26 locus, as indicated by PCR and by Southern Blotting (Figure 20B, 20C). PCR 
shows a 1194 bp band in targeted mice and no amplification in untargeted mice. Southern 
blotting after EcoRV digestion of genomic DNA shows a 4.1kb band in targeted R26 
(fs)Twsg1/+
 mice but only an 11.5 kb band in wild type R26 
+/+
 mice.  
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Figure 20: Targeting Twsg1 to the ROSA26 locus and 
identifying targeted clones and targeted mice.  
 
A) Top to bottom: pBigT plasmid with a splice acceptor (SA) 
sequence followed by a LoxP-flanked cassette containing a 
phosphoglycerate kinase promoter driven Neomycin/G418 
resistance marker (PGK-Neo) for positive selection and a 
triple SV40-polyadenylation transcriptional termination 
sequence (tpA). The cassette is followed by an insertion of the 
mouse Twsg1 CDS into the multiple cloning site (MCS) of the 
plasmid with a final polyadenylation signal (bpA) derived 
from the bovine growth hormone gene.  
 
 
pROSA26PA plasmid contains 5’ and 3’ genomic sequences for homologous recombination (R26 5’ and 3’ 
Seq.) The PacI-AscI fragment from pBigT is cloned into pROSA26PA plasmid at an engineered linker in 
between the 5’ and 3’ homology arms. The plasmid also contains a diptheria toxin negative selection gene 
(PGK-DTA) outside the homology arms.  
 
The ROSA26 genomic locus is illustrated with the endogenous restriction sites. Homologous regions for 
pROSA26-PA are bordered by the SacII and XbaI restriction sites. Binding locations for ROSA26 primers 
P1 and P2 are shown in green and for primers P3 and P4 in purple. P3 and P4 make a 358 bp band with the 
untargeted genomic locus R26+ as a template. P1 and P2 do not amplify without targeting due to absence of 
P2’s target sequence. Southern blot probe binding is indicated by the black rectangle with restriction 
fragments from EcoRV in red, and SacI  in light blue with lengths 11.5 kb and 17.0kb respectively. 
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Generation of mice with global overexpression of Twsg1 
In order to activate the latent conditional allele R26 
(fs)Twsg1
 we mated the 
conditional targeted transgenic line to mice with the EIIa-cre allele, which express Cre 
recombinase in the early embryo (Lakso et al., 1996). We reasoned that in this would 
yield pups that had germline deletion of the inhibitory STOP cassette, generating the 
active overexpression allele (R26
Twsg1
). We were able to mediate cassette excision using 
EIIa-cre as indicated by PCR and confirmed by Southern blotting. The formation of a 
1619 bp band with primers P3 and P4 indicates the deletion of the STOP cassette (Figure 
21A). In the heterozygous state, R26
Twsg1/+
, this band is weak, likely due to competition 
with the shorter 358 bp band amplified from the wild type R26
+
 allele, but in 
homozygous R26
Twsg1/Twsg1
 samples this 1619 bp band produces a strong signal. A 
predicted band at 4285bp (See figure 20A) in targeted but not cassette-deleted mice does 
not form (Figure 21A), likely exceeding amplification length. Southern blotting is able to 
Figure 20, continued: 
 
The targeted but inactive transgenic locus R26(fs)Twsg1 (fs: Floxed STOP) has the floxed neo-tpA STOP 
cassette and Twsg1 CDS insertion.  The primer pair P1 and P2 make a 1194 bp amplicon. P3 and P4 
would be predicted to make a 4285 bp band but in practice this does not amplify. Restriction fragment 
lengths are 4.1kb for EcoRV, and 5.7kb for SacI.  
 
The activated locus R26Twsg1, following Cre-mediated STOP cassette excision. The P1-P2 PCR 
amplicon is still 1194 bp. P3 and P4 now make a 1619bp amplicon. Restriction fragment lengths are 
3.1kb for EcoRV, and 3.1kb for SacI.  
 
B) PCR screening using ROSA26 primer pair 1 was able to identify positive clones, including the 
positive clone which was used for embryo injections. Offspring from the first generation of C57Bl/6 
backcrossing also show positive amplification from tail tip genomic DNA in targeted mice but not in 
untargeted littermates  
 
C) Confirmation of targeting by Southern blotting for EcoRV restriction fragments. ES cell clone and 
mouse 1 show the targeted band at 4.1 kb while mouse 2 does not. 
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confirm the excision of the neo-STOP cassette by the shortening of a SacI restriction 
fragment from 5.7 to 3.1 kb (Figure 21B). Mice with STOP cassette deletion, in the 
homozygous or heterozygous state were viable and fertile with no gross defects apparent 
on examination.  
 
 
 
Confirmation of transcript overexpression in R26
Twsg1
 Mice  
We proceeded to confirm that the R26
Twsg1
 allele overexpressed the inserted 
Twsg1 sequence in embryonic and adult tissues as expected. Based on previous work 
indicating a role for TWSG1 during embryonic development in the developing face and 
Figure 21: Deletion of floxed neo-transcriptional stop cassette.  
A) PCR can be used screen or to genotype genomic DNA samples for both targeting and cassette 
excision. Inactive targeted, active targeted and wild type samples are shown with amplification 
products from ROSA26 primer set 1 and primer set 2. The 1194 bp band indicative of targeting 
(R26(fs)Twsg1, R26Twsg1) is present in both targeted samples (Black triangle). The 1619 bp band (white 
triangle) is seen in the activated targeted allele (R26Twsg1) only. The same primer set also amplifies a 
band from the native locus (+) 358bp amplicon (gray triangle). B) Southern blotting for SacI 
restriction fragments shows a 5.7kb band with the targeted but inactive allele. With the activation of 
the allele by Cre-recombinase to remove the 2.6 kb floxed STOP cassette, a 3.1kb band is seen. 
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specifically in BA1 (Petryk et al., 2004; MacKenzie et al., 2009; Billington et al., 2011a) 
we were interested in whether Twsg1 would be overexpressed in these embryonic tissues. 
We found that Twsg1 was significantly overexpressed in BA1 at E11.5. In heterozygous 
R26
Twsg1/+ 
embryos this overexpression was roughly 2.5-fold over the wild type 
expression, while in homozygous R26
Twsg1/Twsg1 
embryos Twsg1 transcript levels were 
increased by approximately 6-fold (Figure 22A). Overexpression was limited solely to 
CDS sequences. Twsg1 UTR sequences showed no change in expression (Figure 22A). 
To confirm these results, we assayed the same BA1 cDNA samples by two more pairs of 
qPCR primers designed against the CDS and UTRs and found nearly identical results 
(data not shown).  
 
 
 
Figure 22: Increased CDS-specific Twsg1 
transcripts in adult and embryonic tissues 
in R26
Twsg1/+
 and R26
Twsg1/Twsg1
 mice:  
A) cDNA was prepared from embryonic day 
11.5 maxillary and mandibular branchial 
arch 1 (BA1) tissues was assayed for 
expression of both the Twsg1 CDS (black 
bars) and the untranslated regions (UTR) 
present in the Twsg1 native locus but not the 
transgene (white bars). E11.5 BA1s show 
increasing expression of CDS sequences 
with increasing gene dosage from R26+/+ to 
R26Twsg1/+ to R26Twsg1/Twsg1. *** p < 0.001 by 
Student’s t-test compared to R26+/+. ††† p < 
0.001 by Student’s t-test compared to 
R26Twsg1/+ B) Kidney tissue cDNA from 
R26+/+  and R26Twsg1/+ animals shows more 
than 3 fold increase in Twsg1 transcripts of 
the CDS in R26Twsg1/+ with no impact on the 
prevalence of UTR sequences. C) Lung 
tissue cDNA was assayed from R26Twsg1/+ 
animals and shows a more than 7 fold 
increase compared to R26+/+  specifically for 
CDS sequences. *** p < 0.001 by Student’s 
t-test compared to R26+/+. 
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We also assayed adult kidney and lung tissues from two R26 
Twsg1/+ 
and two 
R26
+/+
 mice and found that there were increased levels of Twsg1 CDS sequences. 
R26
Twsg1/+  
overexpressed Twsg1 CDS transcripts by 3-fold in the kidney and by more 
than 7-fold in the lung, compared to the same tissues from wild type mice (Figure 22B, 
22C). UTR sequences were not elevated (Figure 22B, 22C) To confirm these results, we 
assayed the same samples by two more pairs of qPCR primers designed against the CDS 
and UTRs and found similar results (data not shown). 
Osteoclast specific overexpression of Twsg1 limits size and number of osteoclasts  
Based on previous work demonstrating that TWSG1 limits BMP induced 
osteoclastogenesis (Sotillo Rodriguez et al., 2009; Pham et al., 2011) we hypothesized 
that overexpression of Twsg1 in osteoclasts should limit osteoclastogenesis. We 
generated myeloid lineage-specific Twsg1 overexpressing mice by combining the 
conditional targeted R26 
(fs)Twsg1
 allele with a myeloid-specific Cre recombinase 
expressing allele, LysM-cre. We then isolated and cultured osteoclasts from these mice. 
The resulting R26 
Twsg1 
osteoclast cultures showed marked and significant increase in 
their expression of Twsg1 transcripts depending on gene dosage (Figure 23). The cultured 
cells, being from the myeloid lineage, have the Cre-activated form of the allele. The 
osteoclast suppressive effect of Twsg1 overexpression is apparent upon inspection of 
stained culture plates (Figure 24A, 24B, 24C). Increased Twsg1 expression correlated 
with decreases in mature osteoclast number (Figure 24D) and in osteoclast size (Figure 
24E). 
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Figure 23: Cre-mediated overexpression of Twsg1 in osteoclasts. 
Osteoclasts generated from floxed or wild type mice carrying the LysM-cre 
allele show increasing expression of CDS sequences with increasing gene 
dosage from R26+/+ to R26Twsg1/+ to R26Twsg1/Twsg1. *** p < 0.001 by 
Student’s t-test compared to R26+/ 
 
Figure 24: Deletion of floxed neo-transcriptional stop cassette.  
R26+/+, R26(fs)Twsg1/+, and R26(fs)Twsg1/(fs)Twsg1 osteoclasts were generated from floxed or wild type mice 
carrying the LysM-cre allele and stained for tartrate resistant acid phosphatase (TRAP) A) R26+/+ 
osteoclasts show many large multinuclear TRAP+ cells. B, C) R26Twsg1/+ and R26Twsg/Twsg1 show fewer 
TRAP+ multinucleated cells and those present are smaller in size. D) the number of TRAP+ multinucleated 
cells, indicating mature osteoclasts, is decreased with increased gene dosage of the overexpressing allele E) 
Osteoclast size is also decreased with increasing gene dosage of the Twsg1 transgenic allele.  
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Discussion 
The model of Twsg1 overexpression presented here takes advantage of the 
ubiquitous expression of genes inserted into the ROSA26 locus. A floxed transcriptional 
STOP cassette formed by a tripled SV40 derived polyadenylation sequence provided 
control over the overexpression of the inserted Twsg1 sequence. This allows precise 
spatial control of Twsg1 overexpression. We were able to confirm overexpression of 
Twsg1 transcripts in mice with Cre-activated targeted alleles. Both embryonic tissues and 
adult tissues showed significant overexpression. We designed our assays to take 
advantage of the fact that only the CDS was inserted into the transgene. This allowed us 
to confirm that overexpression was coming specifically from the transgene by controlling 
for the untranslated regions (UTRs) in the endogenous transcript. There was no 
upregulation of UTR sequences compared to WT levels, indicating not only that 
additional Twsg1 CDS transcripts are solely from the transgene, but also that the 
overexpression appears to have no impact on the endogenous expression of Twsg1. 
Given TWSG1’s role in the embryonic development of the face (Petryk et al., 
2004; MacKenzie et al., 2009; Billington et al., 2011a) we were particularly interested in 
the ability to increase expression of Twsg1 in the developing facial tissues. We were able 
to see increased Twsg1 transcript levels in isolated BA1s suggesting the utility of this 
mouse model for studies of the effect of Twsg1 overexpression on craniofacial 
development.  
 The increased susceptibility of TWSG1-deficient mice to craniofacial birth 
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defects after certain teratogenic exposures (Billington et al. unpublished observations) 
raises the possibility that TWSG1 overexpression could prove to have an 
embryoprotective role during development. It is conceivable that  TWSG1-
overexpressing transgenic mice will show additional robustness to teratogenic insults 
compared to wild type mice. This hypothesis will be addressed in future studies using the 
mice generated in this report.  
 In addition to the role of TWSG1 in embryonic development, TWSG1 also plays 
an important role in regulation of adult tissues. Research in osteoclast models uncovered 
a role for TWSG1 in limiting osteoclast promoting BMP activity. Without TWSG1 
osteoclasts are overactive, leading to osteopenia (Sotillo Rodriguez et al., 2009). To date 
however the only in vivo studies of TWSG1 action have been models of TWSG1 
deficiency. The effect of increased TWSG1 has only been studied in vitro using using 
exogenous protein or viral transduction in cell culture (Sotillo Rodriguez et al., 2009; 
Pham et al., 2011). These in vitro studies can now be complemented by in vivo studies. 
This will allow better characterization of the action of TWSG in regulating signals that 
govern osteoclast development. Better understanding of osteoclast regulation will allow 
development of better therapies for diseases like osteopetrosis and osteoporosis that are 
characterized by under-or over-activity of osteoclasts.  
 In summary, the ROSA26 targeted conditional Twsg1-overexpressing mouse will 
provide a valuable reagent for future studies of the action of TWSG1 in embryonic and 
adult tissues. 
   116 
References: 
 
Chapter 2 note of previous publication 
Figures, tables and text in Chapter 2 are reprinted with minor editing from the article:  
Billington, C. J., Jr., Fiebig, J. E., Forsman, C. L., Pham, L., Burbach, N., Sun, M., 
Jaskoll, T., Mansky, K., Gopalakrishnan, R., O'Connor, M. B. et al. (2011a). 
Glycosylation of Twisted Gastrulation is Required for BMP Binding and Activity 
during Craniofacial Development. Front Physiol 2, 59. 
“Under … the Frontiers General Conditions for Authors, authors of articles published in 
Frontiers journals retain copyright on their articles, … Authors are therefore free to 
disseminate and re-publish their articles… subject to the original publication being fully 
cited.” (http://www.frontiersin.org/Physiology/about) 
 
Chapter 3 note of previous publication 
Figures, tables and text in Chapter 3 are reprinted with minor editing from the article: 
Billington, C. J., Jr., Ng, B., Forsman, C., Schmidt, B., Bagchi, A., Symer, D. E., Schotta, 
G., Gopalakrishnan, R., Sarver, A. L. and Petryk, A. (2011b). The molecular and 
cellular basis of variable craniofacial phenotypes and their genetic rescue in 
Twisted gastrulation mutant mice. Dev Biol 355, 21-31. 
Journal Authors retain “the right to include the journal article, in full or in part, in a thesis or 
dissertation” (http://www.elsevier.com/wps/find/authorsview.authors/rights#whatrights) 
 
Chapter 4 note of previous publication 
Figures, tables and text in Chapter 4 are reprinted with minor editing from the article: 
Billington, C. J., Jr., Schmidt, B., Zhang, L., Hodges, J. S., Georgieff, M. K., Schotta, G., 
Gopalakrishnan, G., Petryk, A. (2013). Maternal diet supplementation with 
methyl donors and increased parity affect the incidence of craniofacial defects in 
the offspring of Twisted gastrulation mutant mice. J Nutr 143 (3), 332-339. 
“Effective upon acceptance for publication, the American Society for Nutrition will license the 
following nonexclusive rights back to authors: … The right to include their article in their 
thesis or dissertation.” (http://www.nutrition.org/publications/guidelines-and-
policies/permissions/#autogrant)  
 
   117 
Works Cited:  
 
Achón, M., Alonso-Aperte, E., Reyes, L., Ubeda, N. and Varela-Moreiras, G. (2000). 
High-dose folic acid supplementation in rats: effects on gestation and the 
methionine cycle. Br J Nutr 83, 177-183. 
Anderson, R. M., Lawrence, A. R., Stottmann, R. W., Bachilier, D. and 
Klingensmith, J. (2002). Chordin and noggin promote organizing centers of 
forebrain development in the mouse. Development 129, 4975-4987. 
Aoto, K., Shikata, Y., Higashiyama, D., Shiota, K. and Motoyama, J. (2008). Fetal 
ethanol exposure activates protein kinase A and impairs Shh expression in 
prechordal mesendoderm cells in the pathogenesis of holoprosencephaly. Birth 
Defects Res A Clin Mol Teratol 82, 224-231. 
Aoto, K., Shikata, Y., Imai, H., Matsumaru, D., Tokunaga, T., Shioda, S., Yamada, 
G. and Motoyama, J. (2009). Mouse Shh is required for prechordal plate 
maintenance during brain and craniofacial morphogenesis. Dev Biol 327, 106-
120. 
Avsian-Kretchmer, O. and Hsueh, A. J. (2004). Comparative genomic analysis of the 
eight-membered ring cystine knot-containing bone morphogenetic protein 
antagonists. Mol Endocrinol 18, 1-12. 
Bailey, L. B. (1992). Evaluation of a new Recommended Dietary Allowance for folate. J 
Am Diet Assoc 92, 463-468, 471. 
Barbosa, J. A., Santos-Aguado, J., Mentzer, S. J., Strominger, J. L., Burakoff, S. J. 
and Biro, P. A. (1987). Site-directed mutagenesis of class I HLA genes. Role of 
glycosylation in surface expression and functional recognition. J Exp Med 166, 
1329-1350. 
Benjamini, Y. and Hochberg, Y. (1995). Controlling the false discovery rate: a practical 
and powerful approach to multiple testing. Journal of the Royal Statistical 
Society. Series B. 
Benz, I. and Schmidt, M. A. (2001). Glycosylation with heptose residues mediated by 
the aah gene product is essential for adherence of the AIDA-I adhesin. Mol 
Microbiol 40, 1403-1413. 
Berdal, A., Molla, M., Hotton, D., Aïoub, M., Lézot, F., Néfussi, J. R. and Goubin, 
G. (2009). Differential impact of MSX1 and MSX2 homeogenes on mouse 
maxillofacial skeleton. Cells, tissues, organs 189, 126-132. 
Berry, R. J. and Li, Z. (2002). Folic acid alone prevents neural tube defects: evidence 
from the China study. Epidemiology 13, 114-116. 
Berry, R. J., Li, Z., Erickson, J. D., Li, S., Moore, C. A., Wang, H., Mulinare, J., 
Zhao, P., Wong, L. Y., Gindler, J. et al. (1999). Prevention of neural-tube 
   118 
defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube 
Defect Prevention. N Engl J Med 341, 1485-1490. 
Bier, E. (2008). Intriguing extracellular regulation of BMP signaling. Dev Cell 15, 176-
177. 
Billington, C. J., Jr., Ng, B., Forsman, C., Schmidt, B., Bagchi, A., Symer, D. E., 
Schotta, G., Gopalakrishnan, R., Sarver, A. L. and Petryk, A. (2011a). The 
molecular and cellular basis of variable craniofacial phenotypes and their genetic 
rescue in Twisted gastrulation mutant mice. Dev Biol 355, 21-31. 
Billington, C. J., Jr., Fiebig, J. E., Forsman, C. L., Pham, L., Burbach, N., Sun, M., 
Jaskoll, T., Mansky, K., Gopalakrishnan, R., O'Connor, M. B. et al. (2011b). 
Glycosylation of Twisted Gastrulation is Required for BMP Binding and Activity 
during Craniofacial Development. Front Physiol 2, 59. 
Blitz, I. L., Cho, K. W. and Chang, C. (2003). Twisted gastrulation loss-of-function 
analyses support its role as a BMP inhibitor during early Xenopus embryogenesis. 
Development 130, 4975-4988. 
Blom, H. J., Shaw, G. M., den Heijer, M. and Finnell, R. H. (2006). Neural tube 
defects and folate: case far from closed. Nat Rev Neurosci 7, 724-731. 
Bobola, N., Carapuco, M., Ohnemus, S., Kanzler, B., Leibbrandt, A., Neubuser, A., 
Drouin, J. and Mallo, M. (2003). Mesenchymal patterning by Hoxa2 requires 
blocking Fgf-dependent activation of Ptx1. Development 130, 3403-3414. 
Boot, M. J., Steegers-Theunissen, R. P., Poelmann, R. E., Van Iperen, L., 
Lindemans, J. and Gittenberger-de Groot, A. C. (2003). Folic acid and 
homocysteine affect neural crest and neuroepithelial cell outgrowth and 
differentiation in vitro. Dev Dyn 227, 301-308. 
Botto, L. D., Moore, C. A., Khoury, M. J. and Erickson, J. D. (1999). Neural-tube 
defects. N Engl J Med 341, 1509-1519. 
Botto, L. D., Lisi, A., Bower, C., Canfield, M. A., Dattani, N., De Vigan, C., De 
Walle, H., Erickson, D. J., Halliday, J., Irgens, L. M. et al. (2006). Trends of 
selected malformations in relation to folic acid recommendations and 
fortification: an international assessment. Birth Defects Res A Clin Mol Teratol 
76, 693-705. 
Braybrook, C., Doudney, K., Marcano, A. C., Arnason, A., Bjornsson, A., Patton, 
M. A., Goodfellow, P. J., Moore, G. E. and Stanier, P. (2001). The T-box 
transcription factor gene TBX22 is mutated in X-linked cleft palate and 
ankyloglossia. Nat Genet 29, 179-183. 
Bruce, S., Hannula-Jouppi, K., Peltonen, J., Kere, J. and Lipsanen-Nyman, M. 
(2009). Clinically Distinct Epigenetic Subgroups in Silver-Russell Syndrome: The 
Degree of H19 Hypomethylation Associates with Phenotype Severity and Genital 
and Skeletal Anomalies. Journal of Clinical Endocrinology & Metabolism 94, 
   119 
579-587. 
Brugmann, S. A., Kim, J. and Helms, J. A. (2006). Looking different: understanding 
diversity in facial form. Am J Med Genet A 140, 2521-2529. 
Buller, A. L., Hastings, G. A., Kirkness, E. F. and Fraser, C. M. (1994). Site-directed 
mutagenesis of N-linked glycosylation sites on the gamma-aminobutyric acid type 
A receptor alpha 1 subunit. Mol Pharmacol 46, 858-865. 
Burgoon, J. M., Selhub, J., Nadeau, M. and Sadler, T. W. (2002). Investigation of the 
effects of folate deficiency on embryonic development through the establishment 
of a folate deficient mouse model. Teratology 65, 219-227. 
Burren, K. A., Savery, D., Massa, V., Kok, R. M., Scott, J. M., Blom, H. J., Copp, A. 
J. and Greene, N. D. (2008). Gene-environment interactions in the causation of 
neural tube defects: folate deficiency increases susceptibility conferred by loss of 
Pax3 function. Hum Mol Genet 17, 3675-3685. 
Butchbach, M. E., Rose, F. F., Jr., Rhoades, S., Marston, J., McCrone, J. T., Sinnott, 
R. and Lorson, C. L. (2009). Effect of diet on the survival and phenotype of a 
mouse model for spinal muscular atrophy. Biochem Biophys Res Commun. 
Canalis, E., Economides, A. N. and Gazzerro, E. (2003). Bone morphogenetic 
proteins, their antagonists, and the skeleton. Endocr Rev 24, 218-235. 
Canfield, M. A., Collins, J. S., Botto, L. D., Williams, L. J., Mai, C. T., Kirby, R. S., 
Pearson, K., Devine, O. and Mulinare, J. (2005). Changes in the birth 
prevalence of selected birth defects after grain fortification with folic acid in the 
United States: findings from a multi-state population-based study. Birth Defects 
Res A Clin Mol Teratol 73, 679-689. 
Caragea, C., Sinapov, J., Silvescu, A., Dobbs, D. and Honavar, V. (2007). 
Glycosylation site prediction using ensembles of Support Vector Machine 
classifiers. BMC Bioinformatics 8, 438. 
Castilla, E. E. and Orioli, I. M. (1986). Prevalence rates of microtia in South America. 
Int J Epidemiol 15, 364-368. 
Champy, M. F., Selloum, M., Zeitler, V., Caradec, C., Jung, B., Rousseau, S., 
Pouilly, L., Sorg, T. and Auwerx, J. (2008). Genetic background determines 
metabolic phenotypes in the mouse. Mamm Genome 19, 318-331. 
Chang, C., Holtzman, D. A., Chau, S., Chickering, T., Woolf, E. A., Holmgren, L. 
M., Bodorova, J., Gearing, D. P., Holmes, W. E. and Brivanlou, A. H. (2001). 
Twisted gastrulation can function as a BMP antagonist. Nature 410, 483-487. 
Chaoui, R., Heling, K. S., Thiel, G. and Karl, K. (2011). Agnathia-otocephaly with 
holoprosencephaly on prenatal three-dimensional ultrasound. Ultrasound Obstet 
Gynecol 37, 745-748. 
Chase, H. B. (1942). Studies on an Anophthalmic Strain of Mice. III. Results of Crosses 
   120 
with Other Strains. Genetics 27, 339-348. 
Chern, C. L., Huang, R. F., Chen, Y. H., Cheng, J. T. and Liu, T. Z. (2001). Folate 
deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-
dependent overproduction of hydrogen peroxide and enhanced activation of NF-
kappaB in human Hep G2 cells. Biomed Pharmacother 55, 434-442. 
Choi, S. W., Friso, S., Keyes, M. K. and Mason, J. B. (2005). Folate supplementation 
increases genomic DNA methylation in the liver of elder rats. Br J Nutr 93, 31-
35. 
Chong, H. J., Young, N. M., Hu, D., Jeong, J., McMahon, A. P., Hallgrimsson, B. 
and Marcucio, R. S. (2012). Signaling by SHH rescues facial defects following 
blockade in the brain. Dev Dyn 241, 247-256. 
Clausen, B. E., Burkhardt, C., Reith, W., Renkawitz, R. and Forster, I. (1999). 
Conditional gene targeting in macrophages and granulocytes using LysMcre mice. 
Transgenic Res 8, 265-277. 
Cohen, M. M., Jr. and Shiota, K. (2002). Teratogenesis of holoprosencephaly. Am J 
Med Genet 109, 1-15. 
Cooney, C. A., Dave, A. A. and Wolff, G. L. (2002). Maternal methyl supplements in 
mice affect epigenetic variation and DNA methylation of offspring. J Nutr 132, 
2393S-2400S. 
Csiszar, A., Labinskyy, N., Jo, H., Ballabh, P. and Ungvari, Z. (2008). Differential 
proinflammatory and prooxidant effects of bone morphogenetic protein-4 in 
coronary and pulmonary arterial endothelial cells. Am J Physiol Heart Circ 
Physiol 295, H569-577. 
Csiszar, A., Ahmad, M., Smith, K. E., Labinskyy, N., Gao, Q., Kaley, G., Edwards, 
J. G., Wolin, M. S. and Ungvari, Z. (2006). Bone morphogenetic protein-2 
induces proinflammatory endothelial phenotype. Am J Pathol 168, 629-638. 
Czeizel, A. E. and Dudas, I. (1992). Prevention of the first occurrence of neural-tube 
defects by periconceptional vitamin supplementation. N Engl J Med 327, 1832-
1835. 
Dale, J. K., Vesque, C., Lints, T. J., Sampath, T. K., Furley, A., Dodd, J. and 
Placzek, M. (1997). Cooperation of BMP7 and SHH in the induction of forebrain 
ventral midline cells by prechordal mesoderm. Cell 90, 257-269. 
Dale, L. (2000). Pattern formation: a new twist to BMP signalling. Curr Biol 10, R671-
673. 
De-Regil, L. M., Fernandez-Gaxiola, A. C., Dowswell, T. and Pena-Rosas, J. P. 
(2010). Effects and safety of periconceptional folate supplementation for 
preventing birth defects. Cochrane Database Syst Rev, CD007950. 
Depreux, F. F., Darrow, K., Conner, D. A., Eavey, R. D., Liberman, M. C., Seidman, 
C. E. and Seidman, J. G. (2008). Eya4-deficient mice are a model for heritable 
   121 
otitis media. J Clin Invest 118, 651-658. 
Diede, S. J., Guenthoer, J., Geng, L. N., Mahoney, S. E., Marotta, M., Olson, J. M., 
Tanaka, H. and Tapscott, S. J. (2009). DNA methylation of developmental 
genes in pediatric medulloblastomas identified by denaturation analysis of 
methylation differences. Proc Natl Acad Sci U S A. 
Dindot, S. V., Person, R., Strivens, M., Garcia, R. and Beaudet, A. L. (2009). 
Epigenetic profiling at mouse imprinted gene clusters reveals novel epigenetic 
and genetic features at differentially methylated regions. Genome Res 19, 1374-
1383. 
Dixon, M. J., Marazita, M. L., Beaty, T. H. and Murray, J. C. (2011). Cleft lip and 
palate: understanding genetic and environmental influences. Nat Rev Genet 12, 
167-178. 
Dolinoy, D. C. (2007). Epigenetic gene regulation: early environmental exposures. 
Pharmacogenomics 8, 5-10. 
Dolinoy, D. C., Das, R., Weidman, J. R. and Jirtle, R. L. (2007). Metastable epialleles, 
imprinting, and the fetal origins of adult diseases. Pediatr Res 61, 30R-37R. 
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., 
Jr., Butel, J. S. and Bradley, A. (1992). Mice deficient for p53 are 
developmentally normal but susceptible to spontaneous tumours. Nature 356, 
215-221. 
Druker, R., Bruxner, T. J., Lehrbach, N. J. and Whitelaw, E. (2004). Complex 
patterns of transcription at the insertion site of a retrotransposon in the mouse. 
Nucleic Acids Res 32, 5800-5808. 
Du, Y. and Yip, H. (2009). Effects of bone morphogenetic protein 2 on Id expression 
and neuroblastoma cell differentiation. Differentiation. 
Duong, H. T., Hoyt, A. T., Carmichael, S. L., Gilboa, S. M., Canfield, M. A., Case, 
A., McNeese, M. L. and Waller, D. K. (2012). Is maternal parity an independent 
risk factor for birth defects? Birth Defects Res A Clin Mol Teratol 94, 230-236. 
Ekanayake, S. and Hall, B. K. (1997). The in vivo and in vitro effects of bone 
morphogenetic protein-2 on the development of the chick mandible. Int J Dev 
Biol 41, 67-81. 
Esteve, P. O., Chin, H. G. and Pradhan, S. (2005). Human maintenance DNA 
(cytosine-5)-methyltransferase and p53 modulate expression of p53-repressed 
promoters. Proc Natl Acad Sci U S A 102, 1000-1005. 
Feng, W., Leach, S. M., Tipney, H., Phang, T., Geraci, M., Spritz, R. A., Hunter, L. 
E. and Williams, T. (2009). Spatial and Temporal Analysis of Gene Expression 
during Growth and Fusion of the Mouse Facial Prominences. PLoS One 4, e8066. 
Finley, K. R., Tennessen, J. and Shawlot, W. (2003). The mouse secreted frizzled-
related protein 5 gene is expressed in the anterior visceral endoderm and foregut 
   122 
endoderm during early post-implantation development. Gene expression patterns 
: GEP 3, 681-684. 
Fisher, M., Zeisel, S., Mar, M. and Sadler, T. (2001). Inhibitors of choline uptake and 
metabolism cause developmental abnormalities in neurulating mouse embryos. . 
Teratology 64, 114-122. 
FitzPatrick, D. R., Carr, I. M., McLaren, L., Leek, J. P., Wightman, P., Williamson, 
K., Gautier, P., McGill, N., Hayward, C., Firth, H. et al. (2003). Identification 
of SATB2 as the cleft palate gene on 2q32-q33. Human molecular genetics 12, 
2491-2501. 
Fraser, F. C. (1970). The genetics of cleft lip and cleft palate. Am J Hum Genet 22, 336-
352. 
Fukuda, N., Saitoh, M., Kobayashi, N. and Miyazono, K. (2006). Execution of BMP-
4-induced apoptosis by p53-dependent ER dysfunction in myeloma and B-cell 
hybridoma cells. Oncogene 25, 3509-3517. 
Garrigue-Antar, L., Hartigan, N. and Kadler, K. E. (2002). Post-translational 
modification of bone morphogenetic protein-1 is required for secretion and 
stability of the protein. J Biol Chem 277, 43327-43334. 
Gavel, Y. and von Heijne, G. (1990). Sequence differences between glycosylated and 
non-glycosylated Asn-X-Thr/Ser acceptor sites: implications for protein 
engineering. Protein Eng 3, 433-442. 
Gazzerro, E., Deregowski, V., Vaira, S. and Canalis, E. (2005). Overexpression of 
twisted gastrulation inhibits bone morphogenetic protein action and prevents 
osteoblast cell differentiation in vitro. Endocrinology 146, 3875-3882. 
Gazzerro, E., Deregowski, V., Stadmeyer, L., Gale, N. W., Economides, A. N. and 
Canalis, E. (2006). Twisted gastrulation, a bone morphogenetic protein 
agonist/antagonist, is not required for post-natal skeletal function. Bone 39, 1252-
1260. 
Gekas, J., Li, B. and Kamnasaran, D. (2010). Current perspectives on the etiology of 
agnathia-otocephaly. Eur J Med Genet 53, 358-366. 
Gibney, E. R. and Nolan, C. M. (2010). Epigenetics and gene expression. Heredity 
(Edinb) 105, 4-13. 
Graf, D., Nethisinghe, S., Palmer, D. B., Fisher, A. G. and Merkenschlager, M. 
(2002). The developmentally regulated expression of Twisted gastrulation reveals 
a role for bone morphogenetic proteins in the control of T cell development. J Exp 
Med 196, 163-171. 
Graf, D., Timmons, P. M., Hitchins, M., Episkopou, V., Moore, G., Ito, T., 
Fujiyama, A., Fisher, A. G. and Merkenschlager, M. (2001). Evolutionary 
conservation, developmental expression, and genomic mapping of mammalian 
Twisted gastrulation. Mamm Genome 12, 554-560. 
   123 
Graham, A., Francis-West, P., Brickell, P. and Lumsden, A. (1994). The signalling 
molecule BMP4 mediates apoptosis in the rhombencephalic neural crest. Nature 
372, 684-686. 
Groppe, J., Greenwald, J., Wiater, E., Rodriguez-Leon, J., Economides, A. N., 
Kwiatkowski, W., Affolter, M., Vale, W. W., Belmonte, J. C. and Choe, S. 
(2002). Structural basis of BMP signalling inhibition by the cystine knot protein 
Noggin. Nature 420, 636-642. 
Gumienny, T. L. and Padgett, R. W. (2002). The other side of TGF-beta superfamily 
signal regulation: thinking outside the cell. Trends Endocrinol Metab 13, 295-
299. 
Gyorgy, A. B., Szemes, M., de Juan Romero, C., Tarabykin, V. and Agoston, D. V. 
(2008). SATB2 interacts with chromatin-remodeling molecules in differentiating 
cortical neurons. Eur J Neurosci 27, 865-873. 
Hansen, M., Lucarelli, M. J., Whiteman, D. A. H. and Mulliken, J. B. (1996). 
Treacher Collins syndrome: Phenotypic variability in a family including an infant 
with arhinia and uveal colobomas. American Journal of Medical Genetics 61, 71-
74. 
Harland, R. M. (2001). Developmental biology. A twist on embryonic signalling. 
Nature 410, 423-424. 
Hay, S. and Barbano, H. (1972). Independent effects of maternal age and birth order on 
the incidence of selected congenital malformations. Teratology 6, 271-279. 
Hehr, U., Gross, C., Diebold, U., Wahl, D., Beudt, U., Heidemann, P., Hehr, A. and 
Mueller, D. (2004). Wide phenotypic variability in families with 
holoprosencephaly and a sonic hedgehog mutation. European Journal of 
Pediatrics 163, 347-352. 
Heinecke, K., Seher, A., Schmitz, W., Mueller, T. D., Sebald, W. and Nickel, J. 
(2009). Receptor oligomerization and beyond: a case study in bone 
morphogenetic proteins. BMC Biol 7, 59. 
Henderson, G. E., Isett, K. D. and Gerngross, T. U. (2011). Site-Specific Modification 
of Recombinant Proteins: A Novel Platform for Modifying Glycoproteins 
Expressed in E. coli. Bioconjug Chem 22, 903-912. 
Hide, T., Hatakeyama, J., Kimura-Yoshida, C., Tian, E., Takeda, N., Ushio, Y., 
Shiroishi, T., Aizawa, S. and Matsuo, I. (2002). Genetic modifiers of 
otocephalic phenotypes in Otx2 heterozygous mutant mice. Development 129, 
4347-4357. 
Higashiyama, D., Saitsu, H., Komada, M., Takigawa, T., Ishibashi, M. and Shiota, 
K. (2007). Sequential developmental changes in holoprosencephalic mouse 
embryos exposed to ethanol during the gastrulation period. Birth Defects Res A 
Clin Mol Teratol 79, 513-523. 
   124 
Honein, M. A., Paulozzi, L. J., Mathews, T. J., Erickson, J. D. and Wong, L. Y. 
(2001). Impact of folic acid fortification of the US food supply on the occurrence 
of neural tube defects. JAMA 285, 2981-2986. 
Hoyt, P. R., Bartholomew, C., Davis, A. J., Yutzey, K., Gamer, L. W., Potter, S. S., 
Ihle, J. N. and Mucenski, M. L. (1997). The Evi1 proto-oncogene is required at 
midgestation for neural, heart, and paraxial mesenchyme development. Mech Dev 
65, 55-70. 
Hu, D. and Marcucio, R. S. (2009a). Unique organization of the frontonasal ectodermal 
zone in birds and mammals. Dev Biol 325, 200-210. 
Hu, D. and Marcucio, R. S. (2009b). A SHH-responsive signaling center in the 
forebrain regulates craniofacial morphogenesis via the facial ectoderm. 
Development 136, 107-116. 
Ikeya, M., Fukushima, K., Kawada, M., Onishi, S., Furuta, Y., Yonemura, S., 
Kitamura, T., Nosaka, T. and Sasai, Y. (2010). Cv2, functioning as a pro-BMP 
factor via twisted gastrulation, is required for early development of nephron 
precursors. Dev Biol 337, 405-414. 
Jarvis, D. L., Kawar, Z. S. and Hollister, J. R. (1998). Engineering N-glycosylation 
pathways in the baculovirus-insect cell system. Curr Opin Biotechnol 9, 528-533. 
Jaskoll, T., Abichaker, G., Witcher, D., Sala, F. G., Bellusci, S., Hajihosseini, M. K. 
and Melnick, M. (2005). FGF10/FGFR2b signaling plays essential roles during 
in vivo embryonic submandibular salivary gland morphogenesis. BMC Dev Biol 
5, 11. 
Jeong, J., Li, X., McEvilly, R. J., Rosenfeld, M. G., Lufkin, T. and Rubenstein, J. L. 
(2008). Dlx genes pattern mammalian jaw primordium by regulating both lower 
jaw-specific and upper jaw-specific genetic programs. Development (Cambridge, 
England) 135, 2905-2916. 
Jones, N. C., Lynn, M. L., Gaudenz, K., Sakai, D., Aoto, K., Rey, J. P., Glynn, E. F., 
Ellington, L., Du, C., Dixon, J. et al. (2008). Prevention of the neurocristopathy 
Treacher Collins syndrome through inhibition of p53 function. Nat Med 14, 125-
133. 
Juriloff, D. M. and Harris, M. J. (2008). Mouse genetic models of cleft lip with or 
without cleft palate. Birth Defects Res A Clin Mol Teratol 82, 63-77. 
Juriloff, D. M., Sulik, K. K., Roderick, T. H. and Hogan, B. K. (1985). Genetic and 
developmental studies of a new mouse mutation that produces otocephaly. J 
Craniofac Genet Dev Biol 5, 121-145. 
Kalter, H. (1968). Sporadic congenital malformations of newborn inbred mice. 
Teratology 1, 193-199. 
Kamimura, M., Matsumoto, K., Koshiba-Takeuchi, K. and Ogura, T. (2004). 
Vertebrate crossveinless 2 is secreted and acts as an extracellular modulator of the 
   125 
BMP signaling cascade. Dev Dyn 230, 434-445. 
Kitami, T., Rubio, R., O'Brien, W., Quackenbush, J. and Nadeau, J. (2008). Gene-
environment interactions reveal a homeostatic role for cholesterol metabolism 
during dietary folate perturbation in mice. Physiol Genomics 35, 182-190. 
Kontges, G. and Lumsden, A. (1996). Rhombencephalic neural crest segmentation is 
preserved throughout craniofacial ontogeny. Development 122, 3229-3242. 
Kozak, M. (1987). An analysis of 5'-noncoding sequences from 699 vertebrate 
messenger RNAs. Nucleic Acids Res 15, 8125-8148. 
Kuroiwa, Y., Kaneko-Ishino, T., Kagitani, F., Kohda, T., Li, L. L., Tada, M., 
Suzuki, R., Yokoyama, M., Shiroishi, T., Wakana, S. et al. (1996). Peg3 
imprinted gene on proximal chromosome 7 encodes for a zinc finger protein. Nat 
Genet 12, 186-190. 
Lakso, M., Pichel, J. G., Gorman, J. R., Sauer, B., Okamoto, Y., Lee, E., Alt, F. W. 
and Westphal, H. (1996). Efficient in vivo manipulation of mouse genomic 
sequences at the zygote stage. Proc Natl Acad Sci U S A 93, 5860-5865. 
Larrain, J., Oelgeschlager, M., Ketpura, N. I., Reversade, B., Zakin, L. and De 
Robertis, E. M. (2001). Proteolytic cleavage of Chordin as a switch for the dual 
activities of Twisted gastrulation in BMP signaling. Development 128, 4439-
4447. 
Larsen, W. J., Sherman, L. S., Potter, S. S. and Scott, W. J. (2001). Human 
Embryology, 3rd Edition. New York: Churchill Livingstone. 
Li, D., Pickell, L., Liu, Y., Wu, Q., Cohn, J. S. and Rozen, R. (2005). Maternal 
methylenetetrahydrofolate reductase deficiency and low dietary folate lead to 
adverse reproductive outcomes and congenital heart defects in mice. Am J Clin 
Nutr 82, 188-195. 
Lindenthal, C. and Elsinghorst, E. A. (1999). Identification of a glycoprotein produced 
by enterotoxigenic Escherichia coli. Infect Immun 67, 4084-4091. 
Linton, K., Hey, Y., Dibben, S., Miller, C., Freemont, A., Radford, J. and Pepper, S. 
(2009). Methods comparison for high-resolution transcriptional analysis of 
archival material on Affymetrix Plus 2.0 and Exon 1.0 microarrays. Biotechniques 
47, 587-596. 
Lipinski, R. J., Godin, E. A., O'Leary-Moore, S. K., Parnell, S. E. and Sulik, K. K. 
(2010). Genesis of teratogen-induced holoprosencephaly in mice. Am J Med 
Genet C Semin Med Genet 154C, 29-42. 
Little, S. C. and Mullins, M. C. (2004). Twisted gastrulation promotes BMP signaling 
in zebrafish dorsal-ventral axial patterning. Development 131, 5825-5835. 
Liu, B., Rooker, S. M. and Helms, J. A. (2010). Molecular control of facial 
morphology. Semin Cell Dev Biol 21, 309-313. 
   126 
Liu, Y. and Xiao, A. (2011). Epigenetic regulation in neural crest development. Birth 
Defects Res A Clin Mol Teratol 91, 788-796. 
Loeken, M. R. (2004). Free radicals and birth defects. J Matern Fetal Neonatal Med 15, 
6-14. 
Loffredo, L. C., Souza, J. M., Freitas, J. A. and Mossey, P. A. (2001). Oral clefts and 
vitamin supplementation. Cleft Palate Craniofac J 38, 76-83. 
Luedi, P. P., Hartemink, A. J. and Jirtle, R. L. (2005). Genome-wide prediction of 
imprinted murine genes. Genome research 15, 875-884. 
MacKenzie, A., Ferguson, M. W. and Sharpe, P. T. (1992). Expression patterns of the 
homeobox gene, Hox-8, in the mouse embryo suggest a role in specifying tooth 
initiation and shape. Development 115, 403-420. 
MacKenzie, B., Wolff, R., Lowe, N., Billington, C. J., Jr., Peterson, A., Schmidt, B., 
Graf, D., Mina, M., Gopalakrishnan, R. and Petryk, A. (2009). Twisted 
gastrulation limits apoptosis in the distal region of the mandibular arch in mice. 
Dev Biol 328, 13-23. 
March-of-Dimes. (2010). March of Dimes Data Book for Policy Makers: Maternal, 
Infant, and Child Health in the United States. Atlanta, GA: marchofdimes.com. 
Marks, S. C., Jr. (1987). Osteopetrosis--multiple pathways for the interception of 
osteoclast function. Appl Pathol 5, 172-183. 
Mason, E. D., Konrad, K. D., Webb, C. D. and Marsh, J. L. (1994). Dorsal midline 
fate in Drosophila embryos requires twisted gastrulation, a gene encoding a 
secreted protein related to human connective tissue growth factor. Genes Dev 8, 
1489-1501. 
Mason, E. D., Williams, S., Grotendorst, G. R. and Marsh, J. L. (1997). 
Combinatorial signaling by Twisted Gastrulation and Decapentaplegic. Mech Dev 
64, 61-75. 
Mastroiacovo, P., Corchia, C., Botto, L. D., Lanni, R., Zampino, G. and Fusco, D. 
(1995). Epidemiology and genetics of microtia-anotia: a registry based study on 
over one million births. J Med Genet 32, 453-457. 
Matsunaga, E. and Shiota, K. (1977). Holoprosencephaly in human embryos: 
epidemiologic studies of 150 cases. Teratology 16, 261-272. 
Matsuo, I., Kuratani, S., Kimura, C., Takeda, N. and Aizawa, S. (1995). Mouse Otx2 
functions in the formation and patterning of rostral head. Genes Dev 9, 2646-
2658. 
Matsuoka, T., Ahlberg, P. E., Kessaris, N., Iannarelli, P., Dennehy, U., Richardson, 
W. D., McMahon, A. P. and Koentges, G. (2005). Neural crest origins of the 
neck and shoulder. Nature 436, 347-355. 
McMahon, K. and Farrell, P. (1985). Measurement of free choline concentrations in 
   127 
maternal and neonatal blood by micropyrolysis gas chromatography. Clin Chim 
Acta 149, 1-12. 
Melnick, M., Witcher, D., Bringas, P., Jr., Carlsson, P. and Jaskoll, T. (2005). 
Meckel's cartilage differentiation is dependent on hedgehog signaling. Cells 
Tissues Organs 179, 146-157. 
Melnick, M., Petryk, A., Abichaker, G., Witcher, D., Person, A. D. and Jaskoll, T. 
(2006). Embryonic salivary gland dysmorphogenesis in Twisted gastrulation 
deficient mice. Arch Oral Biol 51, 433-438. 
Merritt, L. (2005). Part 1. Understanding the embryology and genetics of cleft lip and 
palate. Adv Neonatal Care 5, 64-71. 
Milman, N., Kirchhoff, M. and Jorgensen, T. (1992). Iron status markers, serum 
ferritin and hemoglobin in 1359 Danish women in relation to menstruation, 
hormonal contraception, parity, and postmenopausal hormone treatment. Ann 
Hematol 65, 96-102. 
Mina, M., Wang, Y. H., Ivanisevic, A. M., Upholt, W. B. and Rodgers, B. (2002). 
Region- and stage-specific effects of FGFs and BMPs in chick mandibular 
morphogenesis. Dev Dyn 223, 333-352. 
Ming, J. E. and Muenke, M. (2002). Multiple hits during early embryonic development: 
digenic diseases and holoprosencephaly. Am J Hum Genet 71, 1017-1032. 
Ming, J. E., Kaupas, M. E., Roessler, E., Brunner, H. G., Golabi, M., Tekin, M., 
Stratton, R. F., Sujansky, E., Bale, S. J. and Muenke, M. (2002). Mutations in 
PATCHED-1, the receptor for SONIC HEDGEHOG, are associated with 
holoprosencephaly. Hum Genet 110, 297-301. 
Morison, I. M., Paton, C. J. and Cleverley, S. D. (2001). The imprinted gene and 
parent-of-origin effect database. Nucleic Acids Res 29, 275-276. 
Morison, I. M., Ramsay, J. P. and Spencer, H. G. (2005). A census of mammalian 
imprinting. Trends Genet 21, 457-465. 
MRC, V. S. R. G. (1991). Prevention of neural tube defects: results of the Medical 
Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 
338, 131-137. 
Muenke, M. and Cohen, M. M., Jr. (2000). Genetic approaches to understanding brain 
development: holoprosencephaly as a model. Ment Retard Dev Disabil Res Rev 6, 
15-21. 
Muenke, M. and Beachy, P. A. (2000). Genetics of ventral forebrain development and 
holoprosencephaly. Curr Opin Genet Dev 10, 262-269. 
Mukhopadhyay, M., Shtrom, S., Rodriguez-Esteban, C., Chen, L., Tsukui, T., 
Gomer, L., Dorward, D. W., Glinka, A., Grinberg, A., Huang, S. P. et al. 
(2001). Dickkopf1 is required for embryonic head induction and limb 
   128 
morphogenesis in the mouse. Dev Cell 1, 423-434. 
Muller, F. and O'Rahilly, R. (2003). The prechordal plate, the rostral end of the 
notochord and nearby median features in staged human embryos. Cells Tissues 
Organs 173, 1-20. 
Muller, S. M., Stolt, C. C., Terszowski, G., Blum, C., Amagai, T., Kessaris, N., 
Iannarelli, P., Richardson, W. D., Wegner, M. and Rodewald, H. R. (2008). 
Neural crest origin of perivascular mesenchyme in the adult thymus. J Immunol 
180, 5344-5351. 
Murray, J. C. (2002). Gene/environment causes of cleft lip and/or palate. Clin Genet 61, 
248-256. 
Mutlu, B., Bas, A. Y., Aksoy, N. and Taskin, A. (2012). The effect of maternal number 
of births on oxidative and antioxidative systems in cord blood. J Matern Fetal 
Neonatal Med 25, 802-805. 
Neuberger, A. and Marshall, R. D. (1968). In Symposium on Foods - Carbohydrates 
and their Roles,  (eds H. W. Schultz R. F. Cain and R. W. Wrolstad), pp. 115-132: 
Avi Publishing Co., Westport, CT. 
Niculescu, M. D. and Zeisel, S. H. (2002). Diet, methyl donors and DNA methylation: 
interactions between dietary folate, methionine and choline. J Nutr 132, 2333S-
2335S. 
Nie, X., Luukko, K. and Kettunen, P. (2006). BMP signalling in craniofacial 
development. Int J Dev Biol 50, 511-521. 
Nora, J. J. (1968). Multifactorial inheritance hypothesis for the etiology of congenital 
heart diseases. The genetic-environmental interaction. Circulation 38, 604-617. 
Northrup, H. and Volcik, K. A. (2000). Spina bifida and other neural tube defects. Curr 
Probl Pediatr 30, 313-332. 
Nosaka, T., Morita, S., Kitamura, H., Nakajima, H., Shibata, F., Morikawa, Y., 
Kataoka, Y., Ebihara, Y., Kawashima, T., Itoh, T. et al. (2003). Mammalian 
twisted gastrulation is essential for skeleto-lymphogenesis. Mol Cell Biol 23, 
2969-2980. 
Nussbaum, R. L., McInnes, R. R., Willard, H. F. and Hamosh, A. (2007). Thompson 
& Thompson Genetics in Medicine. Philadephia: Saunders-Elsevier. 
O'Connor, M. B., Umulis, D., Othmer, H. G. and Blair, S. S. (2006). Shaping BMP 
morphogen gradients in the Drosophila embryo and pupal wing. Development 
133, 183-193. 
Oelgeschlager, M., Larrain, J., Geissert, D. and De Robertis, E. M. (2000). The 
evolutionarily conserved BMP-binding protein Twisted gastrulation promotes 
BMP signalling. Nature 405, 757-763. 
Oelgeschlager, M., Tran, U., Grubisic, K. and De Robertis, E. M. (2004). 
   129 
Identification of a second Xenopus twisted gastrulation gene. Int J Dev Biol 48, 
57-61. 
Oelgeschlager, M., Reversade, B., Larrain, J., Little, S., Mullins, M. C. and De 
Robertis, E. M. (2003). The pro-BMP activity of Twisted gastrulation is 
independent of BMP binding. Development 130, 4047-4056. 
Osborn, N. K., Zou, H., Molina, J. R., Lesche, R., Lewin, J., Lofton-Day, C., Klatt, 
K. K., Harrington, J. J., Burgart, L. J. and Ahlquist, D. A. (2006). Aberrant 
methylation of the eyes absent 4 gene in ulcerative colitis-associated dysplasia. 
Clin Gastroenterol Hepatol 4, 212-218. 
Pandolfi, P. P., Roth, M. E., Karis, A., Leonard, M. W., Dzierzak, E., Grosveld, F. 
G., Engel, J. D. and Lindenbaum, M. H. (1995). Targeted disruption of the 
GATA3 gene causes severe abnormalities in the nervous system and in fetal liver 
haematopoiesis. Nat Genet 11, 40-44. 
Pani, L., Horal, M. and Loeken, M. R. (2002). Rescue of neural tube defects in Pax-3-
deficient embryos by p53 loss of function: implications for Pax-3- dependent 
development and tumorigenesis. Genes Dev 16, 676-680. 
Pantoja, C., de Los Rios, L., Matheu, A., Antequera, F. and Serrano, M. (2005). 
Inactivation of imprinted genes induced by cellular stress and tumorigenesis. 
Cancer Res 65, 26-33. 
Paros, A. and Beck, S. L. (1999). Folinic acid reduces cleft lip [CL(P)] in A/WySn 
mice. Teratology 60, 344-347. 
Pauli, R. M., Pettersen, J. C., Arya, S. and Gilbert, E. F. (1983). Familial agnathia-
holoprosencephaly. Am J Med Genet 14, 677-698. 
Pavlidis, P., Li, Q. and Noble, W. S. (2003). The effect of replication on gene 
expression microarray experiments. Bioinformatics 19, 1620-1627. 
Peaston, A. E. and Whitelaw, E. (2006). Epigenetics and phenotypic variation in 
mammals. Mammalian genome : official journal of the International Mammalian 
Genome Society 17, 365-374. 
Pera, E. M. and Kessel, M. (1997). Patterning of the chick forebrain anlage by the 
prechordal plate. Development 124, 4153-4162. 
Petryk, A., Anderson, R. M., Jarcho, M. P., Leaf, I., Carlson, C. S., Klingensmith, J., 
Shawlot, W. and O'Connor, M. B. (2004). The mammalian twisted gastrulation 
gene functions in foregut and craniofacial development. Dev Biol 267, 374-386. 
Petryk, A., Shimmi, O., Jia, X., Carlson, A. E., Tervonen, L., Jarcho, M. P., 
O'Connor M, B. and Gopalakrishnan, R. (2005). Twisted gastrulation and 
chordin inhibit differentiation and mineralization in MC3T3-E1 osteoblast-like 
cells. Bone 36, 617-626. 
Pfaff, S. L., Mendelsohn, M., Stewart, C. L., Edlund, T. and Jessell, T. M. (1996). 
Requirement for LIM homeobox gene Isl1 in motor neuron generation reveals a 
   130 
motor neuron-dependent step in interneuron differentiation. Cell 84, 309-320. 
Pham, L., Beyer, K., Jensen, E. D., Rodriguez, J. S., Davydova, J., Yamamoto, M., 
Petryk, A., Gopalakrishnan, R. and Mansky, K. C. (2011). Bone 
morphogenetic protein 2 signaling in osteoclasts is negatively regulated by the 
BMP antagonist, twisted gastrulation. J Cell Biochem 112, 793-803. 
Podos, S. D. and Ferguson, E. L. (1999). Morphogen gradients: new insights from DPP. 
Trends Genet 15, 396-402. 
Rakyan, V. K., Blewitt, M. E., Druker, R., Preis, J. I. and Whitelaw, E. (2002). 
Metastable epialleles in mammals. Trends Genet 18, 348-351. 
Rakyan, V. K., Chong, S., Champ, M. E., Cuthbert, P. C., Morgan, H. D., Luu, K. 
V. and Whitelaw, E. (2003). Transgenerational inheritance of epigenetic states at 
the murine Axin(Fu) allele occurs after maternal and paternal transmission. Proc 
Natl Acad Sci U S A 100, 2538-2543. 
Ray, J. G. and Blom, H. J. (2003). Vitamin B12 insufficiency and the risk of fetal 
neural tube defects. QJM 96, 289-295. 
Roessler, E. and Muenke, M. (1999). The molecular genetics of holoprosencephaly: a 
model of brain development for the next century. Childs Nerv Syst 15, 646-651. 
Roessler, E., Belloni, E., Gaudenz, K., Jay, P., Berta, P., Scherer, S. W., Tsui, L. C. 
and Muenke, M. (1996). Mutations in the human Sonic Hedgehog gene cause 
holoprosencephaly. Nat Genet 14, 357-360. 
Ross, J. J., Shimmi, O., Vilmos, P., Petryk, A., Kim, H., Gaudenz, K., Hermanson, 
S., Ekker, S. C., O'Connor, M. B. and Marsh, J. L. (2001). Twisted 
gastrulation is a conserved extracellular BMP antagonist. Nature 410, 479-483. 
Rufer, E. S. (2010). Marginal maternal iron deficiency exacerbates alcohol-induced 
learning deficits and neurodegeneration in offspring. PhD in Molecular and 
Environmental Toxicology, Madison WI: University of Wisconsin. 
Ruppert, R., Hoffmann, E. and Sebald, W. (1996). Human bone morphogenetic 
protein 2 contains a heparin-binding site which modifies its biological activity. 
Eur J Biochem 237, 295-302. 
Sah, V. P., Attardi, L. D., Mulligan, G. J., Williams, B. O., Bronson, R. T. and Jacks, 
T. (1995). A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 10, 
175-180. 
Saremba, S., Nickel, J., Seher, A., Kotzsch, A., Sebald, W. and Mueller, T. D. (2008). 
Type I receptor binding of bone morphogenetic protein 6 is dependent on N-
glycosylation of the ligand. FEBS J 275, 172-183. 
Sasaki, H. and Hogan, B. L. (1993). Differential expression of multiple fork head 
related genes during gastrulation and axial pattern formation in the mouse 
embryo. Development 118, 47-59. 
   131 
Sawala, A., Sutcliffe, C. and Ashe, H. L. (2012). Multistep molecular mechanism for 
Bone morphogenetic protein extracellular transport in the Drosophila embryo. 
Proc Natl Acad Sci U S A 109, 11222-11227. 
Schlange, T., Arnold, H. H. and Brand, T. (2002). BMP2 is a positive regulator of 
Nodal signaling during left-right axis formation in the chicken embryo. 
Development 129, 3421-3429. 
Schmidl, M., Adam, N., Surmann-Schmitt, C., Hattori, T., Stock, M., Dietz, U., de 
Crombrugghe, B., Poschl, E. and von der Mark, K. (2006). Twisted 
gastrulation modulates bone morphogenetic protein-induced collagen II and X 
expression in chondrocytes in vitro and in vivo. Journal of Biological Chemistry 
281, 31790-31800. 
Sclafani, A. M., Skidmore, J. M., Ramaprakash, H., Trumpp, A., Gage, P. J. and 
Martin, D. M. (2006). Nestin-Cre mediated deletion of Pitx2 in the mouse. 
Genesis 44, 336-344. 
Scott, I. C., Blitz, I. L., Pappano, W. N., Maas, S. A., Cho, K. W. and Greenspan, D. 
S. (2001). Homologues of Twisted gastrulation are extracellular cofactors in 
antagonism of BMP signalling. Nature 410, 475-478. 
Scott, J. M. (1999). Folate and vitamin B12. Proc Nutr Soc 58, 441-448. 
Semba, I., Nonaka, K., Takahashi, I., Takahashi, K., Dashner, R., Shum, L., 
Nuckolls, G. H. and Slavkin, H. C. (2000). Positionally-dependent 
chondrogenesis induced by BMP4 is co-regulated by Sox9 and Msx2. Dev Dyn 
217, 401-414. 
Sharma, D. C., Pendse, V., Sahay, K. and Soni, B. L. (1991). The changing pattern of 
maternal and neonatal anemia at Udaipur during 2 decades in relation to poverty, 
parity, prematurity and vegetarianism. Asia Oceania J Obstet Gynaecol 17, 13-17. 
Sharma, S. M., Bronisz, A., Hu, R., Patel, K., Mansky, K. C., Sif, S. and Ostrowski, 
M. C. (2007). MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes 
during osteoclast differentiation. J Biol Chem 282, 15921-15929. 
Shaw, G., Carmichael, S., Yang, W., Selvin, S. and Schaffer., D. (2004). 
Periconceptional dietary intake of choline and betaine and neural tube defects in 
offspring. Am J Epidemiol 160, 102-109. 
Shaw, G. M., Carmichael, S. L., Laurent, C. and Rasmussen, S. A. (2006). Maternal 
nutrient intakes and risk of orofacial clefts. Epidemiology 17, 285-291. 
Shaw, G. M., Lammer, E. J., Wasserman, C. R., O'Malley, C. D. and Tolarova, M. 
M. (1995). Risks of orofacial clefts in children born to women using 
multivitamins containing folic acid periconceptionally. Lancet 346, 393-396. 
Shimmi, O. and O'Connor, M. B. (2003). Physical properties of Tld, Sog, Tsg and Dpp 
protein interactions are predicted to help create a sharp boundary in Bmp signals 
during dorsoventral patterning of the Drosophila embryo. Development 130, 
   132 
4673-4682. 
Shimmi, O., Umulis, D., Othmer, H. and O'Connor, M. B. (2005). Facilitated 
transport of a Dpp/Scw heterodimer by Sog/Tsg leads to robust patterning of the 
Drosophila blastoderm embryo. Cell 120, 873-886. 
Smithells, R. W. and Sheppard, S. (1980). Possible prevention of neural-tube defects by 
periconceptional vitamin supplementation. Lancet 1, 647. 
Soriano, P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. 
Nat Genet 21, 70-71. 
Sotillo Rodriguez, J. E., Mansky, K. C., Jensen, E. D., Carlson, A. E., Schwarz, T., 
Pham, L., MacKenzie, B., Prasad, H., Rohrer, M. D., Petryk, A. et al. (2009). 
Enhanced osteoclastogenesis causes osteopenia in twisted gastrulation-deficient 
mice through increased BMP signaling. J Bone Miner Res 24, 1917-1926. 
Spandidos, A., Wang, X., Wang, H. and Seed, B. (2010). PrimerBank: a resource of 
human and mouse PCR primer pairs for gene expression detection and 
quantification. Nucleic Acids Res 38, D792-799. 
Spensberger, D. and Delwel, R. (2008). A novel interaction between the proto-oncogene 
Evi1 and histone methyltransferases, SUV39H1 and G9a. FEBS Lett 582, 2761-
2767. 
Spiegelstein, O., Mitchell, L. E., Merriweather, M. Y., Wicker, N. J., Zhang, Q., 
Lammer, E. J. and Finnell, R. H. (2004). Embryonic development of folate 
binding protein-1 (Folbp1) knockout mice: Effects of the chemical form, dose, 
and timing of maternal folate supplementation. Dev Dyn 231, 221-231. 
Spiro, R. G. (2002). Protein glycosylation: nature, distribution, enzymatic formation, and 
disease implications of glycopeptide bonds. Glycobiology 12, 43R-56R. 
Spudich, J. L. and Koshland, D. E., Jr. (1976). Non-genetic individuality: chance in the 
single cell. Nature 262, 467-471. 
Srinivas, S., Watanabe, T., Lin, C. S., William, C. M., Tanabe, Y., Jessell, T. M. and 
Costantini, F. (2001). Cre reporter strains produced by targeted insertion of 
EYFP and ECFP into the ROSA26 locus. BMC Dev Biol 1, 4. 
Stanier, P. and Moore, G. E. (2004). Genetics of cleft lip and palate: syndromic genes 
contribute to the incidence of non-syndromic clefts. Hum Mol Genet 13 Spec No 
1, R73-81. 
Stanley, E., Biben, C., Kotecha, S., Fabri, L., Tajbakhsh, S., Wang, C. C., 
Hatzistavrou, T., Roberts, B., Drinkwater, C., Lah, M. et al. (1998). DAN is a 
secreted glycoprotein related to Xenopus cerberus. Mech Dev 77, 173-184. 
Stottmann, R., Anderson, R. and Klingensmith, J. (2001). The BMP Antagonists 
Chordin and Noggin Have Essential but Redundant Roles in Mouse Mandibular 
Outgrowth. Developmental Biology 240, 457-473. 
   133 
Stover, P. J. (2004). Physiology of folate and vitamin B12 in health and disease. Nutr 
Rev 62, S3-12; discussion S13. 
Sulik, K. K., Cook, C. S. and Webster, W. S. (1988). Teratogens and craniofacial 
malformations: relationships to cell death. Development 103 Suppl, 213-231. 
Sun, M., Forsman, C., Sergi, C., Gopalakrishnan, R., O'Connor, M. B. and Petryk, 
A. (2010). The expression of twisted gastrulation in postnatal mouse brain and 
functional implications. Neuroscience 169, 920-931. 
Tanno, T., Porayette, P., Sripichai, O., Noh, S. J., Byrnes, C., Bhupatiraju, A., Lee, 
Y. T., Goodnough, J. B., Harandi, O., Ganz, T. et al. (2009). Identification of 
TWSG1 as a second novel erythroid regulator of hepcidin expression in murine 
and human cells. Blood 114, 181-186. 
Tawfik, H. E., Cena, J., Schulz, R. and Kaufman, S. (2008). Role of oxidative stress in 
multiparity-induced endothelial dysfunction. Am J Physiol Heart Circ Physiol 
295, H1736-1742. 
Tchantchou, F. (2006). Homocysteine metabolism and various consequences of folate 
deficiency. J Alzheimers Dis 9, 421-427. 
Teitelbaum, S. L. and Ross, F. P. (2003). Genetic regulation of osteoclast development 
and function. Nat Rev Genet 4, 638-649. 
ten Berge, D., Brouwer, A., Korving, J., Martin, J. F. and Meijlink, F. (1998). Prx1 
and Prx2 in skeletogenesis: roles in the craniofacial region, inner ear and limbs. 
Development 125, 3831-3842. 
Thomas, T., Kurihara, H., Yamagishi, H., Kurihara, Y., Yazaki, Y., Olson, E. N. 
and Srivastava, D. (1998). A signaling cascade involving endothelin-1, dHAND 
and msx1 regulates development of neural-crest-derived branchial arch 
mesenchyme. Development 125, 3005-3014. 
Todoroff, K. and Shaw, G. M. (2000). Prior spontaneous abortion, prior elective 
termination, interpregnancy interval, and risk of neural tube defects. Am J 
Epidemiol 151, 505-511. 
Tolarova, M. (1982). Periconceptional supplementation with vitamins and folic acid to 
prevent recurrence of cleft lip. Lancet 2, 217. 
Tolarova, M. and Harris, J. (1995). Reduced recurrence of orofacial clefts after 
periconceptional supplementation with high-dose folic acid and multivitamins. 
Teratology 51, 71-78. 
Tomasini, R., Samir, A. A., Carrier, A., Isnardon, D., Cecchinelli, B., Soddu, S., 
Malissen, B., Dagorn, J. C., Iovanna, J. L. and Dusetti, N. J. (2003). 
TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners 
in regulating p53 activity. J Biol Chem 278, 37722-37729. 
Tomiya, N., Narang, S., Lee, Y. C. and Betenbaugh, M. J. (2004). Comparing N-
glycan processing in mammalian cell lines to native and engineered lepidopteran 
   134 
insect cell lines. Glycoconj J 21, 343-360. 
Tovitto, G. and Rodriguez, A. (2007). Otocefalia, Presentación de dos casos. Rev  
Obstet  Ginecol  Venez 67, 275-280. 
Trainor, P. A. (2010). Craniofacial birth defects: The role of neural crest cells in the 
etiology and pathogenesis of Treacher Collins syndrome and the potential for 
prevention. Am J Med Genet A 152A, 2984-2994. 
Tsai, M. J., Weng, C. F., Shyue, S. K., Liou, D. Y., Chen, C. H., Chiu, C. W., Yang, 
T. H., Pan, H. A., Liao, R. I., Kuo, H. S. et al. (2007). Dual effect of 
adenovirus-mediated transfer of BMP7 in mixed neuron-glial cultures: 
neuroprotection and cellular differentiation. J Neurosci Res 85, 2950-2959. 
Tsalavos, S., Segklia, K., Passa, O., Petryk, A., O'Connor, M. B. and Graf, D. (2011). 
Involvement of twisted gastrulation in T cell-independent plasma cell production. 
J Immunol 186, 6860-6870. 
Tsuda, T., Markova, D., Wang, H., Evangelisti, L., Pan, T. C. and Chu, M. L. 
(2004). Zinc finger protein Zac1 is expressed in chondrogenic sites of the mouse. 
Developmental dynamics : an official publication of the American Association of 
Anatomists 229, 340-348. 
Tucker, A. S., Matthews, K. L. and Sharpe, P. T. (1998). Transformation of tooth type 
induced by inhibition of BMP signaling. Science 282, 1136-1138. 
Utkus, A., Kazakevicius, R., Ptasekas, R., Kucinskas, V., Beckwith, J. B. and Opitz, 
J. M. (2001). Human anotocephaly (aprosopus, acrania-synotia) in the Vilnius 
anatomical collection. Am J Med Genet 101, 163-171. 
Varrault, A., Gueydan, C., Delalbre, A., Bellmann, A., Houssami, S., Aknin, C., 
Severac, D., Chotard, L., Kahli, M., Le Digarcher, A. et al. (2006). Zac1 
regulates an imprinted gene network critically involved in the control of 
embryonic growth. Developmental cell 11, 711-722. 
Vieira, A. R. (2004). Birth order and neural tube defects: a reappraisal. J Neurol Sci 217, 
65-72. 
Vieira, A. R. and Orioli, I. M. (2002). Birth order and oral clefts: a meta analysis. 
Teratology 66, 209-216. 
Vieira, A. R. and Taucher, S. C. (2005). Influence of maternal age on the risk for neural 
tube defects, a meta analysis. Revista Medica De Chile 133, 62-70. 
Vilmos, P., Gaudenz, K., Hegedus, Z. and Marsh, J. L. (2001). The Twisted 
gastrulation family of proteins, together with the IGFBP and CCN families, 
comprise the TIC superfamily of cysteine rich secreted factors. Mol Pathol 54, 
317-323. 
Wacker, M., Linton, D., Hitchen, P. G., Nita-Lazar, M., Haslam, S. M., North, S. J., 
Panico, M., Morris, H. R., Dell, A., Wren, B. W. et al. (2002). N-linked 
glycosylation in Campylobacter jejuni and its functional transfer into E. coli. 
   135 
Science 298, 1790-1793. 
Wagner, D. O., Sieber, C., Bhushan, R., Borgermann, J. H., Graf, D. and Knaus, P. 
(2010). BMPs: from bone to body morphogenetic proteins. Sci Signal 3, mr1. 
Walsh, G. and Jefferis, R. (2006). Post-translational modifications in the context of 
therapeutic proteins. Nat Biotechnol 24, 1241-1252. 
Wang, Y. A., Kamarova, Y., Shen, K. C., Jiang, Z., Hahn, M. J., Wang, Y. and 
Brooks, S. C. (2005). DNA methyltransferase-3a interacts with p53 and represses 
p53-mediated gene expression. Cancer Biol Ther 4, 1138-1143. 
Waterland, R. A. and Jirtle, R. L. (2003). Transposable elements: targets for early 
nutritional effects on epigenetic gene regulation. Mol Cell Biol 23, 5293-5300. 
Waterland, R. A. and Jirtle, R. L. (2004). Early nutrition, epigenetic changes at 
transposons and imprinted genes, and enhanced susceptibility to adult chronic 
diseases. Nutrition (Burbank, Los Angeles County, Calif) 20, 63-68. 
Waterland, R. A., Dolinoy, D. C., Lin, J. R., Smith, C. A., Shi, X. and Tahiliani, K. 
G. (2006). Maternal methyl supplements increase offspring DNA methylation at 
Axin Fused. Genesis 44, 401-406. 
Wehby, G. L. and Murray, J. C. (2010). Folic acid and orofacial clefts: a review of the 
evidence. Oral Dis 16, 11-19. 
Westmoreland, J. J., Takahashi, S. and Wright, C. V. (2007). Xenopus Lefty requires 
proprotein cleavage but not N-linked glycosylation to inhibit nodal signaling. Dev 
Dyn 236, 2050-2061. 
Whitelaw, E. and Martin, D. I. (2001). Retrotransposons as epigenetic mediators of 
phenotypic variation in mammals. Nature Genetics 27, 361-365. 
Wills, A., Harland, R. M. and Khokha, M. K. (2006). Twisted gastrulation is required 
for forebrain specification and cooperates with Chordin to inhibit BMP signaling 
during X. tropicalis gastrulation. Dev Biol 289, 166-178. 
Wolff, G. L., Kodell, R. L., Moore, S. R. and Cooney, C. A. (1998). Maternal 
epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. 
FASEB J 12, 949-957. 
Wong, W. T., Tian, X. Y., Chen, Y., Leung, F. P., Liu, L., Lee, H. K., Ng, C. F., Xu, 
A., Yao, X., Vanhoutte, P. M. et al. (2010). Bone morphogenic protein-4 impairs 
endothelial function through oxidative stress-dependent cyclooxygenase-2 
upregulation: implications on hypertension. Circ Res 107, 984-991. 
Wu, Y. I., Munshi, H. G., Sen, R., Snipas, S. J., Salvesen, G. S., Fridman, R. and 
Stack, M. S. (2004). Glycosylation broadens the substrate profile of membrane 
type 1 matrix metalloproteinase. J Biol Chem 279, 8278-8289. 
Xie, J. and Fisher, S. (2005). Twisted gastrulation enhances BMP signaling through 
chordin dependent and independent mechanisms. Development 132, 383-391. 
   136 
Yamaguchi, K., Akai, K., Kawanishi, G., Ueda, M., Masuda, S. and Sasaki, R. 
(1991). Effects of site-directed removal of N-glycosylation sites in human 
erythropoietin on its production and biological properties. J Biol Chem 266, 
20434-20439. 
Yan, J., Jiang, X., West, A. A., Perry, C. A., Malysheva, O. V., Devapatla, S., 
Pressman, E., Vermeylen, F., Stabler, S. P., Allen, R. H. et al. (2012). Maternal 
choline intake modulates maternal and fetal biomarkers of choline metabolism in 
humans. Am J Clin Nutr 95, 1060-1071. 
Ybot-Gonzalez, P., Cogram, P., Gerrelli, D. and Copp, A. J. (2002). Sonic hedgehog 
and the molecular regulation of mouse neural tube closure. Development 129, 
2507-2517. 
Yeh, C. H., Chang, C. K., Cheng, M. F., Lin, H. J. and Cheng, J. T. (2009). The 
antioxidative effect of bone morphogenetic protein-7 against high glucose-
induced oxidative stress in mesangial cells. Biochem Biophys Res Commun 382, 
292-297. 
Yu, K., Srinivasan, S., Shimmi, O., Biehs, B., Rashka, K. E., Kimelman, D., 
O'Connor, M. B. and Bier, E. (2000). Processing of the Drosophila Sog protein 
creates a novel BMP inhibitory activity. Development 127, 2143-2154. 
Zakin, L. and De Robertis, E. M. (2004). Inactivation of mouse Twisted gastrulation 
reveals its role in promoting Bmp4 activity during forebrain development. 
Development 131, 413-424. 
Zakin, L., Reversade, B., Kuroda, H., Lyons, K. M. and De Robertis, E. M. (2005). 
Sirenomelia in Bmp7 and Tsg compound mutant mice: requirement for Bmp 
signaling in the development of ventral posterior mesoderm. Development 132, 
2489-2499. 
Zeisel, S. (2009). Importance of methyl donors during reproduction. Am J Clin Nutr 89, 
673S-677S. 
Zeisel, S. H. and Blusztajn, J. K. (1994). Choline and human nutrition. Annu Rev Nutr 
14, 269-296. 
Zeisel, S. H., Mar, M. H., Zhou, Z. and da Costa, K. A. (1995). Pregnancy and 
lactation are associated with diminished concentrations of choline and its 
metabolites in rat liver. J Nutr 125, 3049-3054. 
Zhan, S. Y., Lian, Z. H., Zheng, D. Z. and Gao, L. (1991). Effect of fathers' age and 
birth order on occurrence of congenital heart disease. J Epidemiol Community 
Health 45, 299-301. 
Zhao, Q., Behringer, R. R. and de Crombrugghe, B. (1996). Prenatal folic acid 
treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 
homeobox gene. Nat Genet 13, 275-283. 
 
   137 
Zhao, Y., Guo, Y. J., Tomac, A. C., Taylor, N. R., Grinberg, A., Lee, E. J., Huang, S. 
and Westphal, H. (1999). Isolated cleft palate in mice with a targeted mutation of 
the LIM homeobox gene lhx8. Proc Natl Acad Sci U S A 96, 15002-15006. 
Zusman, S. B. and Wieschaus, E. F. (1985). Requirements for zygotic gene activity 
during gastrulation in Drosophila melanogaster. Dev Biol 111, 359-371. 
 
 
